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High homocysteine (Hcy) and low folate status are associated with many clinical conditions ranging from
cardiovascular disease to neural tube defects. Hcy and folate levels are affected by diet as well as
lifestyle and genetic factors. Associations between genetic polymorphisms of the enzymes involved in
folate/Hcy metabolism and Hcy levels and folate phenotypes were examined. Genetic polymorphisms
were studied in a range of populations, which included healthy individuals, systemic lupus erythematosus
(SLE) patients, rheumatoid arthritis (RA) patients, and families with a child affected by neural tube defects
(NTDs). Chronic low folate is associated with development of a “proatherosclerotic” phenotype in the
endothelial cell line, EA.hy 926. The effect of the anti-folate, methotrexate (MTX), on the expression of
inflammatory genes was studied in EA.hy 926 cells in the context of folate status and activation by TNFα.
Genotyping was performed by TaqMan allelic discrimination assays or by size difference PCR. Total Hcy
(tHcy) concentrations and levels of plasma and red blood cell (RBC) folate derivatives were measured by
stable isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry. Affymetrix
microarrays were used to assess changes in gene expression in vitro. Candidate inflammatory genes
were then queried using qRT-PCR. ELISAs were performed to confirm changes in protein levels.
Several polymorphisms had effects on tHcy levels and not only on total RBC folate but on individual RBC
folate derivatives. Specifically effects were observed within the studies in healthy men, healthy women,
and RA patients, but not in SLE patients. Also none of the polymorphisms studied showed an association
with increased risk for NTDs using Transmission Disequilibrium Test analyses. Genetic polymorphisms of
the enzymes of the folate/Hcy pathway impact levels of tHcy and folate, which may then impact risk for
various clinical conditions.
MTX increased mRNA expression and protein levels of several inflammatory genes, which included C3
and IL-8. Activation of endothelial cells by TNF-α did not seem to be affected by treatment with MTX, with
exception of the up regulation of C3. MTX lowered intracellular folate and altered the distribution of folate
derivatives, which had an effect on inflammatory gene expression in endothelial cells.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Pharmacology

First Advisor
Alexander S. Whitehead

Keywords
folate, homocysteine, genetics, endothelial cells, methotrexate

Subject Categories
Genetics | Molecular, Genetic, and Biochemical Nutrition | Pharmacology

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/985

THE EFFECTS OF METHOTREXATE AND GENETIC
POLYMORPHISMS ON THE
FOLATE/HOMOCYSTEINE PATHWAY

Carolyn Summers
A Dissertation in Pharmacology

Presented to the Faculties of the University of Pennsylvania
In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy
2011

Alexander S. Whitehead, DPhil, Professor of Pharmacology
Supervisor of Dissertation

Vladimir Muzykantov, MD/PhD, Professor of Pharmacology
Graduate Group Chairperson
Dissertation Committee members:
Ian A. Blair, PhD, Professor of Pharmacology
Wade Berrettini, MD/PhD, Professor of Psychiatry
Caryn Lerman, PhD, Professor of Psychiatry
Liselotte Jensen, PhD, Assistant Professor of Microbiology and Immunology

DEDICATION
I would like to dedicate this thesis to my loving husband, Jared, and his family for their
support, encouragement, and willingness to make sacrifices. I would also like to dedicate
this thesis to my parents for their understanding and unwavering support.

ii

ACKNOWLEGEMENTS
I would like to thank my advisor, Alexander S. Whitehead, for mentoring me over
these past few years. He has trained me in planning and executing experiments, and
provided valuable guidance in developing my writing skills. I would also like to thank all
of my professors, in particular, Andrew Cucchiara, for spending long hours teaching me
SAS programming. I would like to thank all of the past and present members of the
Whitehead lab for their support and advice. In particular I would like to thank Karen
Brown, Carmel Kealey, Anna Stanislawska-Sachadyn, Liselotte Jensen, Zhi-Yong Lu,
and Andrea Hammons. They have given me advice and helped me to learn techniques. I
would like to thank Stefanie Khartulyari, Arnaldo Diaz, Suhong Zhang, and Jasbir Arora
from the Blair lab and Megan Morales from the Von Feldt lab for their collaboration. I
would also like to thank the Assoian lab for their help and sharing of their equipment. I
would like to thank members of my thesis committee, Ian Blair, Wade Berrettini, Caryn
Lerman, and Liselotte Jensen for their guidance. I would like to thank UPenn
Pharmacological Sciences, in particular Linda Leroy, Mary Scott, Sarah Squire, Lise
Miller, Gail Vogel, Rosalyn Rucker, and Camie Minieri for taking care of practical
issues.
The Industrial Workers study was supported by National Institutes of Health
grants AR47663, CA108862, ES013508, HD039195; PA Department of Health grant
4100038714; the Wellcome Trust; and the British Heart Foundation. Initial funding was
obtained through the Institute of Vitamin Research in Berne, Switzerland, courtesy of
Professor Fred Gey.

iii

The Premenopausal Women study was supported by National Institutes of Health
grants AR47663, HD039195, and ES013508.
The Neural Tube Defect study was supported by National Institutes of Health
grants HD039195 and HD039081; Ethel Brown Foerderer Fund for Excellence; and
General Clinical Research Center of the Children’s Hospital of Philadelphia grant M01RR00240.
The Systemic Lupus Erythematosus study was supported by National Institutes of
Health grants AR47663 and ES013508; Lupus Research Institute grants; and Clinical and
Translational Research Center grant UL1RR024134 from the National Center for
Research Resources.
The Rheumatoid Arthritis study was supported by National Institutes of Health
grant AR47663.
The cell culture studies were supported by National Institutes of Health grants
AR47663 and ES013508; and Pennsylvania Department of Health grant 4100038714.

iv

ABSTRACT
THE EFFECTS OF METHOTREXATE AND GENETIC
POLYMORPHISMS ON THE FOLATE/HOMOCYSTEINE PATHWAY

Carolyn Summers
Alexander S. Whitehead

High homocysteine (Hcy) and low folate status are associated with many clinical
conditions ranging from cardiovascular disease to neural tube defects. Hcy and folate
levels are affected by diet as well as lifestyle and genetic factors. Associations between
genetic polymorphisms of the enzymes involved in folate/Hcy metabolism and Hcy
levels and folate phenotypes were examined. Genetic polymorphisms were studied in a
range of populations, which included healthy individuals, systemic lupus erythematosus
(SLE) patients, rheumatoid arthritis (RA) patients, and families with a child affected by
neural tube defects (NTDs). Chronic low folate is associated with development of a
“proatherosclerotic” phenotype in the endothelial cell line, EA.hy 926. The effect of the
anti-folate, methotrexate (MTX), on the expression of inflammatory genes was studied in
EA.hy 926 cells in the context of folate status and activation by TNF-α.
Genotyping was performed by TaqMan allelic discrimination assays or by size
difference PCR. Total Hcy (tHcy) concentrations and levels of plasma and red blood cell
(RBC) folate derivatives were measured by stable isotope dilution liquid chromatography
multiple reaction monitoring mass spectrometry. Affymetrix microarrays were used to
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assess changes in gene expression in vitro. Candidate inflammatory genes were then
queried using qRT-PCR. ELISAs were performed to confirm changes in protein levels.
Several polymorphisms had effects on tHcy levels and not only on total RBC
folate but on individual RBC folate derivatives. Specifically effects were observed within
the studies in healthy men, healthy women, and RA patients, but not in SLE patients.
Also none of the polymorphisms studied showed an association with increased risk for
NTDs using Transmission Disequilibrium Test analyses. Genetic polymorphisms of the
enzymes of the folate/Hcy pathway impact levels of tHcy and folate, which may then
impact risk for various clinical conditions.
MTX increased mRNA expression and protein levels of several inflammatory
genes, which included C3 and IL-8. Activation of endothelial cells by TNF-α did not
seem to be affected by treatment with MTX, with exception of the up regulation of C3.
MTX lowered intracellular folate and altered the distribution of folate derivatives, which
had an effect on inflammatory gene expression in endothelial cells.

vi

TABLE OF CONTENTS
Title Page…..…………………………………………………….………………...………i
Dedication……………………………………………………………………………..…..ii
Acknowledgements……..………………………………………………………….…….iii
Abstract…...……………………………………………………………………...………..v
Table of Contents……….……………...…………………………………….….....…….vii
List of Tables………………….………………………………………………….……....xi
List of Figures…………….……………………………………………………....……..xiii
Chapter 1: General Introduction
1.1 The Folate/Homocysteine Metabolic Pathway………………………..………1
1.2 Folate Transport…………………….…………………………………………3
1.3 Common Functional Polymorphisms…………………………………………3
1.3.1

MTHFR……………………………………………………………4

1.3.2

MTR……………………………………………………….………5

1.3.3

MTRR……………………………………………………………..6

1.3.4

CBS………………………………………………………………..6

1.3.5

DHFR………………………………………………………...…...7

1.3.6

TYMS………………………………………………………….…..8

1.3.7

SHMT1……………………………………………………………8

1.3.8

MTHFD1………………………………………………………….9

1.3.9

RFC1…………………………………………………………..….9

1.4 Summary and Specific Aims………………………………………………...10

vii

Chapter 2: Effect of Polymorphisms on Homocysteine and Folate Levels in Healthy
Individuals
2.1 Abstract………………………………………………………………………12
2.2 Introduction…………………………………………………………………..13
2.2.1 Factors Affecting Hcy Levels……………………………………...13
2.2.2 Interaction of MTHFR 677C>T and CBS 844ins68 genotypes…....13
2.2.3 Racial Distributions of Polymorphisms……………………………14
2.2.4 Association of High Hcy and Low Folate with Cardiovascular
Disease…………………………………………………………………...14
2.2.5 Association of High Hcy and Low Folate with Pregnancy
Complications……………………………………………………………15
2.2.6 Methods of Folate Measurement…………………………………..15
2.3 Methods………………………………………………………………………17
2.3.1 Industrial Workers Study…………………………………………..17
2.3.2 Premenopausal Women Study……………………………………..19
2.4 Results………………………………………………………………………..21
2.4.1 Industrial Workers Study…………………………………………..21
2.4.2 Premenopausal Women Study……………………………………..24
2.5 Discussion……………………………………………………………………37
Chapter 3: Polymorphisms Associated with the Risk of Neural Tube Defects
3.1 Abstract………………………………………………………………………46
3.2 Introduction…………………………………………………………………..47
3.2.1 Neural Tube Defects……………………………………………….47
viii

3.2.2 Folic Acid Fortification…………………………………………….47
3.2.3 Selected Polymorphisms Associated with NTDs………………….49
3.3 Methods………………………………………………………………………54
3.3.1 NTD Study…………………………………………………………54
3.4 Results………………………………………………………………………..56
3.4.1 NTD Study…………………………………………………………56
3.5 Discussion……………………………………………………………………61
Chapter 4: Polymorphisms in the Context of Inflammatory Diseases: Systemic Lupus
Erythematosus and Rheumatoid Arthritis
4.1 Abstract………………………………………………………………………64
4.2 Introduction…………………………………………………………………..66
4.2.1 Systemic lupus erythematosus……………………………………..66
4.2.2 Rheumatoid arthritis………………………………………………..67
4.3 Methods………………………………………………………………………69
4.3.1 SLE Study………………………………………………………….69
4.3.2 RA Study…………………………………………………………...71
4.4 Results………………………………………………………………………..74
4.4.1 SLE Study………………………………………………………….74
4.4.2 RA Study…………………………………………………………...81
4.5 Discussion……………………………………………………………………95
Chapter 5: The Effect of Methotrexate Alone and on the Activation of Endothelial Cells
5.1 Abstract………………………………………………………………..……101
5.2 Introduction…………………………………………………………………102
ix

5.3 Methods……………………………………………………………………..106
5.3.1 EA.hy 926 cell line experiments………………………………….106
5.4 Results………………………………………………………………………110
5.4.1 EA.hy 926 cell line experiments……………………….…………110
5.5 Discussion………………………………………………………….……….130
Chapter 6: General Discussion and Future Directions
6.1 General Discussion…………………………………………………………134
6.2 Future Directions…………………………………………………………...136
6.2.1 Healthy subjects…………………………………………………..136
6.2.2 Families with a child affected by NTDs………………………….137
6.2.3 Inflammatory diseases……………………………………………137
6.2.4 Cell culture……………………………………………………….138
References………………………………………………………………………………139

x

List of Tables
Table 2-1. Associations between CBS 844ins68 genotype and biochemical
parameters………………………………………………………………………..22
Table 2-2. Subject characteristics and biochemical phenotypes (Mean+SD or n%)…….26
Table 2-3. Genotype distributions (n%)………………………………………………….27
Table 2-4. Proportion of variation (R2) in biochemical variables explained by selected
subject characteristics and biochemical phenotypes……………………………..29
Table 2-5. Proportion of variation (R2) in biochemical variables explained by selected
biochemical phenotypes………………………………………………………….31
Table 2-6. Proportion of variation (R2) in biochemical variables explained by selected
genotypes in African Americans…………………………………………………33
Table 2-7. Proportion of variation (R2) in biochemical variables explained by selected
genotypes in Caucasians…………………………………………………………35
Table 2-8. Distribution of MTHFR 677 genotypes in Caucasians by detection of RBC
5,10-MTHF………………………………………………………………………36
Table 2-9. Number of Caucasians in each folate phenotype by MTHFR 677/1298
combined genotypes……………………………………………………………...37
Table 3-1. Genotype frequencies in the NTD study……………………………………..57
Table 3-2. MTHFR 677/1298 combined genotypes……………………………………..58
Table 3-3. TYMS 5’VNTR/1494del6 combined genotypes……………………………..60
Table 3-4. MTHFR 677C>T mating types in child trios with number of allele
transmissions……………………………………………………………………..61
Table 4-1. SLE Study Subject Characteristics…………………………………………...75
Table 4-2. Distributions of genotype frequencies in African American and Caucasian
controls…………………………………………………………………………...77
Table 4-3. Distributions of carrier frequencies between SLE patients and controls by
race……………………………………………………………………………….78
Table 4-4. Correlations with total homocysteine levels………………………………….79
xi

Table 4-5. Analysis of covariance for total homocysteine………………………...…….79
Table 4-6. Analysis of covariance with two factors (group, race) and one covariate
(GFR)…………………………………………………………………………….80
Table 4-7. RA study subject characteristics for categorical variables…………………...82
Table 4-8. RA study subject characteristics for continuous variables…………………...84
Table 4-9. Analyses of selected clinical variables in current users: continuous variables
stratified by categorical variable.………………………………….……………..85
Table 4-10. RA study genotype distributions……………………………………………87
Table 4-11. Effects of MTHFR 677C>T genotypes in Caucasian current users………...89
Table 4-12. Effects of selected genotypes on biochemical variables and current MTX
dose in African American current users………………………………………….90
Table 4-13. Effects of selected genotypes on biochemical variables in Caucasian current
users……………………………………………………………………………...91
Table 4-14. Distribution of MTRR 66A>G genotypes in Caucasian current users by
detection of RBC 5,10-MTHF…………………………………………………...91
Table 4-15. Distribution of MTR 2756A>G genotypes in African American current users
by type of toxicity……………………………..…………………………………92
Table 4-16. Distribution of MTHFD1 1958G>A genotypes in Caucasian current users by
type of toxicity…………………………………………………………………...92
Table 4-17. Analyses between selected continuous variables in African American current
users……………………………………………………………………………...93
Table 4-18. Analyses between selected continuous variables in Caucasian current
users………………………………………………………………………...……94
Table 5-1. Genes up regulated by MTX in Hi and Lo cells…………………………….119
Table 5-2. Genes down regulated by MTX in Hi and Lo cells…………………………124

xii

List of Figures
Figure 1-1. The folate/homocysteine metabolic pathway with common functional
polymorphisms…………………………………………………………………….2
Figure 2-1. Median total homocysteine levels by CBS 844ins68 genotype within each
MTHFR 677C>T genotype class………………….……………………………..23
Figure 2-2. Median serum folate levels by CBS 844ins68 genotype within each MTHFR
677C>T genotype class…………………………………………………………..24
Figure 2-3. Relative amounts of RBC folate derivatives in each folate phenotype in
Caucasians…………………………………………………………….…………37
Figure 5-1. Folate/Homocysteine pathway and MTX inhibition……………………….106
Figure 5-2. MTX dose finding and viability experiments……………………………...113
Figure 5-3. Folate derivatives measured by LC/MRM/MS…………………………….117
Figure 5-4. QRT-PCR…………………………………………………………………..122
Figure 5-5. ELISAs……………………………………………………………………..129

xiii

Chapter 1: Introduction
1.1 The Folate/Homocysteine Metabolic Pathway
The folate/homocysteine pathway supports two biologically important functions,
methylation and nucleotide biosynthesis. Low folate and high homocysteine (Hcy),
hyperhomocysteinemia, is associated with a wide range of pathologies including spina
bifida (van der Put et al. 2001), cardiovascular disease (Refsum et al. 1998), Alzheimer’s
(Mattson and Shea 2003), cancer (Stover 2004), and many others. It remains to be proven
whether it is the high Hcy or low folate levels which present more risk. This is further
complicated by their intrinsic inverse relationship. Dietary intakes of folate and folic acid,
known as vitamin B9, as well as intake of other B vitamins have an inverse relationship
with Hcy levels. B vitamins, such as B6 and B12, are cofactors for several enzymes in the
pathway and thus deficient levels lead to increased Hcy concentrations. Elevated Hcy
levels are also associated with older age, male gender, and lifestyle factors such as
smoking, alcohol intake, coffee consumption, and lack of exercise (Schneede et al. 2000).
Folate is important in methylation because the methyl group from 5methyltetrahydrofolate (5-MTHF) is used for the remethylation of Hcy, which becomes
methionine (Figure 1-1). Methionine then becomes S-adenosylmethionine (SAM) which
is the methyl donor for hundreds of methylation reactions, which includes methylation of
DNA and proteins. Once SAM loses its methyl group it becomes Sadenosylhomocysteine (SAH), which is then converted back to Hcy. Hcy can also be
methylated to become methionine by betaine-homocysteine S-methyltransferase
(BHMT), but this enzyme is found mostly in the liver (Pajares and Perez-Sala 2006) and
uses the methyl group from betaine. The transsulfuration pathway metabolizes Hcy into
1

cystathionine, which is then converted into cysteine and can be used to produce
glutathione. The transsulfuration pathway is present in only four tissues, liver, kidney,
small intestine, and pancreas (Finkelstein 1998). There are two folate derivatives which
are important for nucleotide synthesis. 5,10-methyleneTHF is used for the production of
the pyrimidine, deoxythymidine monophosphate (dTMP), while 10-formylTHF is used
for production of purines.

Figure 1-1. The folate/homocysteine metabolic pathway with common functional
polymorphisms. 5-MTHF, 5-methyltetrahydrofolate, 5,10-MTHF, 5,10methenyltetrahydrofolate, CBS, cystathionine beta-synthase, DHF, dihydrofolate, DHFR,
dihydrofolate reductase, dTMP, deoxythymidine monophosphate, dUMP, deoxyuridine
monophosphate, Hcy, homocysteine, M, methylenetetrahydrofolate dehydrogenase 1,
methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 1958G>A,
MTHFR, methylenetetrahydrofolate reductase, MTR, methionine synthase, MTRR,
methionine synthase reductase, RFC1, reduced folate carrier 1, SAH, Sadenosylhomocysteine, SAM, S-adenosylmethionine, SHMT1, serine
hydroxymethyltransferase 1, THF, tetrahydrofolate, TYMS, thymidylate synthase.
(published in (Summers et al. 2010))
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1.2 Folate Transport
Naturally occurring forms of folate are found mostly in vegetables and some fruits
and are polyglutamated. During digestion folates are hydrolyzed into monoglutamates by
two enzymes, gamma-glutamyl hydrolase (GGH) and folate hydrolase 1 (FOLH1). In the
small intestine reduced folate carrier 1 (RFC1) transports monoglutamated folates and
folic acid. The circulating form of folate is 5-methyltetrahydrofolate (5-MTHF)
monoglutamate and once it enters the cell it becomes polyglutamated by
folylpolyglutamate synthase (FPGS) in order to trap folate within the cell as well as
increasing their affinity for intracellular enzymes (Stover 2004). RFC1 is ubiquitously
expressed and transports folate in many tissues as diverse as the kidneys and the central
nervous system. The folate receptor (FR) family of genes are only expressed in specific
tissues, during certain developmental times, and tend to be overexpressed in certain
cancers (Matherly and Goldman 2003). Red blood cell (RBC) folate levels are a
reflection of folate status during the last 3-4 months while plasma folate levels are a
reflection of recent folate intake.
1.3 Common Functional Polymorphisms
The hereditability of homocysteine was found to be 57% in a twin study (Siva et
al. 2007) and therefore genetic polymorphisms are likely to contribute to the variation in
Hcy levels. Common functional polymorphisms within the enzymes of the folate/Hcy
metabolic pathway affect folate/Hcy phenotype and may therefore increase risk for
clinical conditions that are associated with dysfunction of folate/Hcy metabolism.
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1.3.1 MTHFR
5,10-methylenetetrahydrofolate reductase (MTHFR) irreversibly reduces 5,10methyleneTHF into 5-MTHF, which is the methyl donor for the remethylation of Hcy
into methionine (Figure 1). The cofactor for this enzyme is flavin adenine dinucleotide
(FAD), which is derived from vitamin B2, riboflavin. This enzyme is important because it
directs whether folate is used for methylation or for nucleotide synthesis (Ueland et al.
2001). Frosst et al. (1995) was the first to identify the single nucleotide polymorphism
(SNP) in MTHFR 677C>T (rs1801133), which causes an alanine to valine substitution at
position 222 of the protein and the result is a thermolabile form of the enzyme with
reduced activity. MTHFR 677TT homozygous individuals have higher fasting
homocysteine levels especially when folate levels are low (Harmon et al. 1996; Jacques
et al. 1996). From the study by Guenter et al. (1999) on the homologous mutation in
MTHFR from E. coli the thermolabile properties of the human 677T enzyme are due to
the decreased binding of FAD. When folate levels are low the thermolabile enzyme loses
its FAD cofactor more easily than the wildtype enzyme. Conversely, when folate levels
are high the variant containing enzyme becomes stabilized and less likely to lose its
cofactor.
Bagley and Selhub (1998) were the first to discover that MTHFR 677TT
homozygotes had an altered distribution of folate derivatives, specifically that formylated
folates were present in red blood cells (RBCs), whereas 677CC homozygotes had
predominantly 5-MTHF. Not only does this polymorphism affect Hcy levels and the
distribution of folate derivatives but it also carries increased and decreased risks of
clinical conditions. For example, the 677TT genotype in infants carries a pooled odds
4

ratio of 1.8 for risk of spina bifida in a meta-analysis by Botto and Yang (2000) and in
mothers the pooled odds ratio is 2.0 for risk of carrying a child with spina bifida. Also
677TT homozygotes are at increased risk of cardiovascular disease (Kluijtmans and
Whitehead 2001) but carry an increased protection from colon cancer (Ma et al. 1997),
the rationale for the latter being that the 677T enzyme is inefficient and folates other than
5-MTHF accumulate and are more readily available for nucleotide synthesis. A study by
DeVos et al. (2008) showed that the MTHFR 677TT genotype was associated with 34%
lower DNA uracil content, and the misincorporation of uracil into DNA is believed to be
one of the first steps of colon cancer (Ma et al. 1997).
A second MTHFR SNP, 1298A>C (rs1801131), is in linkage disequilibrium with
the 677C>T SNP, such that the two variant alleles rarely occur together on the same
chromosome (van der Put et al. 1998). The 1298A>C transition encodes a substitution of
glutamic acid to alanine at position 429 of the protein. The 1298A>C polymorphism has
contradictory associations with folate levels in the literature. Parle-McDermott et al.
(Parle-McDermott et al. 2006b) found that within the MTHFR 677CC genotype those
with the 1298CC genotype had higher RBC folate than those with the 1298AA genotype,
while a large-scale study by Ulvik et al. (2007) found that within the MTHFR 677CC
genotype those with the 1298CC genotype had lower serum folate and higher Hcy than
those with the 1298AA genotype. Van der Put et al. (1998) have reported that the double
homozygote 677CT/1298AC is associated with elevated Hcy and lower plasma folate.
1.3.2 MTR
Methionine synthase (MTR) uses the methyl group from 5-MTHF to remethylate
homocysteine. The products of this reaction are methionine and THF. Vitamin B12 is a
5

cofactor for this enzyme. The most studied SNP in this gene is 2756A>G (rs1805087),
which mandates an aspartic acid to glycine change at position 919 in the protein. Harmon
et al. (1999) found that 2756AA homozygotes had higher Hcy levels in a study in Irish
middle-aged men called the Industrial Workers study. Tsai et al. (2009) confirmed this
finding in African Americans in the US, but in Caucasians Hcy levels were not associated
with this polymorphism. A large scale study in Norway also found that 2756AA
homozygotes had higher Hcy levels (Fredriksen et al. 2007).
1.3.3 MTRR
Methionine synthase reductase (MTRR) keeps MTR in its active form via
reductive methylation of B12. There is a polymorphism in this gene at position 66 that has
an A>G transition (rs1801394). This polymorphism leads to an isoleucine to methionine
change at position 22 in the protein. It was found that 66GG homozygotes have high Hcy
levels in the Industrial Workers study in Irish men (Gaughan et al. 2001; Gaughan et al.
2002).
1.3.4 CBS
Cystathionine beta-synthase (CBS) irreversibly metabolizes Hcy as part of the
transsulfuration pathway, and requires vitamin B6 as a cofactor. Within CBS there is a 68
base pair (bp) insertion found in exon 8 referred to as 844ins68. This insertion has been
shown to carry a mutation 833T>C which should cause a premature stop codon but in
vitro studies showed that the inserted sequence is skipped, allowing a full length
functional CBS enzyme (Tsai et al. 1996). Only two studies (Dekou et al. 2001;
Fredriksen et al. 2007) have found that the 844ins68 carriers have lower Hcy levels than

6

noncarriers, while several other studies did not find any association (Bowron et al. 2005;
Kluijtmans et al. 2003; Wang et al. 1999 Sep).
Individuals homozygous for loss of function mutations in CBS, MTR, or MTHFR
have homocystinuria, which is characterized by extremely high levels of Hcy above 100
µM. This rare disease manifests as mental retardation, dislocation of the optic lens,
osteoporosis, and increased cardiovascular events which leads to early mortality (Mudd et
al. 1985). Hyperhomocysteinemia is defined as an intermediate level of Hcy between 15
and 100 µM. High levels of Hcy have been proven to be an independent risk factor for
cardiovascular disease (Refsum et al. 1998).
1.3.5 DHFR
Dihydrofolate reductase (DHFR) metabolizes synthetic folic acid, which is found
in supplements and fortified foods, into dihydrofolate (DHF) and DHFR also metabolizes
this into THF. There is a 19bp insertion/deletion polymorphism within the first intron of
DHFR, which is referred to as c.86 + 60_78. The deletion removes a possible Sp1
transcription factor binding site, which may affect transcriptional regulation (Johnson et
al. 2004). The effect of this polymorphism on folate and Hcy levels was consistent in two
studies in healthy individuals. A study in young reproductive aged adults from Northern
Ireland found that women with the del/del genotype had increased serum and RBC folate
concentrations compared to insertion carriers (Stanislawska-Sachadyn et al. 2008a). A
study from the Netherlands found that del/del homozygotes had decreased Hcy levels
compared to ins/ins homozygotes (Gellekink et al. 2007).
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1.3.6 TYMS
Thymidylate synthase (TYMS) competes with MTHFR for one of its substrates
5,10-methyleneTHF, which is used to convert deoxyuridine monophosphate (dUMP) into
deoxythymidine monophosphate (dTMP). Nucleotide synthesis is important for DNA
replication and repair. There are two common polymorphisms within this gene, one in the
5’ untranslated region (UTR) and one in the 3’ UTR. The polymorphism in the 5’ UTR is
a variable number of tandem repeats (VNTR) consisting of a 28bp repeat with either 2 or
3 repeats being the most common and 4 and 5 repeats being more rare (Luo et al. 2002).
Mandola et al. (2003) suggested that the repeat contains a USF1 transcription factor
binding site, so the higher number of repeats would lead to increased transcription. The
3R/3R homozygotes had lower plasma folate in a study in Singapore Chinese subjects
(Trinh et al. 2002).
The polymorphism in the 3’ UTR of TYMS is a 6bp insertion/deletion
polymorphism referred to as 1494del6 (rs16430). A study by Mandola et al. (2004)
suggests that this polymorphism affects mRNA stability and translation. TYMS del/del
homozygotes were associated with less mRNA. Del/del homozygotes had higher RBC
folate and lower Hcy levels compared to ins carriers in young adults from Northern
Ireland (Kealey et al. 2005). There is linkage disequilibrium between the polymorphisms
in the 5’ and 3’ UTRs such that the 2R allele rarely occurs on the same chromosome with
the del allele (Mandola et al. 2004).
1.3.7 SHMT1
Serine hydroxymethyltransferase 1 (SHMT1) encodes an enzyme which localizes
to the cytoplasm while SHMT2 encodes an enzyme which localizes to the mitochondria.
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SHMT1 and SHMT2 both catalyze the same reaction, the reversible conversion of serine
and THF to glycine and 5,10-methyleneTHF. SHMT1 has a polymorphism 1420C>T
(rs1979277), which substitutes a leucine for a phenylalanine at position 474 of the
protein. In a study in mothers of children with neural tube defects 1420CC homozygotes
had increased Hcy levels compared to 1420T carriers. In the combined group of mothers,
children, and controls 1420CC homozygotes had decreased plasma and RBC folate levels
(Heil et al. 2001).
1.3.8 MTHFD1
Methylenetetrahydrofolate dehydrogenase 1, methenyltetrahydrofolate
cyclohydrolase, formyltetrahydrofolate synthetase (MTHFD1) is a trifunctional enzyme
which catalyzes three different reactions. This enzyme provides precursors for nucleotide
synthesis and converts THF into 10-formylTHF and then into 5,10-methyleneTHF, which
are used in the synthesis of purines and thymidylate, respectively. The 1958G>A
polymorphism (rs2236225) present in MTHFD1 substitutes an arginine for a glutamine at
position 653 in the protein, which is in the formyltetrahydrofolate synthetase region of
the enzyme. Although one study has not identified any effect of this polymorphism on
plasma folate, RBC folate, or Hcy concentrations (Brody et al. 2002) two separate sets of
samples from the Irish population have revealed that the 1958AA genotype is associated
with an increased risk for mothers to carry a child with spina bifida (Brody et al. 2002;
Parle-McDermott et al. 2006a).
1.3.9 RFC1
Reduced folate carrier 1 (RFC1), officially known as solute carrier family 19
member 1 (SLC19A1), transports 5-MTHF bi-directionally with high affinity and also
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facilitates the transport of folic acid but with lower affinity (Matherly and Goldman
2003). RFC1 has a polymorphism 80G>A (rs1051266), which substitutes an arginine for
a histidine at position 27 of the protein. The effect of this polymorphism on folate and
homocysteine levels is varied in the literature. A few studies did not find any association
between RFC1 80G>A genotype and folate or homocysteine levels (Chango et al. 2000;
Devlin et al. 2006; Vesela et al. 2005). A study in young reproductive aged adults from
Northern Ireland found that women with the 80GG genotype had decreased RBC folate
levels compared to 80GA and 80AA genotypes (Stanislawska-Sachadyn et al. 2009). A
study by Morin et al. (2003) found that 80GG homozygous mothers of children with or
without spina bifida had a borderline significant decrease in RBC folate. In contrast, a
large-scale study observed the 80A allele was associated with decreased serum folate but
with only borderline significance (Fredriksen et al. 2007).
1.4 Summary and Specific Aims
Folate/Hcy metabolism is important for nucleotide biosynthesis and methylation.
Dysregulation of folate/Hcy metabolism characterized by low folate and high Hcy levels
is associated with many clinical conditions, ranging from developmental abnormalities to
diseases with an inflammatory component. Polymorphisms within the enzymes of the
folate/Hcy metabolic pathway may have an effect on Hcy and folate levels that could
affect risk for various clinical conditions.
Specific Aims:
1) Examine the effects of the above mentioned polymorphisms on tHcy and
folate levels in healthy men and women.
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2) Examine the risk associated with the above mentioned polymorphisms in
families with children affected by spina bifida.
3) Examine the effects of the above mentioned polymorphisms in patients with
inflammatory diseases such as systemic lupus erythematosus and rheumatoid
arthritis patients taking the anti-folate drug, methotrexate.
4) Examine the effects of methotrexate, alone and when used prior to treatment
with TNF-α, on inflammatory gene expression in an endothelial cell culture
model under high and low folate conditions.
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Chapter 2: Effect of Polymorphisms on Homocysteine and Folate Levels in Healthy
Individuals
2.1 Abstract
High Hcy and low folate levels are associated with many clinical conditions
ranging from cardiovascular disease to spina bifida. Genetic polymorphisms within the
enzymes of the folate/Hcy metabolic pathway may have independent effects or these
effects may synergize or counteract one another. In the Industrial Workers study, which
is composed of healthy middle-aged Irish males, the 844ins68 polymorphism within
cystathionine β-synthase (CBS) was examined alone and in the context of 5,10methylenetetrahydrofolate reductase (MTHFR) 677C>T genotypes for an effect on tHcy
and folate levels. MTHFR 677TT homozygotes had higher tHcy and lower folate
concentrations relative to individuals with 677CC and 677CT genotypes. CBS 844ins68
carriers did not have significantly different tHcy or folate levels, but after stratifying by
MTHFR 677 genotypes, carriers of the 844ins68 allele who were MTHFR 677TT
homozygotes had normalized levels of tHcy and folate compared to 677TT/844ins68
noncarriers.
In the Premenopausal Women study, which was composed of 26 Caucasian and
23 African American healthy premenopausal women, there were 11 polymorphisms
within 9 genes of enzymes of the folate/Hcy metabolic pathway which were examined for
effects on tHcy, plasma folate, and red blood cell (RBC) folate derivative levels. In
African Americans tHcy levels were associated with polymorphisms in methionine
synthase (MTR) and thymidylate synthase (TYMS). RBC folate derivative levels were
associated with polymorphisms in MTR, TYMS, methionine synthase reductase (MTRR),
and reduced folate carrier 1 (RFC1). In Caucasians tHcy levels were associated with
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polymorphisms in 5,10-methylenetetrahydrofolate reductase (MTHFR) and MTR. RBC
folate derivative levels were associated with polymorphisms in MTHFR, TYMS, and
RFC1.
2.2 Introduction
2.2.1 Factors Affecting Hcy Levels
Hcy concentrations are impacted by dietary intake of folate and B vitamins, by
lifestyle factors such as smoking, and by genetic factors such as common functional
polymorphisms in the enzymes of the folate/Hcy metabolic pathway. B12 levels are
inversely related to Hcy levels because B12 is a cofactor for MTR, the enzyme
responsible for the remethylation of Hcy to methionine. The methylfolate trap hypothesis
states that deficient B12 levels lower the activity of MTR such that 5-MTHF is trapped
resulting in the build up of Hcy and was demonstrated in a single case of B12 deficiency
(Smulders et al. 2006). Smoking is associated with increased Hcy, decreased folate, B12,
and B6 levels (Brown et al. 2004b; Gabriel et al. 2006; Nygard et al. 1998). Smoking is
also associated with poor pregnancy outcome, which includes oral clefts, preterm birth,
and low birth weight infants (Meyer et al. 1976; Wyszynski et al. 1997).
2.2.2 Interaction of MTHFR 677C>T and CBS 844ins68 genotypes
Destefano et al. (1998) found that MTHFR 677TT individuals carrying the CBS
844ins68 allele had lower homocysteine levels than noncarriers in a large study in
European men. A large study in British men by Dekou et al. (2001) confirmed the finding
that carriers of the CBS 844ins68 allele who were MTHFR 677TT homozygotes had
lower Hcy levels than 677TT/844ins68 noncarrier individuals. Folate levels were not
reported for either of these studies, and the aim of the Industrial Workers Study described
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here was to examine whether the CBS 844ins68 allele is associated with significantly
different levels of folate and Hcy, either alone or within classes of MTHFR 677C>T
genotypes.
2.2.3 Racial Distributions of Polymorphisms
The population in which the polymorphisms are studied is very important because
the frequencies of the genotypes vary by race. MTHFR 677C>T genotypes vary
significantly in frequency among the different racial groups. The percent of MTHFR
677TT homozygotes ranges from 8-18% in Caucasians, 1% of African Americans, and
12% of Asians (Botto and Yang 2000). MTHFR 677TT homozygotes are more prevalent
in Caucasian than African American populations and the implication maybe that risk of
neural tube defects is higher in Caucasians. The frequency of CBS 844ins68 allele
carriers also varies by race. Carriers of 844ins68 make up 14% of Caucasians, 41% of
African Americans, and are absent in Asians (Franco et al. 1998; Tsai et al. 2009).
2.2.4 Association of High Hcy and Low Folate with Cardiovascular Disease
Homocystinuria, extremely high levels of Hcy, due to an inborn error of
metabolism was first discovered in 1962 (Gerritsen et al. 1962) and was associated with
early onset cardiovascular disease (Mudd et al. 1985). Since then it has been concluded
that Hcy contributes to formation of atherosclerotic plaques (McCully 2007). Specifically
Hcy is capable of damaging arterial tissues by inducing the release of cytokines and other
mediators of inflammation. Hcy also contributes to fibrosis, calcification, and elastic
tissue damage. Hcy can cause oxidative stress which leads to oxidation of LDL, uptake of
which leads macrophages to become foam cells (Loscalzo 1996). Many clinical studies
have established that elevated Hcy is an independent risk factor for cardiovascular
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disease (McCully 2007). A meta-analysis found that a 5 µmol/L increase in Hcy is
associated with a 27% increased risk of venous thrombosis in prospective studies and a
60% increase in retrospective studies (Den Heijer et al. 2005). The best evidence that
adequate folate is protective against cardiovascular disease is in the early 1960s in the US
cardiovascular disease reached a peak and subsequently death rates declined by 60%
(CDC 1999). This time period coincides with the introduction of synthetic folic acid to
the food supply, before it was mandated by the FDA in 1998.
2.2.5 Association of High Hcy and Low Folate with Pregnancy Complications
High Hcy and low folate concentrations are associated with pregnancy
complications such as preeclampsia, premature birth, low birth weight infants, stillbirth,
and recurrent pregnancy loss (D'Uva et al. 2007; Vollset et al. 2000). A high Hcy and low
folate phenotype has also been associated with congenital abnormalities such as NTDs,
clubfoot, heart defects, limb deficiencies, cleft lip/palate, and Down syndrome (Czeizel
1998; James et al. 1999; Little et al. 2008; Vollset et al. 2000). Suboptimal folate status in
the mother is associated with an eight-fold increased risk of carrying a child with an NTD
(Molloy et al. 1998a). The adverse pregnancy outcomes listed above have been shown to
be reduced by maternal periconceptional folic acid supplementation (Bukowski et al.
2009; Czeizel and Dudas 1992; Timmermans et al. 2009; Yang et al. 1997).
2.2.6 Methods of Folate Measurement
There were two common methods by which RBC folate was typically measured.
Microbiological assays were based on the growth of a specific strain of folate-dependent
bacteria which was directly related to folate concentration (Molloy and Scott 1997).
Radiometric competitive binding assays (radioassays) were then developed to measure
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RBC folate via competition of radiolabeled tracer folate and unlabeled folate from the
sample for protein binding sites. The problem that arose was the conflicting association
of RBC folate levels with the MTHFR 677TT genotype. One study had shown that
677TT individuals had higher RBC folate than 677CT or 677CC individuals when using
a radioassay to measure RBC folate (van der Put et al. 1995). Another study measured
RBC folate by microbiological assay and revealed that MTHFR 677TT homozygotes had
lower RBC folate than 677CT heterozygotes or 677CC homozygotes (Molloy et al.
1997). A study by Molloy et al. (1998b) addressed this problem by using both methods of
RBC folate measurement on the same samples of various MTHFR 677C>T genotypes.
The results confirmed that the radioassay measured lower folates in MTHFR 677C
carriers compared to 677TT homozygotes, while the microbiological assay showed the
opposite. The results also showed that the radioassay measured less folate in MTHFR
677CT and 677CC individuals than the microbiological assay while the radioassay
measured more folate in MTHFR 677TT individuals than the microbiological assay.
A possible explanation lies in the difference in the distribution of folate
derivatives between the MTHFR 677C>T genotypes. MTHFR 677TT homozygotes have
an altered distribution of RBC folate derivatives, which favors formylated folates, while
677CC homozygotes have mostly 5-MTHF (Bagley and Selhub 1998). It is possible that
a specific folate derivative may be more readily measurable in the radioassay but not
utilized efficiently by the bacteria in the microbiological assay. The recent development
of stable isotope dilution liquid chromatography multiple reaction monitoring mass
spectrometry (LC/MRM/MS) provides higher specificity than previous methods through
the use of [13C5]-labeled internal standards. Also the capacity to measure three distinct
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folate derivatives (THF, 5-MTHF, and 5,10-MTHF) instead of just total RBC folate gives
this method an advantage. Specifically individual RBC folate derivatives will used to
characterize in detail the effects of polymorphisms in enzymes of folate/Hcy metabolic
pathway. While Smulders et al. (2007) using a similar method has shown that nonmethylfolate accumulation in RBCs is associated with the MTHFR 677TT genotype, it
remains to be explored what effects the other polymorphisms in the enzymes of the
folate/Hcy metabolic pathway have on specific RBC folate derivatives.
Certain genetic variants or folate/Hcy phenotypes may be associated with an
individual woman’s risk of pregnancy complications. The Premenopausal Women Study
was undertaken to examine the relationships of 11 polymorphisms in 9 genes to
folate/Hcy phenotype using stable isotope dilution LC/MRM/MS to measure total Hcy
and folate derivatives in plasma and RBCs. The analyses were divided into two racial
groups, African Americans and Caucasians, because these groups have different
prevalences of certain pregnancy complications.
2.3 Methods
2.3.1 Industrial Workers Study
Subjects
Subjects from the Industrial Workers study (n=614) were recruited from an
industrial company in Belfast, Northern Ireland as previously described (Harmon et al.
1996; Summers et al. 2008b). Subjects were men that were 29-53 years old. The study
was approved by the Research Ethics Committee of the Faculty of Medicine, The
Queen’s University of Belfast. All subjects provided written informed consent. Fasting
subjects gave blood samples for biochemical and genetic analysis.
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Biochemical Assays
THcy concentrations were determined previously using high-performance liquid
chromatography and serum folate concentrations were determined previously using a
commercial kit (ICN Pharmaceuticals) (Harmon et al. 1996).
Genotyping
MTHFR 677C>T genotyping was RFLP based and genotypes for the study
population have previously been reported (Harmon et al. 1996). CBS 844ins68 genotypes
were obtained using a PCR-based size difference method. PCR amplifications were
performed in a total volume of 25 µl containing 50 ng genomic DNA, 0.4 µM of each
forward and reverse primer (sequences of which were previously published (Barbaux et
al. 2000)), 0.8 µM dNTPs, 10x PCR Buffer (Applied Biosystems, Foster City, CA), 1.5
mM MgCl2, and 1U AmpliTaq DNA polymerase (Applied Biosystems). Cycling
conditions were as follows: 94°C 5 min, 35 cycles of 94°C 1 min, 55°C 1 min, 72°C 1
min. PCR products were separated on 3% agarose gels, run for 45 min at 140V, and
stained with ethidium bromide.
Statistics
Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary,
NC). Even after logarithmic transformation, distributions of total homocysteine and
serum folate were positively skewed, so all analyses were performed using untransformed
data. Hardy–Weinberg equilibrium was assessed for the MTHFR 677C>T and CBS
844ins68 genotypes. Differences between genotype groups for homocysteine and serum
folate were assessed using the Wilcoxon rank-sum or Kruskal–Wallis test.
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2.3.2 Premenopausal Women Study
Subjects
Premenopausal female staff and students were recruited at the University of
Pennsylvania School of Medicine from January 9, 2007 to July 26, 2007. A similar
number of subjects who self-reported as Caucasians and African Americans were
recruited. Study subjects who had a major medical condition, such as an autoimmune
disease, or who were currently taking an anti-folate drug, or were pregnant were
excluded. This study was approved by the Institutional Review Board of the University of
Pennsylvania School of Medicine. All subjects gave written informed consent. Subjects
provided fasting blood samples and completed an in-person interview. This study was
previously described (Summers et al. 2010).
Biochemical Assays
THcy levels and plasma and RBC folate derivatives were measured using stable
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry
(LC/MRM/MS) as previously described (Huang et al. 2007; Huang et al. 2008). The
measured folate derivatives include 5-MTHF, THF, and 5,10-MTHF. The measurement
of 5,10-MTHF is representative of the sum of 5-formylTHF and 10-formylTHF, which
under acidic conditions convert to 5,10-MTHF.
Vitamin B12 levels were measured with Immulite 2000 Vitamin B12 Assays
(Diagnostic Products Corp., Los Angeles, CA).
Genotyping
QIAamp DNA Mini Kits (Qiagen, Santa Clarita, CA) were used to extract DNA
from whole blood. TaqMan genotyping methods were previously described for MTHFR
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677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G (Summers et al. 2008a),
MTHFD1 1958G>A, RFC1 80A>G, and SHMT1 1420C>T (Summers et al. 2010).
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA
Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA).
PCR amplifications took place in 20 µl volumes containing 20 ng genomic DNA, forward
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of
an initial incubation at 50°C for 2 min, 95°C for 10 min, and 50 cycles of assay specific
temperatures for denaturation and extension. Dual fluorescence was measured at the end
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis
software, version 2.02 (Bio-Rad).
Size difference PCR methods were used to genotype CBS 844ins68, TYMS
1494del6, TYMS 5’ VNTR, and DHFR c.86+60_78 as previously described (Summers et
al. 2010). Briefly, PCR amplifications were performed using 50 ng genomic DNA,
forward and reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), and
AmpliTaq DNA polymerase (Applied Biosystems) in 25 µl volumes. PCR products were
separated on 3% agarose gels run for 45 min at 140V then stained with ethidium bromide.
Statistics
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary,
NC). Discrete variables were presented as counts and proportions and continuous
variables were presented as means and standard deviations. Total RBC folate is the sum
of RBC 5-MTHF, THF, and 5,10-MTHF. THF values which were not detectable (n=4)
were given a value corresponding to the lower limit of quantitation (4.5 nmol/L) with
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adjustment for individual hematocrit values, allowing both absolute THF levels and the
ratio of RBC 5-MTHF:THF to be analyzed as continuous variables. RBC 5,10-MTHF
levels were not detectable in a large portion of the samples and therefore this variable
was treated as dichotomous (detectable/not detectable).
Hardy-Weinberg equilibrium was calculated for each polymorphism within each
race (Caucasian and African American). Fisher’s Exact test was used to check for
significant differences in genotype distributions between the two groups. Simple linear
regression analyses estimated the coefficient of determination (R2), which measures the
proportion of variation in tHcy and various folates (dependent variable) that is explained
by each predictor variable. Significance in each model was assessed using either the tstatistic or Fisher’s exact test. Unadjusted p values <0.10 were considered significant
because of the small sample size of this study. The large number of comparisons made
are exploratory in nature and the results should be interpreted in that context.
2.4 Results
2.4.1 Industrial Workers Study
MTHFR 677C>T and CBS 844ins68 genotypes were each in Hardy-Weinberg
equilibrium. Frequencies of MTHFR 677C>T genotypes were 45% CC, 43.6% CT,
11.4% TT and frequencies of CBS 844ins68 genotypes were 82.2% W/W, 17.6% W/I,
0.2% I/I. A previous report from the Industrial Workers Study found that MTHFR 677TT
homozygotes had increased homocysteine and decreased serum folate relative to 677CT
and 677CC individuals (Harmon et al. 1996). CBS 844ins68 genotypes did not have
significantly different tHcy and serum folate levels (Table 2-1).
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Table 2-1. Associations between CBS 844ins68 genotype and biochemical
parameters.

Plasma tHcy and serum folate concentrations are expressed as median [interquartile
range]. Statistical significance for CBS genotypes was assessed by Wilcoxon Rank Sum.
1
Combined genotype class comprises 108 W/I and one I/I. (Summers et al. 2008b)

When CBS 844ins68 genotypes were stratified by MTHFR 677 genotypes, CBS
844ins68 carriers had significantly different tHcy levels than noncarriers only within
MTHFR 677TTs. CBS 844ins68 carrier status had no significant impact on tHcy or serum
folate concentrations within either MTHFR 677CT or 677CC genotypes. MTHFR
677TT/CBS 844ins68 carriers had 24.1% lower tHcy levels compared to 677TT/844ins68
noncarriers (6.66 vs 8.77 umol/L, respectively p=0.045) (Figure 2-1).
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Figure 2-1. Median total homocysteine levels by CBS 844ins68 genotype within each
MTHFR 677C>T genotype class. Bars represent total homocysteine levels in each
MTHFR 677C>T genotype class:
regardless of CBS 844ins68 genotype,
in CBS
844ins68 non-carriers, and
in CBS 844ins68 carriers. The number of subjects in each
group is given. † MTHFR 677TT homozygotes have significantly higher total
homocysteine concentrations than CT heterozygotes and CC homozygotes (p<0.0001 by
Kruskal-Wallis). (Summers et al. 2008b)
When CBS genotypes were stratified by MTHFR 677 genotypes, CBS 844ins68
carriers had significantly different serum folate concentrations than noncarriers only
within MTHFR 677TTs. MTHFR 677TT/CBS 844ins68 carriers had 27.7% higher serum
folate concentrations compared to 677TT/844ins68 noncarriers (11.16 vs 8.74 nmol/L,
respectively p=0.034) (Figure 2-2). The tHcy raising and folate lowering effect of the
MTHFR 677TT genotype appears to be ‘counterbalanced’ by the CBS 844ins68 allele.
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Figure 2-2. Median serum folate levels by CBS 844ins68 genotype within each
MTHFR 677C>T genotype class. Bars represent serum folate levels in each MTHFR
677C>T genotype class:
regardless of CBS 844ins68 genotype,
in CBS 844ins68
non-carriers, and
in CBS 844ins68 carriers. The number of subjects in each group is
given. † MTHFR 677TT homozygotes have significantly lower serum folate
concentrations than CT heterozygotes and CC homozygotes (p<0.0001 by KruskalWallis). (Summers et al. 2008b)
2.4.2 Premenopausal Women study
Subject Characteristics
In the study 53% (n=26) self-reported as Caucasian and 47% (n=23) as African
American. Subject characteristics are presented in Table 2-2. Several of the biochemical
variables were significantly different between African Americans and Caucasians. Total
RBC folate was higher in Caucasians (1186.0 vs 939.1 nmol/L, p=0.013). Out of the
individual RBC folate derivatives THF levels were higher (118.2 vs 19.1 nmol/L,
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p=0.030) and 5,10-MTHF was detectable in more Caucasians than African Americans
(61.5% vs 8.7%, p<0.0001). Additionally, plasma 5-MTHF levels were higher in
Caucasians (48.4 vs 33.5 nmol/L, p=0.009), while B12 levels were lower in Caucasians
(390.5 vs 542.4 pmol/L, p=0.013). Since many biochemical variables were different by
race all analyses were performed separately for each group. A Caucasian subset was
created in order to perform analyses without MTHFR 677TT homozygotes, since this
genotype is known to have a profound impact on folate/Hcy phenotype. Removal of these
subjects also ensured that analyses of other variables would not contain 677TT
individuals. Since the Premenopausal Women study is relatively small the 677TT
individuals could be inadvertently grouped together during the analysis of other variables
leading to false associations. All analyses in Caucasians were done in the subset which
excluded 677TT individuals except those analyses designed to examine the effect of the
MTHFR 677TT genotype.
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Table 2-2. Subject characteristics and biochemical phenotypes (Mean+SD or n%).
African American
Caucasian
Caucasian
Subject Characteristics
(N = 23)
(N = 26)
Subset (N=21)1
Age (years)
31.6 + 6.0
33.3 + 6.5
32.7 + 6.1
Body mass index (kg/m2)
28.3 ± 5.9
23.5 ± 3.4
23.6 + 3.8
Smoking
Yes
4 (17.4)
5 (19.2)
4 (19.0)
No
19 (82.7)
21 (80.8)
17 (81.0)
Alcohol use
Yes
16 (69.6)
22 (84.6)
18 (85.7)
No
7 (30.4)
4 (15.4)
3 (14.3)
2
Vitamin use
Yes
15 (65.2)
17 (65.4)
15 (71.4)
No
8 (34.8)
9 (34.6)
6 (28.6)
Biochemical Phenotypes
tHcy (µmol/L)
8.9 ± 2.5
9.6 ± 2.7
8.9 ± 1.9
Total RBC folate (nmol/L)3
939.1 ± 339.0
1186.0 ± 328.5 1165.3 ± 282.6
RBC 5-MTHF (nmol/L)
919.3 ± 334.1
1040.3 ± 333.0 1122.3 ± 278.8
RBC THF (nmol/L)
19.1 ± 9.1
118.2 ± 214.3
37.5 ± 31.2
RBC 5,10-MTHF
Not Detectable
21 (91.3)
10 (38.5)
9 (42.9)
Detectable
2 (8.7)
16 (61.5)
12 (57.1)
Ratio RBC 5-MTHF: THF
51.5 ± 15.3
35.7 ± 23.6
42.9 ± 19.9
Plasma 5-MTHF (nmol/L)
33.5 ± 17.2
48.4 ± 20.5
50.2 ± 22.0
B12 (pmol/L)
542.4 ± 231.6
390.5 ± 176.6
393.0 ± 173.0
1
After exclusion of MTHFR 677TT individuals.
2
Includes multivitamins, B vitamins, and folic acid.
3
Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF) (Summers et
al. 2010)
Genotype Distributions
African American and Caucasian genotype distributions were significantly
different for 5 out of the 11 polymorphisms and included: MTHFR 677C>T, MTRR
66A>G, CBS 844ins68, TYMS 1494del6, and MTHFD1 1958G>A (Table 2-3). MTHFD1
1958G>A was the only polymorphism that was not in Hardy-Weinberg equilibrium and
this was only in Caucasians (data not shown).
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Table 2-3. Genotype distributions (n%).
African
Caucasia
American Caucasian
n Subset
P
1
SNP (dbSNP rs no.)
Genotypes
(N = 23)
(N = 26)
(N=21)
Value2
MTHFR 677C>T
CC
16 (69.6)
8 (30.8)
8 (38.1)
0.009
rs1801133
CT
7 (30.4)
13 (50.0)
13 (61.9)
TT
0
5 (19.2)
0
MTHFR 1298A>C
AA
13 (56.5)
14 (53.8)
9 (42.9)
0.61
rs1801131
AC
10 (43.5)
10 (38.5)
10 (47.6)
CC
0
2 (7.7)
2 (9.5)
MTR 2756A>G
AA
10 (43.5)
15 (57.7)
14 (66.7)
0.17
rs1805087
AG
10 (43.5)
11 (42.3)
7 (33.3)
GG
3 (13.0)
0
0
MTRR 66A>G
AA
13 (56.5)
6 (23.1)
5 (23.8)
0.039
rs1801394
AG
7 (30.4)
17 (65.4)
13 (61.9)
GG
3 (13.0)
3 (11.5)
3 (14.3)
CBS 844ins68
WW
12 (52.2)
21 (80.8)
17 (80.9)
0.040
WI
8 (34.8)
5 (19.2)
4 (19.1)
II
3 (13.0)
0
0
TYMS 5’ VNTR
2R/2R
3 (13.0)
2 (7.7)
1 (4.8)
0.14
2R/3R
8 (34.8)
17 (65.4)
13 (61.9)
3R/3R
9 (39.1)
7 (26.9)
7 (33.3)
2R/4R
2 (8.7)
0
0
3R/4R
1 (4.4)
0
0
TYMS 1494del6
ins/ins
2 (8.7)
9 (34.6)
7 (33.3)
0.006
rs16430
ins/del
11 (47.8)
15 (57.7)
12 (57.1)
del/del
10 (43.5)
2 (7.7)
2 (9.5)
DHFR c.86+60_78
ins/ins
5 (21.7)
6 (23.1)
6 (28.6)
1
ins/del
13 (56.5)
14 (53.8)
12 (57.1)
del/del
5 (21.7)
6 (23.1)
3 (14.3)
RFC1 80A>G
AA
8 (34.8)
7 (26.9)
6 (28.6)
0.59
rs1051266
AG
12 (52.2)
16 (61.5)
13 (61.9)
GG
3 (13.0)
3 (11.5)
2 (9.5)
MTHFD1 1958G>A
GG
13 (56.5)
12 (46.2)
8 (38.1)
0.082
rs2236225
GA
8 (34.8)
5 (19.2)
3 (14.3)
AA
2 (8.7)
9 (34.6)
10 (47.6)
SHMT1 1420C>T
CC
10 (43.5)
14 (53.8)
13 (61.9)
0.59
rs1979277
CT
8 (34.8)
9 (34.6)
8 (38.1)
TT
5 (21.7)
3 (11.5)
0
1
After exclusion of MTHFR 677TT individuals.
2
P values by Fisher’s exact test are comparison of genotype distributions in African
Americans (n=23) and Caucasians (n=26). (Summers et al. 2010)
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Associations with Biochemical Phenotypes
Since this study included a small number of subjects in each group p values <0.10
were considered to be significant.
Lifestyle Factors
Alcohol Use. In African Americans alcohol users had tHcy concentrations that
were 2.0 µmol/L higher than nonusers (9.5 vs 7.5 µmol/L, p=0.068, Table 2-4). In
Caucasians alcohol users had total RBC folate that was 316.5 nmol/L higher than
nonusers (1210.0 vs 893.5 nmol/L, p=0.072) and this was due to RBC 5-MTHF levels
being 288.5 nmol/L higher in alcohol users (1163.5 vs 875.0 nmol/L, p=0.098).
Smoking. Total RBC folate concentrations were 380.1 nmol/L lower in African
American smokers than nonsmokers (625.1 vs 1005.2 nmol/L, p=0.038, Table 2-4). This
difference was largely attributable to the difference in RBC 5-MTHF levels which were
375.4 nmol/L lower in smokers than nonsmokers (609.2 vs 984.6 nmol/L, p=0.038). Also
plasma 5-MTHF levels were 16.4 nmol/L lower in smokers (20.0 vs 36.4 nmol/L,
p=0.083) and B12 levels were 239.6 pmol/L lower in smokers (344.5 vs 584.1 pmol/L,
p=0.058). In Caucasians similar relationships were observed but were not significant. For
example, total RBC folate concentrations were 189.7 nmol/L lower in smokers than
nonsmokers (p=0.24).
Vitamin Use. In Caucasians vitamin users had total RBC folate concentrations
that were 326.5 nmol/L higher than nonusers (1398.6 vs 1072.1 nmol/L, p=0.013) and
this was mostly due to RBC 5-MTHF levels being 326.9 nmol/L higher than nonusers
(1355.8 vs 1028.9 nmol/L, p=0.011). Plasma 5-MTHF levels were 23.7 nmol/L higher in
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users than nonusers (67.2 vs 43.5 nmol/L, p=0.022). Similar associations were not
observed in African Americans.
Table 2-4. Proportion of variation (R2) in biochemical variables explained by
selected subject characteristics and biochemical phenotypes.

Dependent
Variables
tHcy (µmol/L)
Total RBC
folate
(nmol/L) 2

Subject Characteristics
Explanatory
Variables
Alcohol
Intercept-No
Yes
Smoking
Intercept-No
Yes
Alcohol
Vitamin use

RBC 5-MTHF
(nmol/L)

Smoking
Alcohol
Vitamin use

RBC THF
(nmol/L)
Ratio RBC 5MTHF: THF
Plasma 5MTHF
(nmol/L)

RBC 5,10MTHF
RBC 5,10MTHF
Smoking

Vitamin use
B12 (pmol/L)

Smoking

African-American
(N=23)

Caucasian Subset
(N=21)1

Parameter
Estimate (SE)
7.5 (0.9)
2.0 (1.1)
1005.2 (71.7)
-380.1 (171.9)

R2 (Pvalue)
0.15
(0.068)
0.19
(0.038)

Parameter
Estimate (SE)
8.3 (1.1)
0.8 (1.2)
1200.9 (68.0)
-189.7 (155.7)

R2 (Pvalue)
0.02
(0.52)
0.07
(0.24)

Intercept-No
Yes
Intercept-No
Yes
Intercept-No
Yes
Intercept-No
Yes
Intercept-No
Yes
Intercept-ND3
D
Intercept-ND
D
Intercept-No
Yes

1009.7 (130.6)
-103.7 (156.5)
926.4 (90.0)
31.8 (152.6)
984.6 (70.6)
-375.4 (169.4)
987.5 (128.0)
-98.0 (153.5)
910.5 (88.3)
25.2 (149.6)
17.9 (1.8)
13.8 (6.2)
52.0 (3.4)
-6.7 (11.5)
36.4 (3.8)
-16.4 (9.0)

0.02
(0.51)
0.002
(0.84)
0.19
(0.038)
0.02
(0.53)
0.001
(0.87)
0.19
(0.037)
0.02
(0.57)
0.14
(0.083)

897.4 (153.7)
312.6 (166.0)
1072.1 (63.3)
326.5 (118.4)
1155.8 (67.1)
-175.5 (153.8)
875.0 (153.4)
288.5 (165.7)
1028.9 (62.0)
326.9 (116.1)
24.1 (9.9)
23.3 (13.0)
52.3 (6.2)
-16.4 (8.2)
51.1 (5.5)
-4.4 (12.5)

0.16
(0.075)
0.29
(0.013)
0.06
(0.27)
0.14
(0.098)
0.29
(0.011)
0.14
(0.089)
0.18
(0.059)
0.01
(0.73)

Intercept-No
Yes
Intercept-No
Yes

32.1 (4.5)
4.0 (7.7)
584.1 (49.8)
-239.6 (119.5)

0.013
(0.60)
0.16
(0.058)

43.5 (5.1)
23.7 (9.5)
414.1 (41.6)
-110.8 (95.3)

0.25
(0.022)
0.07
(0.26)

The parameter estimate for the intercept refers to the mean, and in the second line the
parameter estimate is the difference between the two categories. Comparisons with Pvalues <0.10 in at least one group are listed.
1
MTHFR 677TT individuals were removed for this analysis.
2
Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)
3
ND = Not Detectable, D = Detectable (Summers et al. 2010)
Biochemical Variables
Relationships between tHcy and folate derivatives. In African Americans tHcy
concentrations were inversely associated with total RBC folate (p=0.022, Table 2-5) and
RBC 5-MTHF levels (p=0.022) and trended towards being inversely associated with
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RBC THF (p=0.12) while being positively associated with plasma 5-MTHF levels
(p=0.028). In Caucasians the ratio of RBC 5-MTHF:THF was inversely related to tHcy
concentrations (p=0.009) and accordingly tHcy was inversely associated with RBC 5MTHF but only as a trend (p=0.12). In contrast to the inverse trend in African Americans,
RBC THF levels were positively associated with tHcy concentrations in Caucasians
(p=0.010).
Relationships among the folate derivatives. African Americans with detectable
levels of RBC 5,10-MTHF had RBC THF levels that were 13.8 nmol/L higher than those
with undetectable levels (31.7 vs 17.9 nmol/L, p=0.037, Table 2-4). In Caucasians a
similar relationship was observed where detectable RBC 5,10-MTHF was associated with
RBC THF levels that were 23.3 nmol/L higher than those with undetectable levels (47.4
vs 24.1 nmol/L, p=0.089). Only in Caucasians was detectable RBC 5,10-MTHF
associated with a lower ratio of RBC 5-MTHF:THF (35.9 vs 52.3, p=0.059). This
suggests that these two folate derivatives, THF and 5,10-MTHF, share some degree of
metabolic control.
In African Americans, RBC 5-MTHF levels were positively associated with RBC
THF levels (p=0.017, Table 2-5). Plasma 5-MTHF levels were positively associated with
total RBC folate (p<0.0001), specifically with RBC 5-MTHF levels (p<0.0001) as well as
the ratio of 5-MTHF:THF (p=0.001). In Caucasians, plasma 5-MTHF levels were
positively associated with total RBC folate concentrations (p=0.017), specifically with
RBC 5-MTHF levels (p=0.015). This relationship was similar to that observed in African
Americans.
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Relationships of tHcy and folate derivatives to B12 levels. In African
Americans B12 levels were inversely associated with tHcy levels (p=0.049) and positively
associated with total RBC folate (p=0.063), in particular with the folate derivatives 5MTHF (p=0.069) and THF (p=0.028). In Caucasians, B12 levels were positively
associated with total RBC folate only as a trend (p=0.13), in particular B12 was
significantly associated with THF levels (p=0.018).
Table 2-5. Proportion of variation (R2) in biochemical variables explained by
selected biochemical phenotypes.
Biochemical
Phenotypes
Dependent
Variables
tHcy (µmol/L)

Explanatory
Variables
Total RBC folate
(nmol/L) 2
RBC 5-MTHF
(nmol/L)
RBC THF (nmol/L)
Ratio RBC 5MTHF: THF
Plasma 5-MTHF
(nmol/L)
B12 (pmol/L)

Total RBC folate
(nmol/L) 2

RBC 5-MTHF
(nmol/L)

RBC THF
(nmol/L)
Ratio RBC 5MTHF: THF

Plasma 5-MTHF
(nmol/L)
B12 (pmol/L)

African-American (N=23)
Parameter
Estimate
(SE)
-0.003
(0.001)
-0.004
(0.001)
-0.090
(0.056)
-0.006
(0.035)
0.065
(0.028)
-0.004
(0.002)
16.12
(2.46)
0.58 (0.29)

RBC THF (nmol/L) 18.06
(6.95)
Plasma 5-MTHF
16.05
(nmol/L)
(2.37)
0.56 (0.29)
B12 (pmol/L)

B12 (pmol/L)
Plasma 5-MTHF
(nmol/L)

0.018
(0.008)
0.57 (0.15)

2

R (P-value)
0.23 (0.022)
0.23 (0.022)
0.11 (0.12)
0.002 (0.86)
0.21 (0.028)
0.17 (0.049)
0.67
(<0.0001)
0.16 (0.063)

Caucasian (N=21)1
Parameter
Estimate
(SE)
-0.002
(0.001)
-0.002
(0.001)
0.034
(0.012)
-0.054
(0.018)
-0.026
(0.019)
0.003
(0.002)
6.63 (2.52)
0.56 (0.35)

0.24 (0.017)

0.46 (2.01)

0.69
(<0.0001)
0.15 (0.069)

6.65 (2.47)
0.46 (0.35)

0.21 (0.028)

0.09 (0.04)

0.41 (0.001)

0.09 (0.21)

R2 (Pvalue)
0.08
(0.22)
0.12
(0.12)
0.30
(0.010)
0.31
(0.009)
0.09
(0.19)
0.07
(0.24)
0.27
(0.017)
0.12
(0.13)
0.003
(0.82)
0.28
(0.015)
0.08
(0.21)
0.26
(0.018)
0.01
(0.68)

Parameter estimate refers to the change in units of the dependent variable for every 1 unit
increase in the explanatory variable. Comparisons with P-values <0.10 in at least one
group are listed. (Summers et al. 2010) 1MTHFR 677TT individuals were removed for
this analysis. 2Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)
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Genetic associations with tHcy concentrations
In African Americans tHcy levels were 2.3 µmol/L higher in TYMS 1494del6
del/del homozygotes than insertion carriers (10.2 vs 7.9 µmol/L, p=0.023, Table 2-6).
MTR 2756AA homozygotes had 2.7 µmol/L higher tHcy than 2756G carriers (10.4 vs 7.7
µmol/L, p=0.006). In Caucasians there were no MTR 2756GG homozygotes, however
there was a significant difference between MTR 2756AA and 2756AG genotypes,
specifically 2756AA homozygotes had 2.0 µmol/L higher tHcy than 2756AG
heterozygotes (9.6 vs 7.6 µmol/L, p=0.017, Table 2-7). Caucasian MTHFR 677TT
homozygotes had 3.2 µmol/L higher tHcy than 677C carriers (12.2 vs 9.0 µmol/L,
p=0.012). MTHFR 1298C carriers had tHcy concentrations that were 1.8 µmol/L higher
than 1298AA homozygotes (9.7 vs 7.9, p=0.031).
Genetic associations with folate derivatives
MTR 2756A>G. African American MTR 2756AA homozygotes had total RBC
folate concentrations that were 286.4 nmol/L lower than 2756G carriers (777.2 vs 1063.6
nmol/L, p=0.042, Table 2-6). In particular RBC 5-MTHF was 280.6 nmol/L lower in
2756AA homozygotes (760.7 vs 1041.3 nmol/L, p=0.043). MTR 2756AA homozygotes
also had 14.1 nmol/L lower plasma 5-MTHF (25.5 vs 39.6 nmol/L, p=0.049). In
Caucasians MTR 2756AA homozygotes had a lower ratio of 5-MTHF:THF (37.2 vs 54.2,
p=0.061, Table 2-7), which indicated that this polymorphism was associated with the
proportional distribution of these two key forms of folate.
MTRR 66A>G. African American MTRR 66G carriers had higher levels of 5MTHF and lower levels of THF than 66AA homozygotes, but neither of these differences
were statistically significant. These differences were substantial enough for 66G carriers
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Table 2-6. Proportion of variation (R2) in biochemical variables explained by
selected genotypes in African Americans.
Dependent
Variables
tHcy (µmol/L)

African-American (N=23)
Parameter
R2
Estimate (SE)
(P-value)

Genotype
MTR
2756A>G

Intercept-AA
G Carrier

10.4 (0.7)
-2.7 (0.9)

TYMS
1494del6

Intercept-del/del
Ins Carrier

10.2 (0.7)
-2.3 (0.9)

0.31
(0.006)
0.22
(0.023)

Total RBC folate
(nmol/L) 1

MTR
2756A>G

Intercept-AA
G Carrier

777.2 (99.2)
286.4 (131.9)

0.18
(0.042)

RBC 5-MTHF
(nmol/L)

MTR
2756A>G

Intercept-AA
G Carrier

760.7 (97.9)
280.6 (130.2)

0.18
(0.043)

RBC THF
(nmol/L)

RFC1
80A>G

Intercept-AA
G Carrier

25.7 (2.8)
-10.2 (3.4)

0.30
(0.007)

Ratio RBC 5MTHF: THF

MTRR
66A>G

Intercept-AA
G Carrier

45.4 (3.9)
13.8 (5.9)

TYMS
5’ VNTR2

Intercept-3R/3R
2R Carrier

41.3 (4.4)
17.2 (5.9)

RFC1
80A>G

Intercept-AA
G Carrier

39.3 (4. 5)
18.7 (5.5)

0.21
(0.028)
0.32
(0.010)
0.35
(0.003)

MTR
2756A>G
TYMS
5’ VNTR2

Intercept-AA
G Carrier
Intercept-3R/3R
2R Carrier

25.5 (5.1)
14.1 (6.8)
26.1 (5.7)
14.4 (7.7)

0.17
(0.049)
0.16
(0.077)

Plasma 5-MTHF
(nmol/L)

P-values <0.10 are listed.
1
Total RBC folate = (RBC 5-MTHF) + (RBC THF) + (RBC 5, 10-MTHF)
2
Genotypes containing 4R were removed from the analysis. (Summers et al. 2010)
to have a higher ratio of 5-MTHF:THF (59.3 vs 45.5, p=0.028). In Caucasians there was
no such relationship observed between this polymorphism and any of the folate
derivatives.
MTHFR 677C>T. In Caucasians, although total RBC folate concentrations were
not significantly different between MTHFR 677C carriers and 677TT homozygotes, the
individual folate derivatives were drastically different. MTHFR 677TT homozygotes had
426.3 nmol/L lower RBC 5-MTHF levels (696.0 vs 1122.3 nmol/L, p=0.007). RBC THF
was 419.7 nmol/L higher in 677TT homozygotes (457.2 vs 37.5 nmol/L, p<0.0001).
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Hence the ratio of RBC 5-MTHF:THF was drastically lower in 677TT homozygotes (5.4
vs 42.9, p=0.0004). RBC 5,10-MTHF was detectable in 4 out of 5 677TT homozygotes,
in 10 out of 13 677CT heterozygotes, and in only 2 out of 8 677CC homozygotes
(p=0.043, Table 2-8). The mean of the detectable concentrations was much higher in
677TT homozygotes than the means of the detectable concentrations in 677CC and CT
genotypes (149.4, 9.8, and 9.7 nmol/L, respectively).
MTHFR 1298A>C. Caucasian MTHFR 1298C carriers had 27.0 nmol/L higher
RBC THF levels than 1298AA homozygotes (49.1 vs 22.1 nmol/L, p=0.046). Although
RBC 5-MTHF levels were not significantly different, the ratio of 5-MTHF:THF was
lower in 1298C carriers (33.4 vs 55.6, p=0.008).
TYMS 5’ VNTR and 1494del6. In African Americans TYMS 5’ VNTR 2R
carriers had higher ratios of 5-MTHF:THF than 3R/3R homozygotes (58.5 vs 41.3,
p=0.010). 2R carriers also had 14.4 nmol/L higher plasma 5-MTHF (40.5 vs 26.1 nmol/L,
p=0.077). In Caucasians TYMS 1494del6 deletion carriers had total RBC folate levels that
were 218.1 nmol/L higher than ins/ins homozygotes (1238.0 vs 1019.9 nmol/L, p=0.096).
Specifically RBC 5-MTHF levels were 217.4 nmol/L higher in 1494del6 deletion carriers
(1194.8 vs 977.4 nmol/L, p=0.092). Plasma 5-MTHF levels were 21.7 nmol/L higher in
1494del6 deletion carriers (57.5 vs 35.8 nmol/L, p=0.030).
RFC1 80A>G. African American RFC1 80G carriers had 10.2 nmol/L lower
RBC THF levels than 80AA homozygotes (15.5 vs 25.7 nmol/L, p=0.007). Even though
RBC 5-MTHF levels were not statistically different, 80G carriers had ratios of 5MTHF:THF that were higher than 80AA homozygotes (58.0 vs 39.3, p=0.003). A similar
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relationship was observed in Caucasians, 80G carriers had higher ratios of 5-MTHF:THF
(49.5 vs 26.5, p=0.012).
Table 2-7. Proportion of variation (R2) in biochemical variables explained by
selected genotypes in Caucasians.
Dependent
Variables
tHcy (µmol/L)

Caucasian (N=26)
Parameter
R2
(P-value)
Estimate (SE)

Genotype
MTHFR
677C>T

Intercept-C Carrier
TT

8.9 (0.5)
3.2 (1.2)

0.24
(0.012)

RBC 5-MTHF
(nmol/L)

MTHFR
677C>T

Intercept-C Carrier
TT

1122.3 (63.6)
-426.3 (145.0)

0.26
(0.007)

RBC THF
(nmol/L)

MTHFR
677C>T

Intercept-C Carrier
TT

37.5 (29.4)
419.7 (67.1)

0.62
(<0.0001)

Ratio RBC 5MTHF: THF

MTHFR
677C>T

Intercept-C Carrier
TT

42.9 (4.0)
-37.6 (9.2)

0.41
(0.0004)

Caucasian (N=21)1
Homocysteine
(µmol/L)

MTHFR
1298A>C

Intercept-AA
C Carrier

7.9 (0.6)
1.8 (0.8)

MTR
2756A>G

Intercept-AA
AG

9.6 (0.5)
-2.0 (0.8)

0.22
(0.031)
0.27
(0.017)

Total RBC folate
(nmol/L) 2

TYMS
1494del6

Intercept-ins/ins
Del Carrier

1019.9 (101.7)
218.1 (124.6)

0.14
(0.096)

RBC 5-MTHF
(nmol/L)

TYMS
1494del6

Intercept-ins/ins
Del Carrier

977.4 (100.2)
217.4 (122.7)

0.14
(0.092)

RBC THF
(nmol/L)

MTHFR
1298A>C

Intercept-AA
C Carrier

22.1 (9.6)
27.0 (12.7)

0.19
(0.046)

Ratio RBC 5MTHF: THF

MTHFR
1298A>C
MTR
2756A>G
RFC1
80A>G

Intercept-AA
C Carrier
Intercept-AA
AG
Intercept-AA
G Carrier

55.6 (5.6)
-22.1 (7.4)
37.2 (5.0)
17.0 (8.6)
26.5 (7.0)
23.0 (8.3)

0.32
(0.008)
0.17
(0.061)
0.29
(0.012)

Plasma 5-MTHF
(nmol/L)

TYMS
1494del6

Intercept-ins/ins
Del Carrier

35.8 (7.5)
21.7 (9.2)

0.23
(0.030)

P-values <0.10 are listed. (Summers et al. 2010)
1
MTHFR 677TT individuals were removed for this analysis.
2
Total RBC folate = (RBC 5-MTH) + (RBC THF) + (RBC 5, 10-MT)
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Table 2-8. Distribution of MTHFR 677 genotypes in Caucasians by detection of RBC
5,10-MTHF.
RBC 5,10-MTHF
Not
Detectable
(n)

Detectable
(n)

CC

6

2

CT

3

10

9.7 [4.9-20.0]

TT

1

4

149.4 [74.6-224.7]

Genotype
MTHFR
677

1

P
Detectable Mean
value (nmol/L) [Range]1
0.043

9.8 [6.8-12.7]

Mean of individuals having detectable levels. (Summers et al. 2010)
Folate Phenotypes
Type I-IV folate phenotypes were defined in the publication of the LC/MRM/MS

method of RBC folate derivative measurements (Huang et al. 2008). A Type I
distribution of RBC folate derivatives was considered to be 5-MTHF >95% of total folate
with THF and 5,10-MTHF each <5%. A Type II was considered to be 5-MTHF <95%
with THF 5-20% and 5,10-MTHF still <5%. A Type III was 5-MTHF >55% with THF
>20% and 5,10-MTHF >5%. A Type IV was 5-MTHF <55% with THF >20% and 5,10MTHF >5%. A depiction of Types I-IV with the Caucasians in this study is presented in
Figure 2-3. When the number of individuals in each folate phenotype was broken down
by MTHFR 677/1298 combined genotypes, it was obvious that the double heterozygotes
(677CT/1298AC) and the 677TT/1298AA homozygotes were associated with Types IIIV, while the four other combined genotypes were strictly Type I (Table 2-9).
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Percent Total RBC Folate

Figure 2-3. Relative amounts of RBC folate derivatives in each folate phenotype in
Caucasians.

100
90
80
70
60
50
40
30
20
10
0
I

II
5-mTHF

Type
THF

III

IV

5,10-mTHF

Table 2-9. Number of Caucasians in each folate phenotype by MTHFR 677/1298
combined genotypes.
MTHFR
Type I II
III IV
677/1298
CC/AA
4
0
0
0
CC/AC
2
0
0
0
CC/CC
2
0
0
0
CT/AA
5
0
0
0
CT/AC
5
3
0
0
TT/AA
1
0
1
3
(n)
2.5 Discussion
High Hcy and low folate are associated with cardiovascular disease, which is
relevant to the male population in the Industrial Workers study. Therefore,
polymorphisms or interactions of polymorphisms which affect Hcy and folate levels
could alter an individual’s risk of developing cardiovascular disease. MTHFR 677TT
individuals have high tHcy levels and low folate levels in the Industrial Workers Study
and other populations (Harmon et al. 1996; Jacques et al. 1996). MTHFR 677 TT
individuals not only have altered folate/Hcy phenotypes but also they have altered risk of
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diseases, whish are associated with high Hcy and low folate. A meta-analysis has
established that MTHFR 677TT individuals are at 20% increased risk of venous
thrombosis compared to 677CC individuals (Den Heijer et al. 2005).
Large-scale studies by Dekou et al. (2001) and Fredriksen et al. (2007) found that
CBS 844ins68 carriers had Hcy levels significantly lower than noncarriers. Other studies
have not been able to find a statistically significant difference in fasting Hcy levels
between CBS 844ins68 genotypes (De Stefano et al. 1998; Kluijtmans et al. 2003; Tsai et
al. 2000; Tsai et al. 2009). Since the 844ins68 allele is reported to result in skipping of
the inserted sequence, the proposed mechanisms by which the 844ins68 allele could have
an effect are: an increase in CBS activity, an up regulation of the amount of mRNA, or
perhaps this polymorphism is in linkage disequilibrium with another functional
polymorphism (Tsai et al. 1996; Tsai et al. 1999).
MTHFR 677C>T and CBS 844in68 genotypes were shown to interact and effect
Hcy levels in two studies in European males. The first study included several countries in
Europe and found that the CBS 844ins68 allele may counterbalance the Hcy raising effect
of the MTHFR 677TT genotype (De Stefano et al. 1998). The second study was from the
United Kingdom and confirmed this finding (Dekou et al. 2001) while a third study also
in the UK did not replicate this finding in a population at high risk for coronary artery
disease (Bowron et al. 2005). The Industrial Workers study was based on a population of
Northern Irish males and the results supported the finding that MTHFR 677TT
homozygotes who were also CBS 844ins68 allele carriers had significantly lower tHcy
levels than 677TT/844ins68 noncarriers. In addition serum folate concentrations were
higher in 677TT/844ins68 carriers and this was a novel finding. Concentrations of tHcy
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and folate in 677TT/844ins68 carriers were similar to those found in 677CC and 677CT
individuals. The interaction of these polymorphisms has an impact on Hcy and folate
phenotypes, therefore it is possible that gene-gene interactions could contribute to risk for
diseases such as cardiovascular disease. The excess risk conferred by MTHFR 677TT
homozygosity may be negated by CBS 844ins68 carrier status. Large studies with enough
power to examine gene-gene interactions will be required to test this observation and to
examine the effects of gene-gene interactions on disease risk.
A high Hcy and low folate phenotype is associated with pregnancy complications
such as neural tube defects (NTDs), which is relevant to the female population in the
Premenopausal Women study. The first proof that multivitamins containing folic acid
could prevent NTDs came from a nonrandomized controlled trial by Smithells et al.
(1980), which showed 0.6% of mothers given multivitamins had a child with an NTD
compared to 5% of unsupplemented mothers who had a child with an NTD. The
Premenopausal Women study represents a relevant population in which to study the
effects of genetic polymorphisms and lifestyle factors on Hcy and folate levels. In this
study African American and Caucasian analyses were carried out separately for several
reasons. Biochemical variables as well as genotype distributions were significantly
different between the two groups. African American and Caucasian women have
different prevalences of pregnancy related complications. Caucasians have a higher
prevalence of carrying a child with spina bifida compared to African Americans
(Feuchtbaum et al. 1999) and conversely, African Americans have a higher prevalence of
preeclampsia (Eskenazi et al. 1991), low-birth-weight infants, and preterm birth (Heron et
al. 2010). An individual woman’s risk for poor pregnancy outcome is multifactorial and
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complex, but may be due to lifestyle factors and genetic background. Therefore the
Premenopausal Women Study was designed to use high precision methodology to
compare the effect of folate related genotypes and lifestyle factors on biochemical
phenotypes in a small number of African American and Caucasian women in order to
elucidate the reasons for the differences in risk detailed above.
The MTHFR 677TT genotype is associated with high Hcy and low folate levels
(Harmon et al. 1996; Jacques et al. 1996), and with increased risk for NTDs (van der Put
et al. 1995; Whitehead et al. 1995). In the Premenopausal Women study there were no
MTHFR 677TT homozygotes in African Americans and there were 5 (19.2%) in
Caucasians. We observed that MTHFR 677TT homozygotes had higher tHcy levels and
altered RBC folate distributions compared to 677C carriers. RBC folate distributions in
677TT homozygotes consisted of relatively high THF and 5,10-MTHF and relatively low
5-MTHF levels. These quantitative changes resulted in ratios of RBC 5-MTHF:THF that
were lower in 677TT homozygotes. These altered RBC folate distributions are consistent
with a study by Bagley and Selhub (1998) which found that MTHFR 677TT
homozygotes had low RBC 5-MTHF and high RBC formylated THF levels. Since the
677TT genotype was responsible for a large amount of the variation present in tHcy and
folate levels, biochemical and genetic analyses in the Premenopausal Women study were
performed in the subset of Caucasians that excluded the 677TT homozygotes.
Logically polymorphisms in enzymes of the folate/Hcy pathway should be
associated with risk for NTDs based on their association with changes in the levels of
Hcy and folate. The following polymorphisms confer risk via the mother’s genotype:
MTR 2756G carriers, MTRR 66A carriers, MTHFD1 1958AA, RFC1 80GG, and DHFR
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c.86+60_78 del/del (Brody et al. 2002; De Marco et al. 2003; Doolin et al. 2002; Johnson
et al. 2004; Wilson et al. 1999). Polymorphisms which have an effect on Hcy and folate
levels in the Premenopausal Women Study therefore are relevant to risk for carrying a
child with NTDs. Genotype distributions for 5 of the 11 polymorphisms which we
studied were significantly different between African American and Caucasian women. Of
the above mentioned risk-associated genotypes only MTHFR 677TT and MTHFD1
1958AA had higher frequencies in Caucasians while the other above mentioned genotype
distributions were not significantly different. In Caucasians, the MTHFD1 1958G>A
polymorphism was the only one that was not in Hardy-Weinberg equilibrium. This
observation has been documented in other control populations, such as the Irish (ParleMcDermott et al. 2006a).
In the Premenopausal Women study polymorphisms other than MTHFR 677C>T
had a significant effect on folate/Hcy phenotype. The ratio of RBC 5-MTHF:THF may be
a better indicator of alterations in RBC folate distribution than the absolute concentration
of either of the individual folate derivatives. The following findings involving the ratio of
5-MTHF:THF have not been previously investigated and are therefore novel. The
MTHFR 1298A>C polymorphism has conflicting associations in the literature. The
1298C allele has been associated with both increased RBC folate (Parle-McDermott et al.
2006b) and increased Hcy (Ulvik et al. 2007). In the Premenopausal Women study
Caucasians 1298C carriers had increased tHcy and were consistent with the finding by
Ulvik et al. (2007). Also we found that Caucasian 1298C carriers had increased RBC
THF and a lower ratio of 5-MTHF:THF.

41

The MTR 2756A>G polymorphism is associated with decreased Hcy levels
(Fredriksen et al. 2007; Harmon et al. 1999; Tsai et al. 2009) and in the Premenopausal
Women study both African American and Caucasian 2756G carriers had lower tHcy
levels. Only African American 2756G carriers had higher total RBC folate, in particular
RBC 5-MTHF, and higher plasma 5-MTHF. This agrees with a study by Chen et al.
(2001) which also found that MTR 2756GG homozygotes had higher plasma folate and
lower Hcy levels.
The TYMS 1494del6 polymorphism has been associated with increased RBC
folate and decreased Hcy levels (Kealey et al. 2005). Results from the Premenopausal
Women study were consistent; Caucasian deletion carriers had higher total RBC folate, in
particular RBC 5-MTHF, and also had higher plasma 5-MTHF concentrations. In
contrast to Caucasians, African American insertion carriers had lower tHcy levels.
African Americans had a different distribution of TYMS 1494del6 genotypes than
Caucasians such that there were not enough ins/ins individuals (n=2) to be analyzed
separately and were therefore combined with the heterozygous genotype for analysis. In
Caucasians the same was true for del/del individuals (n=2) and hence the small number of
study subjects may be limiting the analyses of ‘rare’ homozygotes. The other
polymorphism in TYMS examined in the Premenopausal Women study was the 5’ VNTR
with 2 or 3 repeats (2R or 3R). African American 2R carriers had higher plasma 5-MTHF
levels. This was in agreement with a study by Trinh et al. (2002), which showed that
3R/3R homozygotes had lower plasma folate levels. Also in the Premenopausal Women
study African American 2R carriers had higher ratios of RBC 5-MTHF:THF.
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The RFC1 80A>G polymorphism is associated with lower RBC folate
concentrations (Stanislawska-Sachadyn et al. 2009). Our study found that African
American 80G carriers had lower RBC THF levels and that in both African Americans
and Caucasians 80G carriers had a higher ratio of RBC 5-MTHF:THF. It is unclear
though how this polymorphism, which is in a transport protein, would have an effect on
the distribution of RBC folates.
Multiple reports have established that Hcy and folate levels have an inverse
relationship (Kang et al. 1987; Selhub et al. 1993). In the Premenopausal Women study
total RBC folate, and in particular RBC 5-MTHF, had inverse relationships with tHcy in
African Americans. In Caucasians RBC THF had a direct association with tHcy while the
ratio of RBC 5-MTHF:THF had an inverse relationship with tHcy. This well established
inverse relationship between Hcy and folate levels may not be so simple. Observations
from our study indicate that individual folate derivatives or the ratio of RBC 5MTHF:THF may be more useful in predicting Hcy concentrations. Short term pools of
folate represented by plasma folate should be directly related to long term pools of folate
represented by RBC folate. In the Premenopausal Women study plasma 5-MTHF levels
had a direct association with RBC 5-MTHF levels in both African Americans and
Caucasians.
Vitamin B12 levels were inversely associated with Hcy and directly associated with
folate levels in several studies (Konstantinova et al. 2007; Thuesen et al. 2010). In
African Americans in the Premenopausal Women study B12 levels had an inverse
relationship with tHcy and with the ratio of RBC 5-MTHF:THF and a direct relationship
with total RBC folate, RBC 5-MTHF, and RBC THF. In Caucasians B12 levels only had a
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direct relationship with RBC THF. These relationships indicate that B12 levels are
important determinants of the generation of RBC THF from 5-MTHF, because MTR
requires B12 as a cofactor in this reaction.
Smoking has been associated with higher Hcy and lower folate levels (Brown et al.
2004b; Gabriel et al. 2006; Stanislawska-Sachadyn et al. 2008b) as well as poor
pregnancy outcome, including orofacial clefts, preterm birth, and low-birth-weight
infants (Meyer et al. 1976; Wyszynski et al. 1997). In the Premenopausal Women study
African American smokers had lower total RBC folate, specifically 5-MTHF, as well as
lower plasma 5-MTHF, which is consistent with other studies that found lower RBC
folate in Caucasian smokers (Brown et al. 2004b; Gabriel et al. 2006).
In the literature alcohol use is associated with higher Hcy levels (Jacques et al. 2001;
Laufer et al. 2004) and contradictorily with higher folate levels (Ubbink et al. 1998).
African American alcohol users in the Premenopausal Women study had higher tHcy
levels while Caucasian alcohol users had higher total RBC folate, in particular 5-MTHF.
There are two plausible reasons that alcohol intake could be associated with higher folate
levels. It is possible that the primary alcoholic beverage consumed was beer which
contains folic acid (Ubbink et al. 1998) or that alcohol is capable of inhibiting MTR and
causes a methylfolate trap, allowing for the accumulation of 5-MTHF (Mason and Choi
2005).
Caucasians have a higher risk of carrying a child with spina bifida compared to
African Americans (CDC 2009). The explanation for this difference in prevalence may
lie in the differences in genotype frequencies and in the effect of lifestyle factors on
biochemical phenotypes. The quantitatively precise methods used in this study to
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measure individual folate derivatives allowed a detailed description of the effect of the
polymorphisms in enzymes of the folate/Hcy pathway. Genetic and lifestyle factors
which contribute to a dysregulation of folate/Hcy metabolism may increase risk for
various clinical conditions, such as carrying a child with spina bifida. This study was
relatively small and these preliminary findings should be confirmed in larger studies
using similar analytical methods.
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Chapter 3: Polymorphisms Associated with the Risk of Neural Tube Defects
3.1 Abstract
Spina bifida is a neural tube defect which is associated with high Hcy and low
folate. Spina bifida can be prevented with periconceptional supplementation with folic
acid. The mechanism by which folate can prevent spina bifida is unknown. Common
functional polymorphisms within genes of the enzymes of the folate/Hcy metabolic
pathway are good candidates for examining the effect of genetic variants on the risk of
spina bifida. These genetic variants are capable of conferring risk at both levels, the risk
of the child and the risk of the mother for carrying a child with spina bifida.
In the Neural Tube Defects study, which included approximately 500 families, we
examined 7 polymorphisms within 5 genes of the enzymes of the folate/Hcy pathway.
Transmission disequilibrium tests (TDT) were applied to child trios and mother trios to
check for preferential transmission of any allele at both the level of the child and the
mother. Hardy-Weinberg equilibrium was also assessed within each of the five subject
types, which included children, mothers, fathers, maternal grandmothers, and maternal
grandfathers, as a measure of deviation from the expected, and hence a possible causative
genotype.
We did not find any of the 7 polymorphisms to be significant within the TDT
analyses. There were only two polymorphisms which deviated from Hardy-Weinberg
equilibrium, which were MTHFR 677C>T in fathers and TYMS 1494del6 in children. In
both instances the observed genotypes lacked a significant number of expected
heterozygous genotypes while both wild-type and variant homozygous genotypes were
equally overrepresented. This did not provide any clear evidence of at risk genotypes.
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3.2 Introduction
3.2.1 Neural Tube Defects
Neural tube defect (NTD) is a general term which includes the birth defects spina
bifida, anencephaly, and encephalocele. Spina bifida is itself a broad term for a group of
medical conditions (such as myelomeningocele and meningocele). More specifically
myelomeningocele is an open defect where a herniation of neural tissue is present as a
saclike membrane on the spine due to failure of fusion of the neural tube. Meningocele is
a closed defect, skin covered, where the meninges are herniated through the spine
(Mitchell 2008). Anencephaly refers to failure of the neural tube to close resulting in
missing parts of the brain and skull. Encephalocele refers to a saclike protrusion of the
brain through the skull, again caused by failure of the neural tube to close completely.
Spina bifida is a common congenital defect with a prevalence ranging from 0.2-3
per 1,000 births according to regional and population-specific variation. The health costs
associated with medical care for an individual with spina bifida are substantial because of
increased risk for hydrocephalus, leg weakness and paralysis, bowel and bladder
dysfunction, and orthopedic abnormalities such as hip dislocation (Mitchell et al. 2004).
3.2.2 Folic Acid Fortification
In 1991 a study was published by the Medical Research Council which showed
that folic acid had a 72% protective effect (RR 0.28 [0.12-0.71]) in women who
previously had a pregnancy affected by a NTD (Medical Research Council 1991). This
established that periconceptional folic acid could prevent recurrence of NTDs.
Subsequently a study by Cziezel and Dudas (1992) showed that first occurrence of NTDs
could be prevented by periconceptional folic acid. Although the specific mechanism by
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which folic acid provides a protective effect is unknown, the US Public Health service in
1992 recommended that women planning to get pregnant should have 400 µg of folic
acid per day (CDC 1992). This recommendation was supported by the results of a large
nonrandomized intervention study which took place in the north and south regions of
China (Berry et al. 1999). The protective effect of 400 µg folic acid was greater in the
northern region which had a higher prevalence of NTDs, but still showed a protective
effect in the southern region.
United States
Mandatory folic acid fortification of grain products was in place by 1998. It was
designed to improve the folate status of reproductive aged women by increasing folic
acid intake by an estimated 100 µg a day. A study by Jacques et al. (Jacques et al. 1999)
compared pre- and post-fortification levels of folate and Hcy and found significantly
increased folate and decreased Hcy concentrations as well as a reduction in the
prevalence of folate deficiency (<7 nmol/L in plasma) from 22.0% to 1.7% (p<0.001) and
also a reduction in the prevalence of hyperhomocysteinemia (>13 µmol/L) from 18.7% to
9.8% (p<0.001). Rates of spina bifida births declined by approximately 20% after
fortification (Honein et al. 2001; Williams et al. 2002).
Canada
Folic acid fortification of cereal grain products was mandatory by 1998 in Canada
providing an estimated additional intake of 200 µg a day (Ray et al. 2002b). RBC folate
levels in women of reproductive age increased by 41% after fortification (Ray et al.
2002a). The prevalence of NTDs had declined by 46% when pre- fortification was
compared with post-fortification rates (De Wals et al. 2007).
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South America
In Chile the Ministry of Health has required the addition of folic acid to wheat
flour since 2000. The estimated additional intake of folic acid was designed to be 400 µg
a day. Fortification caused both serum and RBC folate levels to increase in women of
reproductive age when pre- and post-fortification levels were compared (Hertrampf et al.
2003). The prevalence of NTDs decreased by 31% after fortification (Castilla et al.
2003).
Concerns
Reservations about implementing folic acid fortification include the masking of
B12 deficiency and increasing the risk for cancer. B12 deficiency is common in the elderly
due to loss of ability to digest and absorb B12 from food. High intakes of folic acid may
appear to cure macrocytic anemia, which is often the result of B12 deficiency (Johnson
2007). In a recent study in the elderly high serum folate levels accompanying B12
deficiency were associated with twice the rate of anemia and cognitive impairment when
compared with normal serum folate levels and B12 deficiency (Morris et al. 2007). As for
cancer risk, in a study in ischemic heart disease patients those taking folic acid had an
increased rate of cancer, hazard ratio (HR) 1.21 [1.03-1.41] (Ebbing et al. 2009). Folic
acid supplementation is also associated with increased risk of colorectal neoplasia in
those with a recent history of colorectal adenomas (Cole et al. 2007), and hence the worry
is that pre-existing cancers will grow.
3.2.3 Selected Polymorphisms Associated with NTDs
The process of neural tube closure involves tightly controlled expression of genes,
which relies upon specific methylation patterns, proliferation/apoptosis, migration, and
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differentiation of specific cells (Beaudin and Stover 2007). Many of these processes
overlap with important functions of the folate/Hcy pathway such as methylation of DNA
and proteins as well as nucleotide synthesis. Compared to mothers that had normal
pregnancies, mothers that gave birth to children with spina bifida had lower folate levels
and also higher Hcy concentrations (Lucock et al. 1998). This dysregulation of folate/Hcy
phenotype has led to the examination of genetic variants in candidate genes, specifically
of common functional polymorphisms within enzymes of the folate/Hcy metabolic
pathway.
Family history of NTDs is a strong risk factor and in siblings of affected
individuals risk of NTD ranges from 2.4-5.2%, which is much higher than prevalences in
the general population (Carter and Evans 1973; Hunter 1984). There are two basic study
types which are capable of analyzing the risk between genetic variants and NTDs. A
case-control study compares genotype frequencies between these two groups and arrives
at an estimate of the odds ratio (OR). A family-based study uses either the transmission
disequilibrium test (TDT) or log-linear modeling to assess the transmission of alleles or
the frequencies of mating types (parents’ genotypes) and outcomes (child’s genotype),
respectively. Another less specific test for association is whether the genotypes are in
Hardy-Weinberg equilibrium. Overrepresentation of a homozygous genotype above the
expected value calculated from the Hardy-Weinberg equation could mean that the
genotype is associated with the medical condition. This test is less specific because there
is a range of reasons that genotype frequencies could deviate from Hardy-Weinberg
equilibrium, including inbreeding, non-random mating, selection, or even a problem with
the genotyping method itself.
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MTHFR 677C>T and 1298A>C
Two studies initially found that the MTHFR 677TT genotype was associated with
increased risk of spina bifida via case-control studies (van der Put et al. 1995; Whitehead
et al. 1995). Some studies were not able to show that this polymorphism confers risk for
NTDs (Mornet et al. 1997; Papapetrou et al. 1996). A meta-analysis by Botto and Yang
(2000) confirmed that the MTHFR 677TT genotype carried increased risk for spina bifida
in both infants as well as mothers with a pooled odds ratio of 1.8 and 2.0, respectively.
Subsequently Kirke et al. (2004) showed that the 677CT genotype also carried increased
risk in a case-control study. When the population attributable fraction was calculated the
677CT genotype was responsible for a similar number of NTDs within the Irish
population as the 677TT genotype (14.9% vs 11.3%, respectively).
When MTHFR 1298A>C genotypes were studied in combination with the
677C>T genotypes in a NTD study from the Netherlands, none of the combination
genotypes had a significantly increased OR (van der Put et al. 1998), but in vitro
experiments on MTHFR enzyme activity showed the 677CT/1298AC double
heterozygotes had decreased activity compared to heterozygosity for either
polymorphism alone. An Italian NTD study found increased risk for 1298C carriers in
children and mothers (OR 2.2 and 2.7, respectively) although there was no stratification
by 677C>T genotypes (De Marco et al. 2002).
CBS 844ins68
CBS 844ins68 genotypes were not associated with the risk of NTDs in an Irish
study (Ramsbottom et al. 1997). It was noted that in this study among those who were
MTHFR 677TT homozygotes there was a higher percentage of CBS 844ins68 carriers in
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children with NTDs compared to controls (27.0% vs 12.8%, respectively) but this was
not statistically significant. Reanalysis of this study’s data by Botto and Mostroiacovo
(1998) found significantly increased risk of NTDs in MTHFR 677TT/CBS 844ins68
carriers, OR 5.2 [1.4-21.2]. Another study found similar results that the CBS 844ins68
polymorphism alone carries no significant risk but that the combination genotype
MTHFR 677TT/CBS 844ins68 carrier had an OR of 3.69 [1.04-13.50] (de Franchis et al.
2002). A UK study also found that MTHFR 677C>T and CBS 844in68 interacted to
significantly increase NTD risk in children (Relton et al. 2004 Apr). A study in Germany
was unable to replicate these findings using case-control and TDT analyses (Richter et al.
2001). Overall the evidence is compelling that this combination of genotypes may
increase risk for NTDs. Although this combination of genotypes has been associated with
lower Hcy concentrations in men (De Stefano et al. 1998; Dekou et al. 2001; Summers et
al. 2008b), it is possible that during development it could have a different effect.
TYMS 5’ VNTR and 1494del6
A study by Volcik et al. (2003) found that in Caucasians both the TYMS 1494del6
ins/ins genotype, OR 3.6 [1.3-10.1], and the TYMS 5’ VNTR 2R/2R genotype, OR 4.0
[1.8-8.8], were associated with increased NTD risk in children. Also the combined TYMS
ins/ins and 2R/2R genotype was significantly associated with increased risk, OR 4.7 [1.119.8]. A subsequent study in the UK did not find any association between TYMS 5’
VNTR genotypes and risk of NTDs using case-control and TDT analyses (Wilding et al.
2004).
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DHFR c.86+60-78
In a US study by Johnson et al. (2004) found that the DHFR c.86+60_78 del/del
genotype was more frequent in mothers than controls, OR 2.04 [0.94-4.29], and genotype
frequencies were not in Hardy-Weinberg equilibrium in mothers. In contrast a study
found that the DHFR c.86+60_78 deletion allele provided a protective effect in mothers
in an Irish population (Parle-McDermott et al. 2007). A study in the Netherlands did to
find any association between DHFR c.86+60_78 genotypes and NTD risk in a casecontrol study (van der Linden et al. 2007).
MTHFD1 1958G>A
A study by Brody et al. (2002) in the Irish showed that the MTHFD1 1958AA
genotype was overrepresented in mothers of NTD children compared to controls, OR
1.52 [1.16-1.99]. A second Irish study confirmed that the MTHFD1 1958AA genotype
was associated with increased NTD risk in mothers, OR 1.49 [1.07-2.09] (ParleMcDermott et al. 2006a), which was consistent with their earlier finding using a separate
cohort. In an Italian population it was found that both 1958GA (OR 1.69) and 1958AA
(OR 1.91) individuals had increased risk of NTD in children (De Marco et al. 2006). Also
this study found that mothers who were carriers of the 1958A allele had increased risk
(OR 1.67) and that TDT analyses confirmed there was a significant excess transmission
of the 1958A allele.
The selected polymorphisms discussed above were chosen based on their
association with NTD risk and were genotyped in a large family based study in the US
population.

53

3.3 Methods
3.3.1 NTD Study
Subjects
The NTD study included 671 families with at least one member affected with
spina bifida., as previously described (Mitchell 2008). The family structure that this study
intended to capture was a “pent”. A complete pent includes the affected child, mother,
father, and maternal grandparents. This design allows for assessment of maternal and
embryonic genetic effects. Families were recruited between November 1997 and April
2006 by the Spina Bifida Research Resource through the Children’s Hospital of
Philadelphia in Philadelphia, Pennsylvania; the Alfred I. Dupont Hospital for Children in
Wilmington, Delaware; local chapters of the Spina Bifida Association of America;
colleagues; and the study website. The study was approved by the Institutional Review
Boards of the Texas A&M University, the University of Pennsylvania School of
Medicine, and each of the participating hospitals. Each subject gave informed consent
and when appropriate assent was given. Interview information included pregnancy
history, supplement use, and details of the affected individual’s lesion.
Affected individuals and their families were excluded if spina bifida was
determined to be syndromic (due to pregestational diabetes, teratogenic exposure to
anticonvulsant medication, or suspected co-occurring syndrome such as deletion of
22q11), failure to complete the interview, or type of neural tube defect. Subsequent
analyses were based on affected individuals with open spina bifida. The characteristics of
the affected individuals include a slight predominance of females and a majority of nonHispanic Caucasians as previously described (Mitchell 2008). It should be noted that
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interview data was not directly accessible during these statistical analyses and therefore
subgroup analyses are not included.
Genotyping
Genomic DNA was extracted from whole blood using Generation Capture
Columns (Gentra Systems) or using QIAamp DNA Mini Kits (Qiagen) according to the
manufacturer’s instructions. DNA was extracted from saliva samples using Oragene kits
(DNA Genotek Inc, Ontario, Canada) according to the manufacturer’s instructions. DNA
was also extracted from buccal swabs using the following procedure. Samples were
vortexed for 5min in 600ul 50mM NaOH, heated at 95°C for 10min and neutralized with
120ul 1M Tris (pH 8.0).
TaqMan genotyping methods were performed as previously described for
MTHFR 677C>T (Summers et al. 2008a), MTHFR 1298A>C (Summers et al. 2008a),
and MTHFD1 1958G>A (Summers et al. 2010). Genotypes were only accepted as valid
for TaqMan runs in which the Fam or Vic signals crossed the threshold, which was set
based on background signals of Fam and Vic, with Ct fewer than 40 cycles. The MTHFR
677C>T assay had a 10% failure rate compared to 1-3% for the other TaqMan assays;
most of the MTHFR 677C>T assay failures occurred in DNA derived from buccal
samples.
Size difference PCR assays were performed essentially as previously described
for CBS 844ins68 (Summers et al. 2010), DHFR c.86+60_78, TYMS 1494del6 (Summers
et al. 2008a), and TYMS 5’ VNTR (Summers et al. 2010) with the following changes. The
CBS 844ins68 assay used modified primer sequences, forward (5’GGTTTCTCATCCTGCCTCTG-3’) and reverse (5’-GTTGTCTGCTCCGTCTGGTT55

3’). TYMS 5’UTR genotypes were deemed unreliable in buccal samples and therefore
genotypes were accepted for only blood and saliva samples, which were considered to be
high quality DNA samples.
Statistics
All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary,
NC). Hardy-Weinberg equilibrium was tested for all 7 polymorphisms within each of the
subject types. The transmission disequilibrium test (TDT) (Spielman et al. 1993)
determines whether the frequency of allele transmission from heterozygous parents to
affected offspring differs significantly from the Mendelian expectation of equal
transmission of the alleles. TDT analyses were calculated for each polymorphism in child
trios (child, mother, and father) and mother trios (mother, maternal grandmother, and
maternal grandfather). Individuals with TYMS 5’ VNTR genotypes containing the 4R
allele were excluded from the TDT analyses. Families with more than one affected child
were included with one trio for each child.
3.4 Results
3.4.1 NTD Study
After applying exclusion criteria there were 490 children with spina bifida, 501
mothers, 399 fathers, 240 maternal grandmothers, and 182 maternal grandfathers.
Genotype frequencies within each of the subject types are listed in Table 3-1. All
genotypes were in Hardy-Weinberg equilibrium except for MTHFR 677C>T in fathers
and TYMS 1494del6 in children. Deviation from Hardy-Weinberg equilibrium would be
expected if a polymorphism was associated with risk of spina bifida. In fathers the
expected values for MTHFR 677CC, CT, and TT genotypes were 153, 164, and 44,
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respectively. There was a lack of heterozygotes and an almost equal over abundance of
CC and TT individuals, which does not indicate a clear at risk genotype. The same was
true for TYMS 1494del6 genotypes in children for which the expected values for ins/ins,
ins/del, and del/del were 231, 204, and 45, respectively.
Table 3-1. Genotype frequencies in the NTD study.
Child
Mother
197 (44.7)
210 (44.5)
CC
188 (42.6)
204 (43.2)
CT
56 (12.7)
58 (12.3)
TT
234
(50.2)
243
(49.2)
MTHFR
AA
190 (40.8)
201 (40.7)
AC
1298
42
(9.0)
50
(10.1)
CC
407 (86.2)
402 (81.7)
CBS
W/W
62
(13.1)
84 (17.1)
844ins68
W/I
3 (0.6)
6 (1.2)
I/I
147
(31.3)
161 (32.9)
MTHFD1
GG
239 (51.0)
234 (47.9)
1958
GA
83
(17.7)
94 (19.2)
AA
154 (32.2)
165 (33.7)
DHFR
Ins/ins
222
(46.4)
229 (46.8)
c.86+60_78 Ins/del
102 (21.3)
95 (19.4)
Del/del
243
(50.6)*
221
(44.3)
TYMS
Ins/ins
180 (37.5)
220 (44.1)
Ins/del
1494del6
57
(11.9)
58 (11.6)
Del/del
65 (23.6)
65 (21.2)
TYMS 5’
2R/2R
120
(43.6)
153
(50.0)
VNTR
2R/3R
87 (31.6)
86 (28.1)
3R/3R
1 (0.4)
0
2R/4R
2 (0.7)
2 (0.7)
3R/4R
N (%). *Hardy-Weinberg equilibrium p<0.05.
MTHFR
677

Father
161 (44.6)*
147 (40.7)
53 (14.7)
190 (49.1)
154 (39.8)
43 (11.1)
334 (86.5)
50 (13.0)
2 (0.5)
112 (29.0)
197 (51.0)
77 (20.0)
124 (32.5)
183 (47.9)
75 (19.6)
196 (49.6)
165 (41.8)
34 (8.6)
49 (21.3)
116 (50.4)
63 (27.4)
0
2 (0.9)

Maternal
Maternal
Grandmother Grandfather
87 (42.7)
91 (44.6)
26 (12.8)
108 (47.6)
101 (44.5)
18 (7.9)
182 (79.8)
44 (19.3)
2 (0.9)
75 (32.6)
118 (51.3)
37 (16.1)
75 (33.0)
109 (48.0)
44 (19.0)
107 (45.3)
105 (44.5)
24 (10.2)
24 (22.0)
58 (53.2)
27 (24.8)
0
0

77 (51.3)
57 (38.0)
16 (10.7)
82 (48.0)
68 (39.8)
21 (12.3)
145 (84.3)
24 (14.0)
3 (1.7)
63 (36.4)
78 (45.1)
32 (18.5)
57 (33.7)
80 (47.3)
32 (19.0)
85 (48.9)
71 (40.8)
18 (10.3)
20 (27.0)
31 (41.9)
23 (31.1)
0
0

MTHFR 677 and 1298 genotypes were combined and are displayed in Table 3-2
by subject type. The MTHFR 677T allele is in linkage disequilibrium with the 1298A
allele, and therefore the 677T allele does not occur on the same chromosome as the
1298C allele unless a very rare crossover event has occurred. There was evidence of two
such chromosomal crossover events in the genotypes of this study, evidenced by MTHFR
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677TT/1298AC and MTHFR 677CT/1298CC genotypes, which were both found in
mothers.
Table 3-2. MTHFR 677/1298 combined genotypes.
MTHFR 1298
Child
AA
AC
CC
CC 63 (14.4)
93 (21.3)
39 (8.9)
MTHFR 677 CT 101 (23.1) 86 (19.7)
0
TT
55 (12.6)
0
0
MTHFR 1298
Mother
AA
AC
CC
CC 60 (12.8)
99 (21.1)
48 (10.2)
MTHFR 677 CT 111 (23.7) 92 (19.6)
1 (0.2)
TT
57 (12.2)
1 (0.2)
0
MTHFR 1298
Father
AA
AC
CC
CC 44 (12.4)
71 (19.9)
42 (11.8)
MTHFR 677 CT 75 (21.1)
72 (20.2)
0
TT
52 (14.6)
0
0
Maternal
MTHFR 1298
Grandmother
AA
AC
CC
CC 24 (11.9)
47 (23.3)
16 (7.9)
MTHFR 677 CT 47 (23.3)
44 (21.8)
0
TT
24 (11.9)
0
0
Maternal
MTHFR 1298
Grandfather
AA
AC
CC
CC 25 (16.8)
32 (21.5)
20 (13.4)
MTHFR 677 CT 34 (22.8)
23 (15.4)
0
TT
15 (10.1)
0
0
N (overall %).
TYMS 5’ VNTR and 1494del6 genotypes were combined and are displayed in
Table 3-3 by subject type. Since TYMS 5’ VNTR genotypes were completed only on high
quality DNA samples, there were combined genotypes available for only 275 children,
305 mothers, 230 fathers, 109 maternal grandmothers, and 73 maternal grandfathers. The
TYMS 5’ VNTR 2R allele is in linkage disequilibrium with the TYMS 1494del6 insertion
allele, and therefore the 2R allele does not occur on the same chromosome as the
1494del6 deletion allele unless a very rare crossover event has occurred. The TYMS
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2R/2R and del/del combined genotype only appeared in mothers and children and not in
the other subject types. Also the TYMS 2R/3R and del/del combined genotype frequency
was highest in children (2.6%) compared to mothers (2.0%), fathers (1.7%), maternal
grandmothers (1.8%), and maternal grandfathers (absent). The TYMS 5’ VNTR 4R allele
is rare and only appeared in children, mothers, and fathers, although this could be due to
the smaller number of maternal grandparents in the study.
None of the 7 polymorphisms had significant results in the TDT analyses in child
trios and in mother trios (data not shown). An example of the data used in the TDT
analyses is presented in Table 3-4 for MTHFR 677C>T in child trios. There were 304
complete child trios that had no MTHFR 677C>T genotypes missing, and 147 trios were
considered to be non-informative mostly because both parents were homozygous. There
were 191 heterozygous parents which provided informative transmissions and 90 (47.1%)
of those were for the 677T allele.
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Table 3-3. TYMS 5’VNTR/1494del6 combined genotypes.
TYMS 1494del6
Children
Ins/ins
Ins/del
Del/del
2R/2R 52 (18.9)
11 (4.0)
2 (0.7)
2R/3R 67 (24.4)
46 (16.7)
7 (2.6)
TYMS 5’
3R/3R 24 (8.7)
35 (12.7)
28 (10.2)
VNTR
2R/4R 1 (0.4)
0
0
3R/4R 0
2 (0.7)
0
TYMS 1494del6
Mothers
Ins/ins
Ins/del
Del/del
2R/2R 48 (15.7)
15 (4.9)
1 (0.3)
2R/3R 66 (21.6)
81 (26.6)
6 (2.0)
TYMS 5’
3R/3R 21 (6.9)
41 (13.4)
24 (7.9)
VNTR
2R/4R 0
0
0
3R/4R 1 (0.3)
0
1 (0.3)
TYMS 1494del6
Fathers
Ins/ins
Ins/del
Del/del
2R/2R 41 (17.8)
8 (3.5)
0
2R/3R 59 (25.7)
53 (23.0)
4 (1.7)
TYMS 5’
3R/3R 17 (7.4)
32 (13.9)
14 (6.1)
VNTR
2R/4R 0
0
0
3R/4R 1 (0.4)
0
1 (0.4)
Maternal
TYMS 1494del6
Grandmothers
Ins/ins
Ins/del
Del/del
2R/2R 16 (14.7)
8 (7.3)
0
2R/3R 33 (30.3)
23 (21.1)
2 (1.8)
TYMS 5’
3R/3R 5 (4.6)
16 (14.7)
6 (5.5)
VNTR
2R/4R 0
0
0
3R/4R 0
0
0
Maternal
TYMS 1494del6
Grandfathers
Ins/ins
Ins/del
Del/del
2R/2R 17 (23.3)
3 (4.1)
0
2R/3R 17 (23.3)
14 (19.2)
0
TYMS 5’
3R/3R 5 (6.9)
10 (13.7)
7 (9.6)
VNTR
2R/4R 0
0
0
3R/4R 0
0
0
N (overall %).
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Table 3-4. MTHFR 677C>T mating types in child trios with number of allele
transmissions.
Mating Type (Mother Transmission of Number of
x Father = Child)
Specific Allele
Transmissions n(%)
Informative Trios
CC x CT = CC
C
101 (52.9)
CT x CC = CC
CT x CT = CC*
TT x CT = CT
CT x TT = CT
CC x CT = CT
T
90 (47.1)
CT x CC = CT
CT x CT = TT*
TT x CT = TT
CT x TT = TT
Non-Informative Trios
CC x CC = CC
CT x CT = CT
TT x TT = TT
CC x TT = CT
TT x CC = CT
*Counts as transmission of 2 C or 2 T alleles, respectively.
3.5 Discussion
The NTD study investigated 7 polymorphisms in enzymes of the folate/Hcy
metabolic pathway for risk of NTDs. TDT analyses did not find over transmission of any
of the alleles. Hardy-Weinberg equilibrium was distorted for two of the polymorphisms
but examination of expected values revealed no over representation of either homozygous
genotype. In MTHFR 677/1298 combined genotypes two rare crossover events were
observed only in mothers’ genotypes. In TYMS 5’VNTR/1494del6 combined genotypes
children and mothers were the only groups that had the rare 2R/2R and del/del combined
genotypes. It is possible that these rare combination genotypes may carry increased risk.
A large study in NTDs based in California examined 118 SNPs and found that 15
polymorphisms in 7 genes were significantly associated in children with spina bifida
(Shaw et al. 2009). This California based study found that the MTHFR 677C>T
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polymorphism was significantly associated OR 2.0 [1.2-3.1]. Another US study in NTDs
which examined 28 polymorphisms in 11 genes found that only a SNP in betainehomocysteine methyltransferase (BHMT) was significantly associated with NTDs in the
overall data set, although the MTHFR 677C>T polymorphism was not associated with
increased risk. The association with the polymorphism in BHMT was stronger in mothers
who took folate containing supplements before conception and when the MTHFR 677T
allele was also transmitted from parent to offspring (Boyles et al. 2006).
There have been several publications which found that specific genotypes were
associated with risk for NTDs using the early phases of the NTD study before sample
collection had been completed. It was previously published that increased NTD risk was
associated with transcription factor T IVS7C allele in children (Jensen et al. 2004), NOS3
894T in children (Brown et al. 2004a), MCP1 -2518AA in mothers (Jensen et al. 2006a),
and that loss of function polymorphisms in NAT1 protect against spina bifida in mothers
and children (Jensen et al. 2006b). Brown et al. (2004a) evaluated the NOS3 894G>T
genotypes by TDT and log-linear analyses. The TDT revealed no association while the
log-linear analyses revealed that the embryonic, but not maternal, genotype was
associated with risk of spina bifida. While we have genotyped the full collection of
samples, we have used the methodologically simpler TDT analyses and a lack of more
complex analyses may have resulted in failure to see an association with any of these 7
polymorphisms. Another important classification which should be applied would be to
subset the analyses by year of birth to account for folic acid fortification. Some genetic
polymorphisms may have more of an influence on NTD risk in the pre-fortification era
when folate levels were lower.
62

The primary strength of this study was the ability to assess the risk associated
with 7 polymorphisms in 5 genes at the level of the child and the mother. The limitation
of this study is that a control population was not collected during the study and hence the
calculation of odds ratios and gene-gene interactions is absent. Although the results of the
TDT analyses did not indicate that any allele was associated with the risk of spina bifida,
further analyses of these genotypes using other statistical models or subsets of the study
may reveal a significant impact.
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Chapter 4: Polymorphisms in the Context of Inflammatory Diseases: Systemic
Lupus Erythematosus and Rheumatoid Arthritis
4.1 Abstract
High Hcy and low folate levels are associated with inflammatory diseases such as
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In healthy
individuals common functional polymorphisms of enzymes in the folate/Hcy pathway
have a significant impact on these metabolite levels. The SLE study was designed to
examine the effects of these polymorphisms on tHcy concentrations and coronary artery
calcification (CAC) scores. Genotypes for 7 polymorphisms within 6 genes of the
enzymes of the folate/Hcy pathway were completed in 163 female SLE cases and 160
matched controls. African American SLE cases had higher tHcy levels than Caucasian
cases and African American controls. For 6 of the 7 polymorphisms genotype
distributions were significantly different between African American and Caucasian
controls. There were no significant differences in genotype distributions between SLE
cases and controls even after stratification by race.
The effects of genetic polymorphisms on tHcy levels were examined within
general linear models which adjusted for glomular filtration rate (GFR) as a covariate
because it was strongly negatively correlated to tHcy levels. In SLE patients of both races
none of the 7 polymorphisms had a significant impact on tHcy levels. In Caucasian
controls MTHFR 677CT and 677TT individuals had higher tHcy levels than 677CC
homozygotes. Also in Caucasian controls MTHFR 1298C carriers had lower tHcy levels
than 1298AA homozygotes. None of the polymorphisms were associated with CAC
scores in SLE patients or controls even after stratification by race. In SLE cases
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polymorphisms in folate/Hcy metabolizing enzymes do not have an impact on tHcy
concentrations or CAC scores.
Rheumatoid arthritis is a chronic inflammatory disease associated with elevated
Hcy levels. Methotrexate (MTX), an anti-folate, is classified as a disease-modifying antirheumatic drug (DMARD), and used at low doses to treat inflammatory diseases.
Polymorphisms in the enzymes of the folate/Hcy pathway are involved in the metabolism
of MTX and may therefore influence efficacy and/or toxicity. The RA study was
designed to examine the effects of these polymorphisms on tHcy and folate derivative
levels in plasma and red blood cells. Also associations between these polymorphisms and
clinical variables, such as physician global assessment (PGA) scores, were examined. In
the RA study there were 252 RA subjects defined as current users of MTX and 37 RA
subjects defined as discontinued users of MTX. Genotypes were completed for 11
polymorphisms in 9 genes in enzymes of folate/Hcy metabolism. THcy, plasma folic
acid, and folate derivatives in plasma and red blood cells were measured using stable
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry.
C reactive protein and B12 levels were measured and PGA scores and American
Rheumatism Association classes were assigned by physicians.
In African Americans MTHFD1 1958G>A genotypes had significantly different
distributions when current users and discontinued users were compared. MTHFD1
1958G>A genotypes may be associated with discontinuation of MTX therapy. In
Caucasians discontinuation of MTX therapy was associated with MTHFR 1298A>C
genotypes. Several of the investigated polymorphisms were found to have a significant
impact on tHcy and folate derivative levels in African American and Caucasian current
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users. MTR 2756A>G genotypes were associated with attributable toxicities in African
American current users. In Caucasian current users MTHFD1 1958G>A genotypes were
associated with attributable toxicities. In both African American and Caucasian current
users CRP levels were positively correlated with total RBC folate levels and with levels
of specific RBC folate derivatives.
4.2 Introduction
4.2.1 Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which
predominates in women and African Americans (Simard and Costenbader 2007).
Premature atherosclerotic cardiovascular disease is a common comorbidity in those with
SLE (Manzi et al. 1997). Electron beam computed tomography (EBCT) is used to
measure coronary artery calcification (CAC), which is a subclinical sign of premature
atherosclerotic cardiovascular disease. CAC scores are positively correlated with risk of
future cardiovascular events (Arad et al. 2005). Atherosclerosis progression depends on
multiple factors and a low folate/high Hcy phenotype is associated with increased risk of
cardiovascular disease. In the general population elevated Hcy levels are associated with
a relative risk (RR) of 2.2 [1.6-2.9] for cardiovascular disease (Graham et al. 1997). SLE
patients have higher Hcy concentrations compared to matched controls (Afeltra et al.
2005; Bruce et al. 2003; Von Feldt et al. 2006). Hcy levels were found to be positively
correlated with CAC scores in SLE patients (Von Feldt et al. 2006). The SLE study was
undertaken to examine if polymorphisms in enzymes of the folate/Hcy metabolic
pathway have any effect on tHcy levels and/or CAC scores in SLE patients.
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4.2.2 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic inflammatory disease where
inflammation leads to joint damage and eventually functional impairment. RA affects
about 1% of the general population (Pugner et al. 2000). RA is associated with elevated
Hcy levels compared to controls (Hernanz et al. 1999; Wallberg-Jonsson et al. 2002).
High Hcy levels were associated with atherothrombotic events in a study in RA patients
from Sweden (Berglund et al. 2009).
Methotrexate
Low dose methotrexate (MTX) therapy is one of the most commonly prescribed
disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid
arthritis (Whittle and Hughes 2004). MTX therapy is associated with decreases in joint
swelling and pain as well as stopping progression of joint damage (Brinker and
Ranganathan 2010). MTX is an anti-folate drug, which at high doses is used to treat
cancers due to its anti-proliferative effect. The anti-inflammatory mechanisms of MTX in
the treatment of RA have not been clearly defined. MTX is transported into cells by
reduced folate carrier 1 (RFC1) and once it enters the cell it becomes polyglutamated.
MTX is a structural analog of folic acid that inhibits enzymes involved in folate
metabolism and nucleotide synthesis. MTX inhibits the following enzymes: dihydrofolate
reductase (DHFR), thymidylate synthase (TYMS), glycinamide ribonucleotide
transformylase (GART), and aminoimidazolecarboxamide ribonucleotide transformylase
(AICART) (Kremer 2004).
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Folic acid
RA patients taking MTX also take folic acid supplements for the prevention of
adverse events (Whittle and Hughes 2004). Evidence from a randomized placebocontrolled trial of folic acid supplementation showed that folic acid decreased toxicity
without affecting efficacy in RA patients taking MTX (Morgan et al. 1990). The
protective effect of folic acid was confirmed by a randomized, double-blind study in
which the substitution of placebo for folic acid in RA patients that had been taking MTX
and folic acid for a mean of 30 months showed that placebo was associated with
discontinuation of MTX because of adverse events (Griffith et al. 2000). The use of MTX
alone to treat RA is associated with increased Hcy levels and addition of folic acid is
associated with decreased Hcy levels (van Ede et al. 2002). Concomitant folic acid is
protective against adverse events and favorably affects Hcy levels.
Associations of specific polymorphisms with efficacy or toxicity
Genetic polymorphisms may be able to predict an individual’s therapeutic
outcome and this field of science is known as pharmacogenetics. Pharmacogenetics is the
study of how interindividual differences in drug response are due to polymorphisms in
genes for drug metabolizing enzymes, drug transporters, and drug targets (Evans and
McLeod 2003). Several polymorphisms in enzymes of the folate/Hcy pathway are
associated with either MTX efficacy or toxicity. An RA study in Slovenia found that the
RFC1 80GG genotype was associated with increased risk of overall toxicity with OR
3.57 and that the MTHFR 1298CC genotype was associated with a protective effect OR
0.17 (Bohanec Grabar et al. 2008). A study in US RA patients found that a favorable
response to MTX was associated with the RFC1 80AA genotype (Dervieux et al. 2004).
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RFC1 80AA genotype was also found to be associated with decreased RA symptoms and
the frequency of the 80A allele was higher in MTX responders (Drozdzik et al. 2007).
The RFC1 80AA genotype seems to be consistently associated with MTX efficacy. In a
study in Dutch RA patients MTHFR 1298AA genotype was associated with efficacy and
less overall toxicities (Wessels et al. 2006), which is in contrast to the RA study from
Slovenia. In a US-based RA study TYMS 5’ VNTR 2R/2R genotype was associated with
a specific toxicity, alopecia, OR 5.6 (Weisman et al. 2006). Polymorphisms in enzymes
of folate/Hcy metabolism require further study to establish their predictive ability.
4.3 Methods
4.3.1 SLE Study
Subjects
Nonpregnant women attending University of Pennsylvania clinics with SLE and
race and age matched controls were invited to participate in the study. There were 163
SLE cases and 160 controls enrolled in the study. SLE cases fulfilled at least 4 of the
American College of Rheumatology revised criteria for the classification of SLE
(Hochberg 1997). Controls had no underlying inflammatory disease or exposure to
corticosteroids. The study was approved by the Institutional Review Board of the
University of Pennsylvania. Each participant gave written informed consent. This study
was previously described (Summers et al. 2008a).
Biochemical Assays
All subjects’ medical histories and fasting blood samples were collected, as well
as undergoing electron beam computed tomography (EBCT) (Von Feldt et al. 2006).
Framingham point scores were calculated based on a published method of scoring various
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cardiovascular risk factors (National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(Adult Treatment Panel III) 2002). Glomular filtration rate (GFR) was calculated using
the Modification of Diet in Renal Disease equation (Levey et al. 2003). Plasma tHcy
levels were measured by fluorescence polarization immunoassay (AxSYM
Homocysteine; Abbott Laboratories, Abbott Park, IL), which was performed by the
hospital’s clinical laboratory.
Genotyping
Generation Capture Column kits (Gentra Systems, Minneapolis, MN) were used
to isolate DNA from whole blood. A heteroduplex generator method was used for
MTHFR 677C>T genotypes (Barbaux et al. 2000) and a portion of samples were repeated
using the TaqMan assay. MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, and
MTRR 66A>G TaqMan assays were previously described (Summers et al. 2008a).
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA
Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA).
PCR amplifications took place in 20ul volumes containing 20ng genomic DNA, forward
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of
an initial incubation at 50°C for 2min, 95°C for 10min, and 50 cycles of assay specific
temperatures for denaturation and extension. Dual fluorescence was measured at the end
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis
software, version 2.02 (Bio-Rad).

70

Size-difference PCR methods were used to genotype CBS 844ins68, TYMS
1494del6, and DHFR c.86+60_78 as previously described (Summers et al. 2008a).
Briefly, PCR amplifications were performed using 50ng genomic DNA, forward and
reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), MgCl2, and AmpliTaq
DNA polymerase (Applied Biosystems) in 25ul volumes. PCR products were separated
on 3% agarose gels run for 45min at 140V then stained with ethidium bromide.
Statistics
All statistical analyses were performed with SAS version 9.1 and p values were
considered significant if <0.05. Log-transformation of tHcy was necessary to better
approximate normality. Hardy-Weinberg equilibrium for each polymorphism was
assessed by chi-square test. Differences in genotype distributions between African
American and Caucasian controls and between case and control groups were assessed by
chi-square and Fisher’s Exact test. Pearson’s correlation coefficients for age, GFR, and
Framingham point scores were assessed in relation to log tHcy. The effects of smoking
status, use of B6, B12, and folic acid on log tHcy were assessed by Student’s t-test. The
above significantly correlated variables were used in general linear modeling as
covariates in the assessment of the effect of genotype on log tHcy. Results of log tHcy
analyses were back-transformed to report results in original measurement units (µmol/L).
4.3.2 RA Study
Subjects
Subjects were recruited who fulfilled the 1987 American College of
Rheumatology revised criteria for rheumatoid arthritis (Arnett et al. 1988). This study
was approved by the Institutional Review Board of the University of Pennsylvania
71

School of Medicine. All subjects provided written informed consent. Study subjects
described as current users were taking MTX for a minimum of 17 weeks, and were
excluded if they did not report that they were taking folic acid. Study subjects described
as discontinued users had taken MTX previously but were not currently taking the drug.
Subjects gave a blood sample for biochemical and genetic analysis and completed a short
in-person interview. The interview questions covered alcohol use, smoking status, folic
acid supplementation, and medical history. Doctors performed physical assessments and
gave physician global assessment (PGA) scores and American Rheumatism Association
(ARA) classes.
Biochemical Assays
THcy, FA, and folate derivatives were measured in plasma and RBCs using stable
isotope dilution liquid chromatography multiple reaction monitoring mass spectrometry
(LC/MRM/MS) as previously described (Huang et al. 2007; Huang et al. 2008).
C-reactive protein (CRP) levels were measured by the clinical laboratory of the
Hospital of the University of Pennsylvania using VITROS MicroSlides (Ortho-Clinical
Diagnostics, Rochester, NY). Vitamin B12 levels were measured with the Immulite 2000
Vitamin B12 assay (Diagnostic Products Corp., Los Angeles, CA).
Genotyping
QIAamp DNA Mini Kits (Qiagen, Santa Clarita, CA) were used to extract DNA
from whole blood. TaqMan genotyping methods were previously described for MTHFR
677C>T, MTHFR 1298A>C, MTR 2756A>G, MTRR 66A>G (Summers et al. 2008a),
MTHFD1 1958G>A, RFC1 80A>G, and SHMT1 1420C>T (Summers et al. 2010).
Briefly, real-time polymerase chain reaction (PCR) assays were performed on a DNA
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Engine Opticon 2 continuous fluorescence detection system (Bio-Rad, Hercules, CA).
PCR amplifications took place in 20ul volumes containing 20ng genomic DNA, forward
and reverse primers, Fam and Vic labeled allele-specific probes, and TaqMan Universal
PCR Master Mix (Applied Biosystems, Foster City, CA). Cycling conditions consisted of
an initial incubation at 50°C for 2min, 95°C for 10min, and 50 cycles of assay specific
temperatures for denaturation and extension. Dual fluorescence was measured at the end
of each cycle. Genotype interpretations were performed with Opticon Monitor Analysis
software, version 2.02 (Bio-Rad).
Size difference PCR methods were used to genotype CBS 844ins68, TYMS
1494del6, TYMS 5’ VNTR, and DHFR c.86+60_78 as previously described (Summers et
al. 2010). Briefly, PCR amplifications were performed using 50ng genomic DNA,
forward and reverse primers, dNTPs, 10x PCR buffer (Applied Biosystems), and
AmpliTaq DNA polymerase (Applied Biosystems) in 25µl volumes. PCR products were
separated on 3% agarose gels run for 45min at 140V then stained with ethidium bromide.
Statistics
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary,
NC). Discrete variables were presented as counts and proportions and continuous
variables were presented as medians and interquartile ranges. Total RBC folate was the
sum of RBC 5-MTHF, THF, and 5,10-MTHF. THF values which were not detectable
(n=4) were given a value corresponding to the lower limit of quantitation (4.5nmol/L),
allowing both absolute THF levels and the ratio of RBC 5-MTHF:THF to be analyzed as
continuous variables. RBC 5,10-MTHF levels were not detectable in a large portion of
the samples and therefore was treated as a dichotomous (detectable/not detectable)
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variable. CRP values reported by the clinical laboratory as <0.3 were given values of 0.3
and B12 values reported as >1000 were given values of 1000 in order to analyze the data
with nonparametric tests, which is based on ranking values.
For the purposes of classification, severe toxicities included pneumonitis,
hemorrhagic enteritis, and bone marrow depression; attributable toxicities included the
severe toxicities and leucopenia, thrombocytopenia, abnormal mcv, abnormal
ALP/ALT/AST, other abnormal LFTs, elevated homocysteine,
photosensitivity/hyperpigmentation, urticaria/puritis, alopecia, and mucositis; and any
toxicity was defined as having at least one of the twenty five defined events or otherwise
listed as other event.
4.4 Results
4.4.1 SLE Study
Subject Characteristics
The study included 163 SLE cases and 160 controls, of which approximately 50%
self-reported as African American, 39% as Caucasian, 5% as Asian, 4% as Hispanic, and
1% as other as presented in Table 4-1. The average age in SLE cases and controls was
about 43 years. Median CAC scores were significantly higher in SLE cases than controls
(p=0.0003). THcy levels were also higher in SLE cases than controls (10.4 vs 9.2
µmol/L, p<0.0001). When analyses were applied to specific races, African American
SLE cases had higher tHcy levels than African American controls (12.1 vs 9.7 µmol/L,
p<0.0001). Caucasian SLE cases had higher tHcy levels than Caucasian controls but this
was not statistically significant (10.0 vs 9.0 µmol/L, p=0.12). African American SLE
cases had higher tHcy levels than Caucasian SLE cases (p=0.0009), but African
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American controls did not have significantly different tHcy levels than Caucasian
controls (p=0.21). Framingham point scores and GFR were not significantly different
between SLE cases and controls.
Table 4-1. SLE Study Subject Characteristics.
Characteristic
SLE cases
Controls
P value
No.
163
160
ND
Age, yrs, mean ± SD
43.3 ± 11.0
43.5 ± 10.5
0.90
Race, %(n)
African American
50.3 (82)
50.6 (81)
1.00
Caucasian
39.3 (64)
39.4 (63)
Asian
4.9 (8)
5.0 (8)
Hispanic
4.3 (7)
3.8 (6)
Other
1.2 (2)
1.2 (2)
CAC, median [IQR]
0 [0-7.2]
0 [0-0]
0.0003
tHcy, µmol/L, mean ± SD 10.4 ± 1.4
9.2 ± 1.4
<0.0001
(n)
African American*
12.1 ± 1.4 (82)
9.7 ± 1.3 (81) <0.0001
Caucasian
10.0 ± 1.3 (64)
9.0 ± 1.5 (63) 0.12
Framingham point scores, 8 [3-13] (161)
8 [2-12] (156) 0.39
median [IQR] (n)
GFR, ml/min/1.73m2,
90.0 ± 32.5
94.5 ± 20.8
0.14
mean ± SD
SD = standard deviation, ND = not determined, IQR = interquartile range.
*For African American SLE cases vs. Caucasian SLE cases p=0.0009; for African
American controls vs. Caucasian controls p=0.21(Summers et al. 2008a)
Genotype frequencies in African American and Caucasian controls
SLE cases and controls were genotyped for 7 polymorphisms in 6 genes in the
folate/Hcy metabolic pathway and included: MTHFR 677C>T and 1298A>C, MTR
2756A>G, MTRR 66A>G, CBS 844ins68, TYMS 1494del6, and DHFR c.86+60_78. All
genotypes were in Hardy-Weinberg equilibrium for SLE cases and controls even after
stratification by race. The genotype frequency distributions were significantly different
between African American and Caucasian controls for all of the polymorphisms except
for MTR 2756A>G (Table 4-2). For example, MTHFR 677TT homozygotes made up
2.5% of African American controls compared to 19.0% of Caucasian controls
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(p=0.0003). The wildtype genotype tends to be the higher frequency homozygote and the
lower frequency homozygote is usually the variant genotype. For 3 of the polymorphisms
(MTRR 66A>G, TYMS 1494del6, and DHFR c.86+60_78) the homozygous genotype that
had the higher frequency in African Americans had the lower frequency in Caucasians. In
analyses involving genotypes African Americans and Caucasians were therefore analyzed
separately.
Risk of SLE as determined by genotype frequency
Specific genotypes may be associated with development of SLE if SLE cases
have an overrepresentation in genotype frequency when compared to the control
frequency. None of the carrier frequencies of the 7 polymorphisms were significantly
different when stratified by race (Table 4-3). The only polymorphism that approached
significance was in Caucasians, MTR 2756G carriers were overrepresented in controls
(p=0.07) meaning that 2756AA homozygotes are at increased risk of developing SLE.
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Table 4-2. Distributions of genotype frequencies in African American and
Caucasian controls.
African
Polymorphism
Genotype Americans Caucasians
P
MTHFR 677C>T
CC
67.9 (55)
39.7 (25)
0.0003
CT
29.6 (24)
41.3 (26)
TT
2.5 (2)
19.0 (12)
MTHFR 1298A>C

AA
AC
CC

69.1 (56)
30.9 (25)
0

55.6 (35)
38.1 (24)
6.3 (4)

0.0347

MTHFR 677/1298

CC/AA
CC/AC
CC/CC
CT/AA
CT/AC
TT/AA

46.9 (38)
21.0 (17)
0
19.7 (16)
9.9 (8)
2.5 (2)

11.1 (7)
22.2 (14)
6.3 (4)
25.4 (16)
15.9 (10)
19.0 (12)

<0.0001

CBS 844ins68

WW
WI
II

58.0 (47)
39.5 (32)
2.5 (2)

87.3 (55)
12.7 (8)
0

0.0005

MTR 2756A>G

AA
AG
GG

58.0 (47)
33.3 (27)
8.7 (7)

47.6 (30)
47.6 (30)
4.8 (3)

0.19

MTRR 66A>G

AA
AG
GG

48.2 (39)
40.7 (33)
11.1 (9)

20.6 (13)
50.8 (32)
28.6 (18)

0.0009

TYMS 1494del6

Ins/ins
Ins/del
Del/del

19.7 (16)
53.1 (43)
27.2 (22)

39.7 (25)
54.0 (34)
6.3 (4)

0.0012

Ins/ins
19.7 (16)
38.1 (24)
Ins/del
45.7 (37)
47.6 (30)
Del/del
34.6 (28)
14.3 (9)
%(n). P values by χ2 test. (Summers et al. 2008a)

0.0068

DHFR c.86+60_78
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Table 4-3. Distributions of carrier frequencies between SLE cases and controls by
race.
Genotype
SLE cases Controls
p
MTHFR 677T carriers
African American
31.7 (26)
32.1 (26)
1.00
Caucasian
65.6 (42)
60.3 (38)
0.58
MTHFR 1298C carriers
African American
32.9 (27)
30.9 (25)
0.87
Caucasian
54.7 (35)
44.4 (28)
0.29
CBS 844ins68 carriers
African American
48.8 (40)
42.0 (34)
0.43
Caucasian
15.6 (10)
12.7 (8)
0.80
MTR 2756G carriers
African American
46.3 (38)
42.0 (34)
0.64
Caucasian
35.9 (23)
52.4 (33)
0.07
MTRR 66G carriers
African American
43.9 (36)
51.9 (42)
0.35
Caucasian
78.1 (50)
79.4 (50)
1.00
TYMS 1494del6 ins carriers
African American
63.4 (52)
72.8 (59)
0.24
Caucasian
89.1 (57)
93.7 (59)
0.53
DHFR c.86+60_78 ins carriers
African American
59.8 (49)
65.4 (53)
0.52
Caucasian
78.1 (50)
85.7 (54)
0.36
Carriers of alleles subset by race %(n). P values by Fisher’s exact test. (Summers et al.
2008a)
Predictors of tHcy concentrations
The continuous variables which were selected for correlation analysis with tHcy
concentrations were age, GFR, and Framingham point scores. Displayed in Table 4-4 are
the Pearson’s correlation coefficients and corresponding p values for all study subjects.
All 3 continuous variables were significantly correlated with tHcy concentrations. Age
and Framingham point scores were positively correlated while GFR was negatively
correlated with tHcy concentrations. Uncontrolled sources of variation were categorical
variables and the following were selected for analysis: folic acid use, B6 use, B12 use, and
smoking status. None of these variables were significantly associated with tHcy
concentrations (data not shown). The results of the above analyses were similar when
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stratified by group (SLE cases and controls) except that smoking status was significantly
associated with tHcy concentrations in controls (smokers 11.8 (n=25) vs nonsmokers 9.5
(n=133), p=0.0046).
Table 4-4. Correlations with homocysteine levels.
Pearson’s Correlation
Variable
Coefficient
n
p
Age
0.22917
323
<0.0001
GFR
-0.42930
323
<0.0001
Framingham
Point Scores 0.22249
317
<0.0001
(Summers et al. 2008a)
From the above analysis the explanatory variables age, GFR, and Framingham
point scores along with race and group were put into a general linear model with tHcy as
the dependent variable, with no interactions between any of the terms. In this analysis of
covariance GFR along with race and group were the only variables significantly
associated with tHcy (Table 4-5). These variables were used in modeling the effect of
genotype on tHcy concentrations.
Table 4-5. Analysis of covariance for homocysteine.
Source Variation Sum of Squares Df F
p
GFR
1.11
1
60.18
<0.0001
Group*
5.53
1
12.04
0.0006
Race†
2.14
1
23.28
<0.0001
*Refers to case and control groups
†
Refers to African Americans and Caucasians(Summers et al. 2008a)
Modeling the effects of polymorphisms of folate/Hcy metabolizing enzymes on
tHcy concentrations
More complex models were explored and a clinically sound parsimonious model
was arrived at with variables that significantly contributed to the variation in tHcy. For
each polymorphism a general linear model was used with tHcy as the dependent variable
and classified by race, group, and genotype with the addition of the covariate GFR and its
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interaction with that genotype. The classification resulted in 4 categories, which were
African American SLE cases, African American controls, Caucasian SLE cases,
Caucasian controls. The least-square mean estimates of tHcy were adjusted for the
uncontrolled variable GFR. Two polymorphisms (MTHFR 1298A>C and CBS 844ins68)
were modeled based on carriers of the variant allele, which is the combination of
heterozygotes and variant homozygotes. This was because there were no variant
homozygotes present in at least one of the four categories. Out of the 7 polymorphisms
only 2 were significantly associated with tHcy concentrations. In Caucasian controls
MTHFR 677CC homozygotes had lower tHcy levels than 677CT heterozygotes (7.7 vs
9.4 µmol/L, p=0.0196) and 677CC homozygotes also had lower tHcy levels than 677TT
homozygotes (7.7 vs 9.8 µmol/L, p=0.0275). Also MTHFR 1298AA homozygotes had
higher tHcy levels than 1298C carriers (9.6 vs 7.8 µmol/L, p=0.0083) (Table 4-6).
Table 4-6. Analysis of covariance with two factors (group, race) and one covariate
(GFR).
Adjusted means of
Category
Genotype
tHcy
P*
Caucasian Controls
MTHFR 677 CC
7.7
CT
9.4
0.0196
TT
9.8
0.0275
Caucasian Controls
MTHFR 1298 AA
9.6
AC/CC† 7.8
0.0083
*p value for comparison to wildtype genotype
†
These genotypes were combined because of low numbers of homozygotes(Summers et
al. 2008a)
CAC scores and polymorphisms of folate/Hcy metabolizing enzymes
None of the genotypes were associated with median CAC scores even after
stratification by race (data not shown).
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4.4.2 RA Study
Subject Characteristics
The RA study included 252 subjects classified as current (MTX) users, of which
47 (18.7%) were African American and 37 subjects classified as discontinued (MTX)
users, of which 11 (29.7%) were African American (Table 4-7). Toxicities were reported
and categorized into several categories. Severe toxicities would require discontinuation of
MTX, and therefore were present only in the discontinued users group. Attributable
toxicities are those known to be associated with MTX therapy, such as elevated liver
function tests (LFTs), and could require a decrease in MTX dose. Non-attributable
toxicities were side effects which could have come from a different source, such as
headache and diarrhea. ARA class 1 was defined as RA having almost no impact on the
subject’s daily activities while class 4 was defined as RA having a severe impact on the
subject’s daily activities resulting in limitations in ability to perform daily activities.
RBC 5,10-MTHF levels were measured and due to a large number of undetectable values
were determined to be either detectable or undetectable for subsequent analyses.
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Table 4-7. RA study subject characteristics for categorical variables.
African American
Caucasian
Current
DiscontinCurrent
DiscontinUsers
ued Users
Users
ued Users
Gender – Male
6 (12.8)
1 (9.1)
62 (30.2)
6 (23.1)
Female
41 (87.2)
10 (90.9)
143 (69.8)
20 (76.9)
Smoker – Yes
8 (17.8)
1 (11.1)
29 (14.6)
0
No
37 (82.2)
8 (88.9)
170 (85.4)
23 (100.0)
Drinker – Yes
7 (16.3)
4 (44.4)
88 (44.0)
11 (50.0)
No
36 (83.7)
5 (55.6)
112 (56.0)
11 (50.0)
Severe Toxicity
0
3 (27.3)
0
2 (7.7)
Attributable Toxicity
5 (10.6)
4 (36.4)
28 (13.7)
6 (23.1)
Non-Attributable
12 (25.5)
4(36.4)
49 (23.9)
13 (50.0)
Toxicity
No Toxicity
30 (63.8)
0
128 (62.4)
5 (19.2)
Morning Stiffness – Yes
36 (80.0)
10 (90.9)
132 (68.0)
17 (68.0)
No
9 (20.0)
1 (9.1)
62 (32.0)
8 (32.0)
ARA Class I
15 (35.7)
1 (10.0)
75 (40.5)
12 (52.2)
II
18 (42.9)
3 (30.0)
89 (48.1)
8 (34.8)
III
7 (16.7)
5 (50.0)
13 (7.0)
2 (8.7)
IV
2 (4.8)
1 (10.0)
8 (4.3)
1 (4.4)
RBC 5,10-MTHF – D*
16 (39.0)
3 (50.0)
96 (54.9)
3 (27.3)
ND
25 (61.0)
3 (50.0)
79 (45.1)
8 (72.7)
N (%)
*D=Detectable, ND=Not Detectable
Continuous variables were assessed for differences between African American
current users and Caucasian current users (Table 4-8). The following observations were
associated with p values <0.05. African Americans were taking slightly higher doses of
MTX than Caucasians (17.5 vs 15.0 mg, respectively). PGA scores were slightly higher
in African Americans (32 vs 24). RBC THF levels were slightly lower in African
Americans (24.7 vs 29.4 nmol/L) and therefore the ratio of 5-MTHF:THF was slightly
higher (39.1 vs 29.4). When current users were compared to discontinued users in
African Americans PGA scores were much higher in discontinued users (61 vs 32). Since
current users were taking folic acid, levels of plasma folic acid were higher in current
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users (12.4 vs 0 nmol/L). Total RBC folate levels were decreased in current users (993.1
vs 1283.4 nmol/L) and this possibly due to the anti-folate effects of MTX. Also 5-MTHF
levels were lower in current users (957.8 vs 1004.3 nmol/L). When Caucasian current
users were compared to discontinued users plasma 5-MTHF levels were lower in current
users (35.9 vs 66.1 nmol/L). In Caucasians similar observations were seen as those
observed in African Americans with respect to plasma folic acid (FA), total RBC folate,
and RBC 5-MTHF.
Clinical variables of RA severity are associated
The clinical continuous variables PGA score and CRP levels were stratified by the
clinical categorical variables morning stiffness and ARA class to assess differences in
median levels of the continuous variables within current users (Table 4-9). In Caucasians
PGA scores were higher in those who experienced morning stiffness compared to those
that did not experience morning stiffness (27 vs 17, p=0.0003). In African Americans
PGA scores were higher in those who experienced morning stiffness but this was not
statistically significant. PGA scores in African Americans were higher in individuals
categorized as ARA classes II-IV compared to those categorized as ARA class I (41 vs
18, p=0.0005).
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Table 4-8. RA study subject characteristics for continuous variables.
Current Users
Discontinued Users
African
African
American
Caucasian
American
Caucasian
Age, years 57 [46-67] (47) 56 [48-66]
59 [54-64] (10) 56 [38-71] (26)
(202)
Current
17.5 [12.5-20.0] 15.0 [10.0-17.5] MTX Dose, (46)
(202)*
mg
Cumulative 539.8 [346.5556.1 [325.0851.6 [480.0556.1 [267.5MTX Dose, 3038.6] (40)
3513.6] (194)
2780.0] (10)
2380.0] (22)
mg
PGA score 32 [18-50] (41) 24 [12-35]
61 [41-72] (10) 29 [11-56] (23)
(187)*
†
Plasma 533.4 [21.3-46.0] 35.9 [24.9-47.7] 58.6 [26.2-66.2] 66.1 [33.6MTHF,
(41)
(178)
(6)
96.4] (11) ‡
nmol/L
Plasma
12.4 [1.0-35.1] 12.6 [1.1-52.7] 0 [0-0.8] (6) †
1.1 [0-5.4] (11)
Folic Acid, (41)
(178)
‡
nmol/L
Total RBC 993.1 [855.21095.4 [863.21283.4 [1108.8- 1489.8
1160.9] (41)
1382.0] (175)
1752.9] (6) †
[1132.5folate°,
2251.5] (11) ‡
nmol/L
RBC 5957.8 [746.91004.3 [768.01249.3 [1049.0- 1464.1
MTHF,
1055.0] (41)
1273.8] (175)
1700.5] (6) †
[1033.4nmol/L
2220.4] (11) ‡
RBC THF, 24.7 [16.9-37.4] 29.4 [15.8-44.7] 34.9 [24.2-43.2] 35.5 [25.7nmol/L
(41)
(175)*
(6)
71.7] (11)
Ratio 539.1 [26.6-48.8] 29.4 [15.8-44.4] 41.9 [38.1-44.0] 39.2 [20.8MTHF:TH (41)
(176)*
(6)
60.8] (11)
F
0.7 [0.4-1.2]
0.5 [0.3-1.0]
1.3 [0.7-2.4] (8) 0.4 [0.3-0.9]
CRP°,
(44)
(174)
(11)
mg/L
600 [354-855]
615 [388-839]
907 [708-1000] 736 [356B12°,
pmol/L
(37)
(169)
(6)
1000] (12)
tHcy,
10.5 [9.3-13.6] 10.4 [9.0-12.3] 10.2 [7.0-12.1] 12.9 [9.3-14.3]
µmol/L
(41)
(178)
(6)
(11)
Median [IQR] (n)
* p values <0.05 for comparison of African American current users to Caucasian current
users by Wilcoxon
† p values <0.05 for comparison of African American current users to African American
discontinued users by Wilcoxon
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‡ p values <0.05 for comparison of Caucasian current users to Caucasian discontinued
users by Wilcoxon
° Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000
In Caucasians the same observation was significant, individuals in ARA classes
II-IV had higher PGA scores (31 vs 12, p<0.0001). CRP levels in Caucasians were higher
in individuals in ARA classes II-IV (0.7 vs 0.4, p=0.001). Although CRP levels in
African Americans were higher in individuals in ARA classes II-IV, this was not
statistically significant. It was observed that worse RA severity in clinical continuous
variables was associated with worse RA severity in clinical categorical variables.
Table 4-9. Analyses of selected clinical variables in current users: continuous
variables stratified by categorical variables.
Continuous
Race
Variables
Categorical Variables
P Values
Morning
Stiffness – Yes
No
African
PGA
34 [19-58] (32)
26 [10-41] (9)
0.17
American
Caucasian PGA
27 [14-37] (123) 17 [8-28] (58)
0.0003
ARA Class I
ARA Classes II-IV
African
PGA
18 [12-22] (14)
41 [30-61] (27)
0.0005
American
Caucasian PGA
12 [5-19] (75)
31 [22-38] (109)
<0.0001
African
CRP*
0.5 [0.4-0.7] (13) 1.0 [0.3-1.8] (26)
0.18
American
Caucasian CRP*
0.4 [0.3-0.7] (64) 0.7 [0.3-1.2] (92)
0.001
*CRP values of “<0.3” were given the value of 0.3
Differences in genotype distribution between races
Genotyping was completed for 11 polymorphisms in 9 genes of the enzymes of
the folate/Hcy pathway. Genotype distributions are presented in Table 5-10. In current
users the genotype frequencies were compared by Fisher’s Exact test. There were
significant differences in genotype distributions between African American and
Caucasian current users. Only 3 of the 11 polymorphisms were not significantly different.
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Genotype distribution differences between current and discontinued users
Overall there were 3 polymorphisms which were not in Hardy-Weinberg
equilibrium. In African American current users there were two polymorphisms, which
deviated from Hardy-Weinberg equilibrium: MTHFR 677C>T (p=0.047) and DHFR
c.86+60_78 (p=0.045). In Caucasian current users there was only one polymorphism not
in Hardy-Weinberg equilibrium and that was MTHFR 1298A>C (p=0.021). Deviation
from Hardy-Weinberg equilibrium suggests that there may be increased risk of RA
associated with these polymorphisms. Without a healthy control group with which to
compare genotype frequencies the conclusion cannot be made that these genotypes
increase risk for RA. The discontinued users served as a reference group for assessing the
tolerability of MTX therapy. African American discontinued users had significantly
different genotype frequencies for the polymorphism MTHFD1 1958A>G when
compared to African American current users. Examination of these genotype frequencies
suggests that there were more MTHFD1 1958GA and 1958AA individuals. This suggests
that the 1958A allele may be associated with discontinuation of MTX therapy in African
Americans. In Caucasian discontinued users the distribution of MTHFR 1298A>C
genotypes were significantly different from current users. There seemed to be more
1298CC homozygotes when compared to current users, which suggests that this genotype
may be associated with discontinuation of MTX therapy.

86

Table 4-10. RA study genotype distributions.
Current Users
Discontinued Users
African
African
American Caucasian
American
Caucasian
MTHFR
CC
37 (82.2)
83 (40.7)*
8 (72.7)
10 (43.5)
677C>T
CT
6 (13.3)
102 (50.0)
2 (18.2)
10 (43.5)
TT
2 (4.4)
19 (9.3)
1 (9.1)
3 (13.0)
MTHFR
AA
33 (73.3)
93 (45.6)*
6 (54.6)
9 (39.1) ‡
1298A>C
AC
12 (26.7)
98 (48.0)
5 (45.4)
7 (30.4)
CC
0
13 (6.4)
0
7 (30.4)
CBS 844ins68
WW
30 (66.7)
177 (86.8)* 7 (63.6)
18 (78.3)
WI
12 (26.7)
26 (12.8)
3 (27.3)
5 (21.7)
II
3 (6.7)
1 (0.5)
1 (9.1)
0
MTR
AA
29 (64.4)
137 (67.2)
7 (63.6)
16 (69.6)
2756A>G
AG
14 (31.1)
61 (29.9)
4 (36.4)
6 (26.1)
GG
2 (4.4)
6 (2.9)
0
1 (4.4)
MTRR 66A>G AA
18 (40.0)
45 (22.1)*
7 (63.6)
4 (17.4)
AG
24 (53.3)
95 (46.6)
4 (36.4)
15 (65.2)
GG
3 (6.7)
64 (31.4)
0
4 (17.4)
MTHFD1
GG
33 (73.3)
68 (33.3)*
4 (36.4) †
7 (30.4)
1958G>A
GA
10 (22.2)
91 (44.6)
4 (36.4)
10 (43.5)
AA
2 (4.4)
45 (22.1)
3 (27.3)
6 (26.1)
SHMT1
CC
22 (48.9)
98 (48.0)
6 (54.6)
9 (39.1)
1420C>T
CT
21 (46.7)
87 (42.7)
5 (45.4)
11 (47.8)
TT
2 (4.4)
19 (9.3)
0
3 (13.0)
DHFR
del/del 12 (26.7)
44 (21.6)*
3 (27.3)
5 (21.7)
c.86+60_78
ins/del 30 (66.7)
104 (51.0)
8 (72.7)
13 (56.5)
ins/ins 3 (6.7)
56 (27.5)
0
5 (21.7)
TYMS 5’
2R/2R 7 (15.9)
41 (20.1)
4 (36.4)
8 (34.8)
VNTR
2R/3R 25 (56.8)
103 (50.5)
5 (45.5)
8 (34.8)
3R/3R 12 (27.3)
59 (28.9)
1 (9.1)
6 (26.1)
2R/4R 0
1 (0.5)
0
0
3R/4R 0
0
1 (9.1)
1 (4.4)
TYMS
del/del 14 (31.1)
23 (11.3)*
3 (27.3)
3 (13.0)
1494del6
ins/del 23 (51.1)
86 (42.2)
5 (45.4)
12 (52.2)
ins/ins 8 (17.8)
95 (46.6)
3 (27.3)
8 (34.8)
RFC1 80A>G
AA
27 (60.0)
41 (20.1)*
6 (54.5)
5 (21.7)
AG
16 (35.6)
101 (49.5)
4 (36.4)
15 (65.2)
GG
2 (4.4)
62 (30.4)
1 (9.1)
3 (13.0)
n(%)
* p values <0.05 for comparison of African American current users to Caucasian current
users by Fisher’s Exact Test
† p values <0.05 for comparison of African American current users to African American
discontinued users by Fisher’s Exact Test
‡ p values <0.05 for comparison of Caucasian current users to Caucasian discontinued
users by Fisher’s Exact Test
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MTHFR 677C>T substantially impacts biochemical variables
In African American current users there were only 2 MTHFR 677TT
homozygotes and this was not enough to support further analyses. In Caucasian current
users there were enough MTHFR 677TT homozygotes to permit the analysis of the effect
of this genotype on biochemical variables. MTHFR 677TT individuals had marginally
higher tHcy levels than 677C carriers but this was not statistically significant (Table 511). Although MTHFR 677TT homozygotes had slightly more total RBC folate, which
was not significant, they had drastically lower levels of RBC 5-MTHF (679.8 vs 1022.3
nmol/L, p=0.002). MTHFR 677TT homozygotes had substantially more RBC THF
(447.8 vs 34.0 nmol/L, p<0.0001). This alteration of the distribution of RBC folate
derivatives led to a dramatically lower ratio of 5-MTHF:THF in 677TT individuals (1.8
vs 30.9, p<0.0001). RBC 5,10-MTHF levels were detectable in 16 out of 18 (88.9%)
MTHFR 677TT individuals compared to 80 out of 157 (51.0%) 677C carriers (p=0.002).
Vitamin B12 levels were also impacted by this polymorphism. MTHFR 677TT
homozygotes had lower levels of B12 (541 vs 634 pmol/L, p=0.002). Since the 677TT
genotype had such a widespread and substantial impact on folate/Hcy metabolism, all
MTHFR 677TT individuals were excluded for analyses which involved metabolites of the
folate/Hcy pathway.
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Table 4-11. Effects of MTHFR 677C>T genotypes in Caucasian current users.
MTHFR 677
CC/CT
TT
P Value
tHcy, µmol/L
10.4 [9.0-12.3] (160)
11.2 [9.2-14.1] (18)
0.50
Total RBC Folate*,
1088.2 [869.2-1361.2] 1155.5 [863.2-1745.4]
nmol/L
(157)
(18)
0.29
RBC 5-MTHF,
1022.3 [832.5-1279.5] 679.8 [537.0-1068.5]
nmol/L
(157)
(18)
0.002
34.0 [22.6-60.5]
447.8 [118.6-492.6]
RBC THF, nmol/L
(157)
(18)
<0.0001
Ratio 5-MTHF:THF
30.9 [18.7-47.6] (157)
1.8 [0.9-7.5] (18)
<0.0001
RBC 5,10-MTHF - D† 80 (51.0)
16 (88.9)
0.002
ND 77 (49.0)
2 (11.1)
B12*, pmol/L
634 [401-858] (152)
541 [289-600] (17)
0.018
Median [IQR] (n)
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; B12 values of
“>1000” were given values of 1000
†D=Detectable, ND=Not Detectable
Effects of other polymorphisms on biochemical variables
In African American current users the DHFR c.86+60_78 polymorphism had an
effect on RBC THF levels and the ratio of 5-MTHF:THF. DHFR del/del homozygotes
had lower THF levels than ins carriers (15.3 vs 27.7 nmol/L, p=0.008, Table 5-12). This
difference influenced the ratio of 5-MTHF:THF such that del/del individuals had higher
ratios (53.3 vs 37.4, p=0.010). DHFR del/del individuals were also being prescribed
lower doses of MTX (15.0 vs 20.0 mg, p=0.025). Another polymorphism was also
associated with currently prescribed dose. TYMS 1494del6 ins/ins individuals were
prescribed 12.5 mg, which was lower than 20.0 mg for del/ins and 16.3 mg for del/del
individuals (p=0.028).
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Table 4-12. Effects of selected genotypes on biochemical variables and current MTX
dose in African American current users.
Genotype
Biochemical Variable
P Value
RBC THF, nmol/L
DHFR c.86+60_78
Ins carriers 27.7 [19.1-37.9] (27)
0.008
Del/del
15.3 [13.5-32.3] (11)
Ratio of 5-MTHF:THF
DHFR c.86+60_78
Ins carriers 37.4 [25.9-45.7] (27)
0.010
Del/del
53.3 [39.1-72.1] (11)
Current MTX Dose, mg
DHFR c.86+60_78
Ins carriers 20.0 [15.0-20.0] (31)
0.025
Del/del
15.0 [10.0-17.5] (11)
TYMS 1494del6
Del/del
16.3 [12.5-17.5] (14)
0.028
Del/ins
20.0 [15.0-20.0] (20)
Ins/ins
12.5 [11.3-17.5] (8)
Median [IQR] (n)
In Caucasian current users total RBC folate concentrations were lowest in RFC1
80AA homozygotes (934.5 vs 1071.5 for AG vs 1293.0 for GG, p=0.001, Table 5-13). In
particular RBC 5-MTHF levels were lowest in 80AA homozygotes (859.4 vs 1002.1 for
AG vs 1252.1 for GG, p=0.0005). The MTRR 66A>G polymorphism altered RBC folate
derivative distributions. MTRR 66GG individuals had the lowest level of RBC THF (22.7
vs 42.8 for AG vs 43.1 for AA, p<0.0001). Consequently the ratio of 5-MTHF:THF was
highest in GG individuals (44.8 vs 24.7 for AG vs 23.7 for AA, p<0.0001). B12 levels
were lower in MTR 2756AA homozygotes compared to 2756G carriers (590.0 vs 784.0,
p=0.006).
The MTRR 66A>G polymorphism not only affected RBC THF levels and the
ratio of 5-MTHF:THF but also determined whether RBC 5,10-MTHF levels were
detectable or not. In Caucasian current users there were 16 out of 52 (32.7%) MTRR
66GG individuals who had detectable RBC 5,10-MTHF levels compared to 60% of
66AA and 66AG individuals (p=0.006, Table 5-14).
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Table 4-13. Effects of selected genotypes on biochemical variables in Caucasian
current users.
Genotype
Biochemical Variable
P Value
Total RBC Folate*, nmol/L
RFC1 80A>G
AA
934.5 [763.4-1156.7] (33)
0.001
AG
1071.5 [875.4-1306.5] (80)
GG
1293.0 [997.4-1514.3] (44)
RBC 5-MTHF, nmol/L
RFC1 80A>G
AA
859.4 [680.2-1085.6] (33)
0.0005
AG
1002.1 [836.1-1242.4] (80)
GG
1252.1 [946.9-1464.3] (44)
RBC THF, nmol/L
MTRR 66A>G
AA
43.1 [28.0-79.4] (35)
<0.0001
AG
42.8 [25.5-72.3] (70)
GG
22.7 [17.5-35.9] (52)
Ratio 5-MTHF:THF
MTRR 66A>G
AA
23.7 [14.1-34.4] (35)
<0.0001
AG
24.7 [16.5-37.5] (70)
GG
44.8 [32.3-56.3] (52)
B12*, pmol/L
MTR 2756A>G
AA
590.0 [359.0-793.0] (103)
0.006
G
784.0 [514.0-908.0] (49)
carriers
Median [IQR] (n)
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; B12 values of
“>1000” were given values of 1000
Table 4-14. Distribution of MTRR 66A>G genotypes in Caucasian current users by
detection of RBC 5,10-MTHF.
MTRR 66A>G
RBC 5,10-MTHF
AA
AG
GG
Detectable
21 (60.0)
42 (60.0)
17 (32.7)
Not Detectable
14 (40.0)
28 (40.0)
35 (67.3)
n(%), Fishers Exact P=0.006
Genotypes associated with toxicities
Genotype distributions were compared between various categories of toxicities. In
African American current users MTR 2756G carriers had 5 out of 16 (31.2%) individuals
experience an attributable toxicity compared to 0 out of 29 individuals who were
2756AA homozygotes (p=0.004, Table 5-15). The same association was significant for
attributable toxicities compared to no toxicities (data not shown). In Caucasian current
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users MTHFD1 1958GG homozygotes had 14 out of 68 (20.6%) individuals experience
an attributable toxicity compared to 12.1% of 1958GA and 4.4% of 1958AA individuals
(p=0.043, Table 5-16). The same association was significant for attributable toxicities
compared to no toxicities (data not shown).
Table 4-15. Distribution of MTR 2756A>G genotypes in African American current
users by type of toxicity.
MTR 2756A>G
AA
AG/GG
Attributable
0
5 (31.2)
Toxicity
Non-Attributable 29 (100.0) 11 (68.8)
and No
Toxicities
n (%), Fishers exact p=0.004
Table 4-16. Distribution of MTHFD1 1958G>A genotypes in Caucasian current
users by type of toxicity.

Attributable
Toxicity
Non Attributable
and No
Toxicities

MTHFD1 1958G>A
GG
GA
AA
14 (20.6)
11 (12.1)
2 (4.4)
54 (79.4)

80 (87.9)

43 (95.6)

n (%), Fishers exact p=0.043
Associations among biochemical and other continuous variables
In African American current users tHcy levels were negatively correlated with
plasma 5-MTHF levels (p=0.011) and positively correlated with age (p=0.003, Table 517). Plasma 5-MTHF levels were positively correlated with total RBC folate levels
(p=0.003) and specifically there was a positive correlation with RBC 5-MTHF (p=0.005).
Total RBC folate was positively correlated with CRP levels (p=0.004) and B12 levels
(0.027). In particular RBC 5-MTHF was positively correlated with CRP levels (p=0.034)
and B12 levels (p=0.042). Plasma folic acid was positively associated with age (p=0.021).
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There was a profile which develops and consists of the following relationships being
associated with high tHcy: low plasma 5-MTHF, older age, low total RBC folate, low
RBC 5-MTHF, low CRP, low B12, and high plasma folic acid.
Table 4-17. Correlation of selected continuous variables in African American
current users.
Spearman
Correlation
Significant
Coefficient (n)
P values
tHcy
Plasma 5-MTHF -0.39 (41)
0.011
Age
0.46 (41)
0.003
Plasma 5-MTHF
Total RBC folate 0.46 (41)
0.003
RBC 5-MTHF
0.43 (41)
0.005
Total RBC folate*
CRP*
0.45 (41)
0.004
B12*
0.36 (37)
0.027
RBC 5-MTHF
CRP*
0.33 (41)
0.034
B12*
0.34 (37)
0.042
Plasma FA
Age
0.36 (41)
0.021
*Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000
In Caucasian current users tHcy levels were positively correlated with age
(p=<0.0001) and plasma folic acid (p=0.013, Table 5-18). Plasma 5-MTHF was
positively correlated with total RBC folate (p<0.0001) and in particular RBC 5-MTHF
(p<0.0001). Plasma 5-MTHF was negatively correlated with plasma folic acid (p=0.047).
Total RBC folate was positively correlated with the following: plasma folic acid
(p=0.025), CRP (p<0.0001), and age (p=0.002). In particular it was RBC 5-MTHF which
was positively correlated with the following: plasma folic acid (p=0.018), CRP
(p=0.0003), and also B12 (p=0.029). RBC THF was another folate derivative also
positively correlated with plasma folic acid (p=0.020) and CRP (p=0.046). In addition
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RBC THF was positively correlated with age (p=0.011). Plasma folic acid was positively
correlated with age (p<0.0001) and B12 (p=0.0002). PGA scores were positively
correlated with CRP levels (p=0.003). CRP was negatively correlated with B12 (p=0.014).
B12 was positively correlated with age (p=0.006). There were no clear profiles which
developed because plasma folic acid was negatively correlated with plasma 5-MTHF and
positively correlated with total RBC folate but plasma 5-MTHF was positively correlated
with total RBC folate.
Table 4-18. Correlation of selected continuous variables in Caucasian current users.
Spearman
Correlation
Significant
Coefficient (n)
P values
tHcy
Age
0.35 (175)
<0.0001
Plasma FA
0.19 (178)
0.013
Plasma 5-MTHF
Total RBC folate 0.32 (175)
<0.0001
RBC 5-MTHF
0.34 (175)
<0.0001
Plasma FA
-0.15 (178)
0.047
Total RBC folate*
Plasma FA
0.17 (175)
0.025
CRP*
0.34 (168)
<0.0001
Age
0.24 (172)
0.002
RBC 5-MTHF
Plasma FA
0.18 (175)
0.018
CRP*
0.29 (168)
0.0003
B12*
0.17 (167)
0.029
RBC THF
Plasma FA
0.18 (175)
0.020
CRP*
0.15 (168)
0.046
Age
0.19 (172)
0.011
Plasma FA
Age
0.37 (175)
<0.0001
B12
0.28 (168)
0.0002
PGA
CRP*
0.24 (157)
0.003
CRP*
B12*
-0.19 (161)
0.014
B12*
Age
0.21 (166)
0.006
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* Total RBC folate = RBC 5-MTHF + RBC THF + RBC 5,10-MTHF; CRP values of
“<0.3” were given the value of 0.3; B12 values of “>1000” were given values of 1000
4.5 Discussion
The SLE study was designed to study associations between polymorphisms of
enzymes in the folate/Hcy pathway and elevated Hcy levels. Since elevated Hcy is
predictive of CAC scores (Von Feldt et al. 2006), associations between genetic variants
and CAC scores was also analyzed. African Americans had significantly different
genotype distributions than Caucasians and therefore the analyses were performed within
each race. Previous reports have shown that African American and Caucasian genotype
frequencies are significantly different. For example MTHFR 677C>T and 1298A>C
polymorphisms have higher frequencies of the variant genotype in Caucasians as
compared to African Americans (Tsai et al. 2009). Also MTR 2756A>G (Tsai et al.
2009), MTRR 66A>G (Shi et al. 2003; Tsai et al. 2009), CBS 844ins68 (Pepe et al. 1999;
Tsai et al. 2009), and TYMS 1494del6 (Ranganathan et al. 2004) have all been reported
to have different genotype frequencies when African Americans and Caucasians were
compared. In the SLE study frequencies of DHFR c.86+60_78 genotypes also differed
between races. None of the polymorphisms which were examined had significantly
different distributions when comparing SLE cases and controls in each race. This
indicated that none of the polymorphisms in the SLE study were related to increased risk
of SLE. The literature suggests that in some populations these polymorphisms may carry
increased risk. An Italian study reported that the MTHFR 677TT genotype was
overrepresented in SLE patients (Afeltra et al. 2005). While a Polish study could not
replicate the finding regarding MTHFR 677C>T genotypes but instead observed an
overrepresentation of the MTR 2756G allele in SLE patients (Burzynski et al. 2007).
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As far as the effects of polymorphisms on Hcy levels of SLE patients there was a
report in the literature which was consistent with our findings. A study by Fijnheer et al.
(1998) found that MTHFR 677C>T genotypes were not associated with Hcy levels in
SLE patients. In our control group the MTHFR 677TT genotype was associated with
higher tHcy levels. Also in the control group MTHFR 1298C carriers had lower tHcy
levels. These findings are consistent with reports from the literature. In healthy Irish men
from the Industrial Workers study the MTHFR 677TT genotype was associated with
elevated tHcy concentrations (Harmon et al. 1996). A study by Parle-McDermott et al.
showed that the MTHFR 1298C allele was associated with increased RBC folate levels
(Parle-McDermott et al. 2006b). There was a report from a large scale study that was not
consistent with the MTHFR 1298 allele having a decreased Hcy/increased folate
phenotype. The MTHFR 1298C allele was associated with higher Hcy levels and lower
serum folate concentrations in a large scale study in healthy individuals (Ulvik et al.
2007). In the SLE study folate, B12, and B6 levels were not available but instead use of
vitamin supplements was studied as a surrogate. Vitamin use did not have any effect on
Hcy levels. Kidney function as measured by GFR was negatively correlated with Hcy
levels, which was consistent with reports from the literature. A study in the US showed
that low GFR was significantly associated with elevated Hcy concentrations (Francis et
al. 2004).
Although the SLE study has some limitations, the magnitude of the difference in
tHcy levels between SLE cases and controls suggested that genetic factors might be
responsible for the elevation of tHcy in SLE cases. THcy concentrations of Caucasian
controls were associated with MTHFR 677C>T and 1298A>C genotypes. In SLE cases
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tHcy concentrations were not associated with any of the 7 polymorphisms even with
adjustment for covariates, such as GFR. Also none of the 7 polymorphisms were
associated with CAC scores. We acknowledge that the size of our study population
precludes a conclusion that there are no contributing genetic factors for elevated tHcy
levels. Our SLE study suggests that if genetic factors are involved it is likely that they
would have a relatively small effect. The higher tHcy levels observed in SLE cases is
likely due to inflammatory aspects of the SLE disease process itself, which might
dominate over any genetic effects.
In the RA study, which measured tHcy and folate derivatives using a high
precision method, several polymorphisms in enzymes of the folate/Hcy metabolism were
associated with levels of these metabolites in current MTX users. In Caucasians the
MTHFR 677C>T polymorphism had a large impact on folate derivative levels. The
distribution of RBC folate derivatives was significantly altered. RBC 5-MTHF levels in
MTHFR 677TT homozygotes were much lower and RBC THF levels were much higher
than 677C carriers. The ratio of 5-MTHF:THF was therefore impacted and was
dramatically lower in 677TT individuals. Detection of RBC 5,10-MTHF was associated
with the 677TT genotype. These results are similar to those observed in Caucasians in the
Premenopausal Women study {{597 Summers,C.M. 2010}}, except that 677TT
individuals in the Premenopausal Women study had increased tHcy levels while there
was no such association in RA patients currently taking MTX. The impact of this
polymorphism was large enough to warrant the removal of individuals with the 677TT
genotype from further analyses involving tHcy and folate derivatives in the RA study.
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In Caucasian current users RFC1 80A>G was another polymorphism which was
associated with altered levels of folate derivatives. RFC1 80AA homozygotes had lower
total RBC folate and lower RBC 5-MTHF levels. This seems to be consistent with
findings in the Premenopausal Women study where African American RFC1 80G
carriers had lower RBC THF levels and higher ratios of 5-MTHF:THF (Summers et al.
2010). In Caucasian current users the MTRR 66A>G polymorphism was found to be
associated with lower RBC THF, higher ratios of 5-MTHF:THF, and also was associated
with non-detectable RBC 5,10-MTHF. These were novel associations.
In African Americans the DHFR del/del genotype was associated with lower RBC
THF levels and higher ratios of 5-MTHF:THF. DHFR del/del genotype is associated in
the literature with higher serum and RBC folate in healthy women (StanislawskaSachadyn et al. 2008a). Our finding seems to be inconsistent, but since total RBC folate
levels were not significantly different in African Americans with RA currently taking
MTX it is hard to draw any final conclusion. African American DHFR del/del individuals
were being prescribed lower doses of MTX. The TYMS 1494del6 polymorphism in
African Americans was also associated with current MTX dose. TYMS ins/ins
individuals were being prescribed lower doses of MTX. These polymorphisms may be
associated with efficacy at a lower dose of MTX but further studies will be needed to
validate this observation.
A Middle Eastern study in RA patients found that the MTR 2756GG genotype
was overrepresented in RA patients when compared to controls (Berkun et al. 2007). The
RA study did not have controls available to replicate this finding but instead found MTR
2756G carriers were associated with attributable toxicities while taking MTX. It is
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possible that this polymorphism may increase risk for RA as well as increase toxicities
while on MTX therapy.
In an RA study in Slovenia the MTHFR 1298CC genotype was associated with a
protective effect, a decreased risk of overall toxicity (Bohanec Grabar et al. 2008). While
the RA study did not replicate this finding we instead found that the MTHFR 1298CC
genotype in Caucasians was associated with discontinuation of MTX therapy. This
finding in Caucasians is consistent with a study in Dutch RA patients that found the
MTHFR 1298AA genotype was associated with efficacy and less overall toxicities
(Wessels et al. 2006). The RA study also found that the MTHFD1 1958GG genotype in
Caucasians was associated with increased attributable toxicities. This finding was
contradictory to the finding that the MTHFD1 1958AA genotype in African Americans
was associated with discontinuation of MTX therapy. There is not any biological
explanation as to why the same polymorphism in different races would carry very
different associations.
The RFC1 80GG genotype in an RA study in Slovenia was associated with
increased risk of overall toxicity (Bohanec Grabar et al. 2008). A study in US RA
patients found that a favorable response to MTX was associated with the RFC1 80AA
genotype (Dervieux et al. 2004). Although the RFC1 80G>A polymorphism has
consistent results in the literature, this finding was not replicated in the RA study. Overall
the RA study has found that different polymorphisms in African Americans and
Caucasians are associated with differences in tHcy and folate metabolites, being
prescribed lower doses of MTX, and increased risk for attributable toxicities and
discontinuation of MTX.
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Elevated CRP levels are indicative of systemic inflammation, are associated with
presence of an inflammatory disease, and are also associated with increased risk for
cardiovascular disease (Windgassen et al. 2011). In the RA study CRP levels were
positively associated with total RBC folate and specific RBC folate derivatives in both
African American and Caucasian subjects. This association is not easily explained and it
is possible that folic acid taken with MTX may be blocking some of its anti-inflammatory
effect, although further studies are required to support this finding. The RA study has
provided evidence that polymorphisms in enzymes of the folate/Hcy metabolic pathway
may be able to predict therapeutic outcome. Larger studies with special attention to race
and which make use of high precision methods for measurement of folate/Hcy
metabolites will be required to validate these findings.
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Chapter 5: The Effect of Methotrexate Alone and on the Activation of Endothelial
Cells
5.1 Abstract
Mild folate deficiency is known to be associated with a proatherosclerotic
phenotype in endothelial cells. EA.hy 926 endothelial cells grown in low (Lo) folate
conditions had higher levels of monocyte chemoattractant protein 1 (MCP-1) then cells
grown in normal (Hi) folate conditions. Methotrexate (MTX) is an anti-folate drug used
to treat a broad range of diseases including inflammatory diseases. MTX seems to have
conflicting properties of anti-folate and anti-inflammatory, therefore Hi and Lo cells were
treated with MTX at concentrations relative to peak plasma concentrations after low dose
administration in rheumatoid arthritis patients. Tumor necrosis factor alpha (TNF-α) is a
cytokine which is involved in systemic inflammation. The effect of MTX in the presence
of TNF- α, an inflammatory stimulus, was examined by pre-treating the cells with MTX
for 24hrs before exposing the cells to TNF-α. Activation of endothelial cells by TNF-α
stimulates inflammatory gene expression. It was investigated whether MTX treatment
was associated with an anti-folate effect or an anti-inflammatory effect at concentrations
relative to those seen in the treatment of rheumatoid arthritis.
When Hi and Lo cells were treated with MTX cellular proliferation was inhibited,
total intracellular folate was depleted, the composition of intracellular folate derivatives
was altered, and levels of unmetabolized folic acid were higher. Microarray analysis was
used to examine MTX induced gene expression in Hi and Lo cells. There were over 100
two-fold or higher differentially expressed genes. Specifically there was differential gene
expression of several inflammatory genes which included up regulation of C3 and IL-8,
and down regulation of a large set of genes involved in mitosis. Dihydrofolate reductase
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(DHFR), an enzyme in folate metabolism and target of MTX, was also down regulated.
There was no change in MCP-1 levels. Selected targets were confirmed by quantitative
RT-PCR and ELISA. MTX treatment may involve a more complex modulation of
inflammation than previously assumed.
5.2 Introduction
Elevated circulating levels of the intermediate amino acid Hcy, referred to as
hyperhomocysteinemia, has been associated with a wide range of human pathologies
including cardiovascular disease, stroke (Refsum et al. 1998), Alzheimer’s disease
(Mattson and Shea 2003), some cancers (Weinstein et al. 2001), and birth defects (van
der Put et al. 2001). Hyperhomocysteinemia is generally underpinned by low folate
status, in which both the absolute (Kang et al. 1987; Selhub et al. 1996) and relative
(Mitchell et al. 2009) concentrations of intracellular folate derivatives may be altered.
Historically elevated Hcy was considered to be the pathogenic component in the
conditions with which hyperhomocysteinemia has been associated because of its direct
toxic effects on redox thiol status and ER stress response (Koch et al. 1998). However,
alternative causative mechanisms implicating low folate concentrations and their negative
impact on processes such as nucleic acid synthesis and methylation have been suggested
(Lucock 2000).
Many of the medical conditions which are associated with a high Hcy and low
folate phenotype have inflammatory aspects and involve damage to, or dysfunction of,
the vasculature and its constituent cell types, in particular endothelial cells. Inappropriate
or sustained activation of immunologically active endothelial cell products might
contribute to ongoing pathology at the local and possibly also systemic level. In recent
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studies, EA.hy 926 endothelial cells grown under low folate conditions adopted a
‘proatherosclerotic’ phenotype compared to cells grown under high folate conditions
without displaying any significant differences in intracellular or extracellular Hcy levels
(Brown et al. 2006). This low folate phenotype was characterized by elongated cell
morphology with prominent networks of stress fibers and impaired barrier function. A
significantly increased synthesis and export of monocyte chemoattractant protein 1
(MCP-1) was observed in the cells grown under low folate conditions (Brown et al.
2006). MCP-1, a potent chemokine encoded by the CCL2 gene, is synthesized by various
cell types including vascular smooth muscle cells in response to oxidized lipid. MCP-1
facilitates the transmigration of monocytes from the circulation across the endothelium
and is a key contributor to the early stages of atheroma formation (Schwartz et al. 1991).
In cultured human monocytes Hcy induced the secretion of MCP-1 and IL-8, a neutrophil
chemoattractant (Zeng et al. 2003). The above in vitro observation has been corroborated
in vivo in a study of young healthy adults in whom serum MCP-1 levels were inversely
associated with serum and red blood cell folate concentrations, and positively associated
with circulating tHcy concentrations (Hammons et al. 2009). These finding have
reinforced speculation that folate stress, which is indicative of poor nutritional status,
might augment aspects of baseline inflammatory preparedness to facilitate a more
vigorous initial responses to infectious challenges in individuals weakened by
malnutrition (Lu et al. 2009).
The central role of folate in nucleotide synthesis has been exploited
pharmacologically via the development of potent anti-folate drugs for the treatment of
neoplastic and auto-immune conditions. One of the most widely used anti-folate drugs is
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methotrexate (MTX), which inhibits the key enzymes dihydrofolate reductase (DHFR),
thymidylate synthase (TYMS), glycinamide ribonucleotide transformylase (GART), and
aminoimidazolecarboxamide ribonucleotide transformylase (AICART) (Kremer
2004)(Figure 5-1). High dose MTX is a component of diverse therapeutic regimens for
several cancers including acute lymphoblasic leukemia, while lower doses are used to
treat inflammatory diseases such as rheumatoid arthritis (RA). In the latter condition,
MTX tends to be well tolerated with relatively minor side effects and there is clear
therapeutic benefit in reducing the inflammatory aspects of the disease that contribute to
joint damage (Coury and Weinblatt 2010). However, RA patients have significant
cardiovascular comorbidity (Nurmohamed 2009) and there is controversy as to whether
MTX exacerbates or ameliorates this serious source of co-mortality. An early study in
the use of MTX in the treatment of rheumatoid arthritis patients with existing CVD
indicated that mortality was increased (Landewe et al. 2000). Conversely, several more
recent studies have suggested that MTX use is associated with a decrease in the incidence
of CVD events and mortality (Choi et al. 2002; Naranjo et al. 2008; van Halm et al.
2006), although it remains unclear whether such a decrease would reflect a full or only
partial amelioration of inflammation-attributable CVD.
Over expression of TNF-α is involved in many inflammatory diseases including
rheumatoid arthritis and atherosclerosis (Parameswaran and Patial 2010). The possibility
that low folate status, due to nutritional variables or the use of anti-folate drugs,
contributes to human disease by inducing a subset of potentially pathogenic
inflammation-associated molecules, including MCP-1, is of considerable public health
interest. The characterization of changes to the inflammatory profile that might be
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induced by drugs such as MTX, alone and prior to exposure to TNF-α, would serve as the
foundation for future studies to define the precise relationship between dysregulation of
folate metabolism and inflammation. This study was designed to investigate the effect of
pharmacologically relevant doses of MTX on the absolute and relative concentrations of
key folate derivatives and gene expression in the EA.hy 926 endothelial cell line. The
potential implications of observations concerning the up-regulation of key inflammatory
proteins are discussed.
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Figure 5-1. Folate/Homocysteine pathway and MTX inhibition. 5-MTHF, 5methyltetrahydrofolate; 5,10-MTHF, 5,10-methenyltetrahydrofolate; DHF, dihydrofolate;
DHFR, dihydrofolate reductase; dTMP, deoxythymidine monophosphate; dUMP,
deoxyuridine monophosphate; Hcy, homocysteine; MTX, methotrexate; SAH, Sadenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate; TYMS,
thymidylate synthase.

5.3 Methods
5.3.1 EA.926 cell line experiments
Cell Culture
The EAhy.926 cell line is a fusion product between human umbilical vascular
endothelial cells (HUVECs) and the epithelial cell line A549 derived from a human lung
carcinoma (Edgell et al. 1983). EA.hy 926 cells were maintained in DMEM with 10%
fetal calf serum (FCS), gentamycin, penicillin, streptomycin, and fungizone. Lo cells
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were adapted to growth under low folate conditions for three weeks in Medium 199
(Gibco, Invitrogen, Carlsbad, CA), which contains 23nM folic acid, and supplemented
with 10% FCS, non-essential amino acids, gentamycin, penicillin, streptomycin, and
fungizone. Hi cells were cultured in parallel in Medium 199 with the addition of 4mg/L
(9uM) folic acid and supplemented as above as previously described (Brown et al. 2006).
BrdU Cell Proliferation Assays
Hi and Lo cells were seeded in their respective media into 96-well plates at a
density of 1x10^4 cells per well. After overnight incubation triplicate cultures were given
fresh media containing 0, 0.1, 0.25, or 0.5uM MTX (Sigma-Aldrich, St. Louis, MO).
After 24 and 48 hours media was removed and adherent cells were fixed and stained
using the Cell Proliferation ELISA, BrdU Colorimetric kit (Roche Diagnostics,
Indianapolis, IN) according to the manufacturer’s instructions. Colorimetric analyses
were performed with an ELISA plate reader (Dynex Technologies, Chantilly, VA).
Cell Viability Assays
Hi and Lo cells, grown to confluence in 6-well plates, were maintained for 24
hours in fresh medium prior to the addition of 0, 0.1, 0.25, or 0.5µM MTX. After a
further 48 hours the numbers of live cells remaining were determined in duplicate with an
electronic cell counter (Scepter, Millipore, Bedford, MA). For experiments involving
TNF-α (Invitrogen), cells were treated for 24hrs with 0.5µM MTX followed by the
addition of 10ng/mL TNF- α for an additional 24hrs. The numbers of live and dead cells
in each treatment group were also determined by counting using a hematocytometer and a
dye exclusion assay using 0.4% w/v trypan blue solution (Mediatech, Herndon, VA).
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Alamar Blue Assays
Fresh medium was added to confluent Hi and Lo cell cultures grown in 96-well
plates, and treated 24 hours later with 0, 0.1, 0.25, 0.5µM MTX. After 2, 8, 16, 24, and 48
hours metabolic activity was measured in biological triplicates by Alamar Blue Assay
(Trek Diagnostic Systems, West Lake, OH) according to the manufacturer’s directions.
For experiments involving TNF-α, cells were treated for 24hrs with 0.5µM MTX
followed by the addition of TNF- α for an additional 24hrs.
Biochemical Phenotyping
Confluent Hi and Lo cells were maintained for 24 hours in fresh medium prior to
treatment with 0.5µM MTX for 48hrs. For experiments involving TNF-α, cells were
treated for 24hrs with 0.5µM MTX followed by the addition of TNF- α for an additional
24hrs. Intracellular folate derivatives, i.e. 5-MTHF, THF, 5,10-methenyltetrahydrofolate
(5,10-MTHF), and unmetabolized folic acid (FA), were measured in biological triplicates
by stable isotope dilution liquid chromatography, multiple reaction monitoring, mass
spectrometry (LC/MRM/MS) as described previously (Huang et al. 2008).
Affymetrix Microarrays
RNA was isolated from biological triplicates with the RNeasy kit (Qiagen Inc.,
Valencia, CA) and reverse transcribed to cDNA using the Affymetrix WT Expression kit
(Ambion, Austin, TX). Subsequent experimental procedures and statistical analyses of
microarray signals were performed by the University of Pennsylvania Microarray and
Bioinformatics core facilities respectively as follows. The purity and size distribution of
cDNA was assessed using the Agilent Bioanalyzer and RNA6000 Nano LabChips
(Agilent, Palo Alto, CA), and quantitation was performed using a Nanodrop
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spectrophotometer (Thermo Scientific, Wilmington, DE), prior to their hybridization to
Affymetrix Human Gene 1.0 ST microarrays. Washing and staining of the microarrays
was done on an Affymetrix 450 series fluidics machine. Scanning of each microarray was
performed with an Affymetrix Gene Chip Scanner 3000 to produce Cel files that were
imported into Partek Genomics Suite v6.5 (Partek Inc., St Louis, MO) where robust
multi-array analysis (RMA) was applied. A fold change of >2 and false discovery rate of
5%, corresponding to a corrected p-value of <0.05 were chosen as the cutoffs. The
microarray data have been deposited in the National Center for Biotechnology
Information Gene Expression Omnibus (GEO, http://www.nlm.nih.gov/geo/) and are
accessible through GEO Series accession number [will be available soon].
Quantitative Real Time PCR (qRT-PCR)
RNA was prepared from biological triplicates of control and MTX treated Hi and
Lo cells using the RNeasy kit (Qiagen Inc.). For experiments involving TNF-α, RNA was
prepared from biological triplicates of control, MTX treated, TNF-α treated, and
MTX/TNF-α treated Hi and Lo cells. Reverse transcription was carried out with MMLV
reverse transcriptase (Promega, Madison, WI) as described previously (Brown et al.
2006). To determine the amount of target mRNA relative to that transcribed from the
housekeeping gene GAPDH, qRT-PCR was carried out in 20ul reactions containing 1ul
cDNA, 1ul Taqman Gene Expression Assay (Applied Biosystems, Foster City, CA) in
Taqman Universal master mix (Applied Biosystems). The Applied Biosystems assay ID
numbers were Hs01100879_m1 for C3, Hs00174103_m1 for IL-8 (encoded by CXCL8),
Hs00758822_s1 for DHFR, Hs00365486_m1 for VCAM-1, Hs00164932_m1 for ICAM1, and Hs00174057_m1 for E-selectin. GAPDH and MCP-1 (encoded by CCL2) qRT109

PCR assays were performed as previously described (Brown et al. 2006). All samples
were assayed in duplicate.
ELISA Assays
Confluent Hi and Lo cells were maintained for 24 hours in fresh medium prior to
treatment with 0.5µM MTX. After a further 48hrs MCP-1, IL-8, and C3 concentrations in
medium from MTX treated and untreated control cells were measured in biological
triplicates. For experiments involving TNF-α, cells were treated for 24hrs with 0.5µM
MTX followed by the addition of TNF- α for an additional 24hrs. Secreted proteins were
measured using an MCP-1 ELISA kit (PeproTech, Inc, Rocky Hill, NJ), an IL-8 ELISA
kit (BD Biosciences, San Diego, CA), and a C3 ELISA kit (Innovative Research, Novi,
MI) with adjustment for protein content in the corresponding cell fraction. All samples
were assayed in duplicate.
Statistics
Differences between means were compared by two-tailed Student’s t-test.
Statistical analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).
5.4 Results
5.3.1 EA.926 cell line experiments
MTX Dose finding
Peak concentrations of plasma MTX in patients undergoing treatment for RA
have been reported to fall within a range of 0.37-1.36µM (Lebbe et al. 1994). This
guided our selection of test MTX doses (i.e. 0.1, 0.25, and 0.5µM) that were applied to
Ea.hy 926 cells to identify a concentration that was pharmacologically relevant but did
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not cause excessive cell death or compromise overall metabolic activity. Several methods
were used as detailed below.
The Effect of MTX on EA.hy 926 Cell Proliferation
BrdU cell proliferation assays were performed on Hi and Lo cells following 24
and 48 hours of treatment with all test doses of MTX. A dose dependent inhibition of
proliferation in MTX treated Hi cells was observed relative to control untreated cells
(Figure 5-2A), whereas MTX significantly inhibited proliferation at all concentrations
tested in Lo cells (p<0.05) (Figure 5-2B). Comparable proliferation readouts were
observed for untreated Hi and Lo cells and similar levels of inhibition (approximately
84%) were observed for both using the 0.5µM dose of MTX.
The Effect of MTX and TNF-α on EA.hy 926 Cell Viability
The proportions of Hi and Lo cells that remained viable after treatment with
0.5µM MTX, TNF-α, and MTX/TNF-α were determined using two independent methods.
By Trypan Blue exclusion assay, the percentages of live cells treated with MTX, TNF-α,
MTX/TNF-α, and untreated Hi cells were 96%, 95%, 92%, and 99% respectively. The
percentages of live cells treated with MTX, TNF-α, MTX/TNF-α, and untreated Lo cells
were 67%, 94%, 53%, and 96% respectively (data not shown). Direct counting using a
handheld electronic cell counter, the Scepter, indicated that MTX treated Hi cells had
77% as many live cells as controls (p=0.001) and TNF-α treated had 81% (p=0.001) and
MTX/TNF-α treated had 66% (p<0.0001). The percent of live cells for MTX treated Lo
cells was 69% compared to controls (p=0.002) and TNF-α treated had 84% (p=0.020)
and MTX/TNF-α had 53% (p<0.0001) (data not shown). Thus, by both methods 0.5µM
MTX had only a minimal impact on Hi cell viability and a moderate impact on Lo cell
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viability. TNF-α had a minimal impact on viability alone and therefore MTX/TNF- α
treated cells showed similar viability to MTX treatment alone.
The Effect of MTX on EA.hy 926 Cell Metabolic Activity
Alamar Blue assays were performed on confluent Hi and Lo cell cultures
following treatment with all test concentrations of MTX (i.e. 0.1, 0.25, 0.5µM) for 2, 8,
16, 24, and 48 hours in order to estimate reductions in basic metabolic activity over time.
None of the MTX concentrations had a substantial impact on metabolic activity in either
series (Figure 5-2C and 5-2D). Hi and Lo cells treated with the highest dose of MTX
(0.5µM) for 48 hours retained more than 79% (p= 0.005) and 82% (p=0.029) of the
untreated control Alamar Blue readouts respectively, indicating that metabolism
remained largely intact in MTX treated cells.
Alamar blue assays were performed on Hi and Lo cells treated with 0.5µM MTX
alone, TNF-α alone, and the combination of MTX/TNF-α and were compared to control
readouts. MTX treated Hi cells maintained 78% metabolic activity (p=0.003) (Figure 52E). TNF-α treated Hi cells had 99% and MTX/TNF-α treated Hi cells had 70%
(p=0.005) metabolic activity compared to controls. In Lo cells treated with MTX
metabolic activity was 72% (p=0.006) compared to controls. TNF-α treated Lo cells had
83% (p=0.007) and MTX/TNF-α treated Lo cells had 67% (p=0.004) metabolic activity
compared to controls.
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Figure 5-2. MTX dose finding and viability experiments. A, Recently plated EA.hy
926 Hi cells were incubated overnight and plating medium was replaced with Hi medium
containing various concentrations of MTX (0.1, 0.25, 0.5uM). After 24 and 48 hours the
medium was removed and adherent cells were fixed and stained according to the
manufacturer’s instructions for BrdU quantitation. Each bar represents the mean±SD of
three samples. This experiment is representative of a total of three experiments with
similar results. B, Lo cells were submitted to the above described experiments for BrdU
quantitation. C, Hi confluent cells received a media change containing various
concentrations of MTX (0.1, 0.25, 0.5uM). Cells were incubated with alamar blue for 2
hours. After 2, 8, 16, 24, and 48 hours of exposure to MTX absorbance was measured
and calculated as the percentage of control. Each bar represents the mean±SD of three
samples. This experiment is representative of a total of three experiments with similar
results. D, Lo cells were submitted to the above described experiments for the alamar
blue assay. E, Confluent Hi and Lo cells received a media change, 24hrs later 0.5uM
MTX was added. Then 24hrs later 10ng/mL TNF-α was added and after 22hrs alamar
blue was incubated with the cells for 2hrs. Absorbance was measured and calculated as
the percentage of control. Each bar represents the mean±SD of three samples. This
experiment is representative of a total of three experiments with similar results. *P
values <0.05 compared with respective control.
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Taken together the above results suggested that MTX at a concentration of 0.5µM
would be an appropriate, pharmacologically relevant dose at which to explore the impact
of anti-folate drug treatment on folate phenotype and gene expression profile. Also the
above results suggested that TNF-α did not substantially impact cell viability and
metabolic activity beyond that of MTX.
Modulation of Folate Phenotype in EA.hy 926 Cells by MTX
Exposure of confluent Hi and Lo EA.hy 926 cell cultures to 0.5µM MTX for 48
hours resulted in qualitative and quantitative changes to folate phenotype in both. There
was a dramatic almost 20-fold increase in unmetabolized folic acid from a mean of 32.9
ng per mg protein in untreated Hi cells to 630.4 ng per mg protein in MTX treated Hi
cells (p=0.003, Figure 5-3A). This indicated that Hi cells were able to take up folic acid
from the medium in the presence of MTX and that the drug efficiently inhibited DHFR
activity to prevent the step-wise conversion of folic acid to DHF and THF and its
subsequent entry into the cellular pool of natural folates. The accumulation of folic acid
in MTX treated Hi cells was accompanied by a quantitative reduction in total intracellular
folate (i.e. the sum of the three derivatives 5-MTHF, THF, and 5,10-MTHF) from 2099.1
ng per mg protein in untreated cells to 144.2 ng per mg protein (p=0.003) in MTX treated
cells, which is a reduction to only 7% of the levels observed in untreated control cells.
Although the concentrations of each of the individual folate analytes also fell (i.e. 5MTHF levels from 901.8 to 8.9 ng per mg protein p<0.001, THF levels from 506.3 to
45.5 ng per mg protein p=0.001, and 5,10-MTHF levels from 690.0 to 89.8 ng per mg
protein p=0.008) they did so with different degrees. MTX treated Hi cells had 5-MTHF,
THF, and 5,10-MTHF concentrations that were respectively 1%, 9%, and 13% those
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observed in untreated cells. Thus the individual folates represented very different
proportions of total folate in untreated Hi cells compared to MTX treated Hi cells (43%
to 6% for 5-MTHF, 24% to 32% for THF, and 33% to 62% for 5,10-MTHF).
Folic acid levels were estimated to be 12.4 ng per mg protein in untreated Lo cells
compared to 22.6 ng per mg protein in MTX treated Lo cells (Figure 5-3B). Although
this increase was not statistically significant Lo cells were able to take up folic acid in the
presence of MTX but were unable to process it due to inhibition of DHFR. Total folate
levels did not change significantly and went from 102.1 ng per mg protein in untreated
Lo cells to 107.5 ng per mg protein in MTX treated Lo cells. Estimates of individual
folate derivatives also did not change significantly. 5-MTHF levels were estimated to be
16.8 ng per mg protein in untreated Lo cells compared to an estimate of 15.8 ng per mg
protein in MTX treated Lo cells. THF levels were estimated to be 12.4 ng per mg protein
in untreated Lo cells compared to an estimate of 15.8 ng per mg protein in MTX treated
cells (p=0.005). 5,10-MTHF levels were 72.9 ng per mg protein in untreated Lo cells
compared to 75.8 ng per mg protein in MTX treated cells.
TNF-α treated Hi and Lo cells had folate derivative distributions that were similar
to control cells (Figure 3C and 3D). MTX/TNF-α treated Hi and Lo cells had folate
derivative distributions that were similar to MTX treated cells. The results described
above regarding the effect of MTX alone were similar in this experiment. In Hi cells total
folate decreased from 1241.7 ng per mg protein in control cells to 111.3 ng per mg
protein in MTX treated cells, which represented a drop to 9% of control levels. Folic acid
levels increased from 5.0 ng per mg protein in control Hi cells to 338.2 ng per mg protein
in MTX treated Hi cells. This was a 67.6 fold increase in folic acid levels. In Lo control
116

cells total folate levels decreased from 19.1 ng per mg protein to 1.9 ng per mg protein in
MTX treated Lo cells. Total folate levels dropped to 9.9% of control levels. Folic acid
levels were not significantly different; they were 2.3 ng per mg protein in control cells
and 3.8 ng per mg protein in MTX treated cells. This was a 1.7 fold increase in folic acid
levels.
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Figure 5-3. Folate derivatives measured by LC/MRM/MS. A, Hi confluent cells were
treated with 0.5uM MTX for 48 hours. Each bar represents the mean±SD of three
samples. This experiment is representative of a total of three experiments with similar
results. B, Lo confluent cells were treated with 0.5uM MTX for 48 hours. Each bar
represents the mean±SD of three samples. This experiment is representative of a total of
three experiments with similar results except that in some experiments MTX treated Lo
cells did have decreased levels of folate derivatives. C, Confluent Hi cells received a
media change, 24hrs later 0.5uM MTX was added. Then 24hrs later 10ng/mL TNF-α was
added and after 24hrs cells were harvested. Each bar represents a single sample and
hence p values were not calculated. This experiment is representative of a total of three
experiments with similar results. D, Lo cells were treated as in the above described
experiment. *P values <0.05 compared with respective control.
In Hi cells it was observed that MTX not only dramatically increased folic acid
and decreased total folate, but also modified the relative proportions of folate derivatives,
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while in Lo cells MTX was estimated to have little effect on folate derivative levels and
only a small increase in folic acid.
MTX Attributable Changes in Gene Expression
The impact of the anti-folate drug, MTX, on gene expression was profiled in both
Hi and Lo cells using Affymetrix Human Gene 1.0 ST microarrays. Using an arbitrary
threshold of at least 2.0 fold change in microarray signal in reference to untreated
controls and adjusted p value <0.05, expression doubled for 47 genes in MTX treated Hi
cells and 48 genes in MTX treated Lo cells (Table 5-1); of these 37 were in common.
When the threshold was broadened to include the top 200 positive fold changes which
were significant, there were 22 inflammatory related genes in MTX treated Hi cells and
18 in MTX treated Lo cells.
Table 5-1. Genes Up Regulated by MTX in Hi and Lo Cells.
Gene name
complement component 3
interleukin 1 receptorlike 1
DNA-damage-inducible
transcript 3
amphiregulin
spermidine/spermine N1acetyltransferase 1
interleukin 8
interleukin 1, alpha
myosin, heavy chain 16
pseudogene
ankyrin repeat, family A,
2
Rho family GTPase 3
arginase, type II
small nucleolar RNA
host gene 12 (non-protein
coding)
enkurin, TRPC channel
interacting protein
basic helix-loop-helix
family, member e40
TNF receptor-associated
factor 1
CCAAT/enhancer
binding protein (C/EBP),

RefSeq
NM_000064
NM_016232

Hi MTX vs. Hi Control
Corrected
Fold
p-value
Change
0.004518
6.09
0.03152
5.44

Lo MTX vs. Lo Control
Corrected
Fold
p-value
Change
0.012688
4.26
0.064945
4.16

DDIT3

NM_004083

0.000816

5.10

0.000896

4.59

AREG
SAT1

NM_001657
NR_027783

0.036354
0.004794

4.74
4.47

0.037236
0.007019

4.74
3.98

IL8
IL1A
MYH16

NM_000584
NM_000575
NR_002147

0.035674
0.018629
0.006217

4.06
3.32
3.20

0.095036
0.021271
0.012298

3.00
3.21
2.75

ANKRA2

NM_023039

0.003436

3.14

0.003602

3.10

RND3
ARG2
SNHG12

NM_005168
NM_001172
AY277594

0.014241
0.000208
0.019755

2.82
2.76
2.68

0.053128
0.000332
0.018825

2.15
2.45
2.72

ENKUR

NM_145010

0.029449

2.63

0.073982

2.17

BHLHE40

NM_003670

0.017717

2.61

0.045509

2.17

TRAF1

NM_005658

0.004209

2.59

0.001149

3.43

CEBPB

NM_005194

0.004179

2.57

0.009084

2.22

Gene
Symbol
C3
IL1RL1
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beta
tumor necrosis factor
receptor superfamily,
member 9
interleukin 11
NIPA-like domain
containing 4
jumonji C domain
containing histone
demethylase 1 homolog
D
leukemia inhibitory
factor (cholinergic
differentiation factor)
baculoviral IAP repeatcontaining 3
chromosome 9 open
reading frame 72
ATP-binding cassette,
sub-family A (ABC1),
member 1
nuclear factor, interleukin
3 regulated
kelch repeat and BTB
(POZ) domain containing
8
GTP binding protein
overexpressed in skeletal
muscle
ectonucleoside
triphosphate
diphosphohydrolase 7
sestrin 2
arylacetamide
deacetylase (esterase)
carcinoembryonic
antigen-related cell
adhesion molecule 1
ribosomal RNA
processing 12 homolog
tumor protein p53
inducible protein 3
protein phosphatase 1,
regulatory (inhibitor)
subunit 15A
growth arrest and DNAdamage-inducible, alpha
GTP cyclohydrolase 1
dual-specificity tyrosine(Y)-phosphorylation
regulated kinase 3
major facilitator
superfamily domain
containing 2
nuclear factor of kappa
light polypeptide gene
enhancer in B-cells 2
zinc finger protein 79
MAX dimerization
protein 1
TAF4b RNA polymerase

TNFRSF9

NM_001561

0.000725

2.50

0.000255

3.15

IL11
NIPAL4

0.005749
0.007065

2.45
2.44

0.006503
0.012427

2.38
2.20

JHDM1D

NM_000641
NM_0010992
87
NM_030647

0.032722

2.42

0.042911

2.30

LIF

NM_002309

0.026925

2.37

0.021945

2.48

BIRC3

NM_001165

0.017913

2.36

0.007347

2.82

C9orf72

NM_018325

0.000208

2.33

0.000185

2.40

ABCA1

NM_005502

0.002318

2.32

0.00375

2.12

NFIL3

NM_005384

0.018743

2.30

0.067535

1.85

KBTBD8

NM_032505

0.031108

2.30

0.025622

2.40

GEM

NM_005261

0.003204

2.24

0.005476

2.04

ENTPD7

NM_020354

0.004725

2.23

0.0067

2.10

SESN2
AADAC

NM_031459
NM_001086

0.000397
0.02442

2.21
2.20

0.000584
0.027336

2.04
2.17

CEACAM1

NM_001712

0.070458

2.20

0.039634

2.49

RRP12

NM_015179

0.004518

2.18

0.00673

2.05

TP53I3

NM_004881

0.032257

2.16

0.037508

2.11

PPP1R15A

NM_014330

0.000131

2.14

5.13E-05

2.28

GADD45A

NM_001924

0.000544

2.13

0.000302

2.32

GCH1
DYRK3

NM_000161
NM_0010040
23

0.011519
0.001218

2.12
2.12

0.004697
0.001422

2.45
2.05

MFSD2

NM_0011364
93

0.0273

2.10

0.034258

2.02

NFKB2

NM_002502

0.002867

2.09

0.00178

2.25

ZNF79
MXD1

NM_007135
NM_002357

0.003083
0.024596

2.09
2.08

0.003641
0.022273

2.04
2.12

TAF4B

NM_005640

0.005503

2.06

0.007019

1.99
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II, TATA box binding
protein (TBP)-associated
factor
ankyrin repeat domain
20B
ring finger protein 114
interleukin 32

ANKRD20
B
RNF114
IL32

kelch-like 21
alkaline ceramidase 2

KLHL21
ACER2

SH2 domain protein 2A

SH2D2A

CD274 molecule
activating transcription
factor 3
FBJ murine osteosarcoma
viral oncogene homolog
B
nuclear receptor
subfamily 1, group D,
member 1
NUAK family, SNF1like kinase, 2
SERTA domain
containing 1
interleukin 13 receptor,
alpha 2
tribbles homolog 3
testis derived transcript
poliovirus receptorrelated 4

CD274
ATF3

NR_003366

0.016499

2.06

0.032682

1.86

NM_018683
NM_0010126
31
NM_014851
NM_0010108
87

0.000884
0.001376

2.03
2.02

0.001126
0.000794

1.92
2.15

0.00111
0.018718

2.01
2.01

0.001354
0.063154

1.92
1.69

0.382362

Greater than 2 fold change in Lo only
1.69
0.049093
2.90

0.121863
0.004794

1.81
1.91

0.034584
0.001585

2.27
2.26

FOSB

NM_0011614
41
NM_014143
NM_0010406
19
NM_006732

0.070182

1.75

0.016166

2.21

NR1D1

NM_021724

0.000599

1.89

0.000276

2.11

NUAK2

NM_030952

0.012792

1.76

0.003594

2.09

SERTAD1

NM_013376

0.007894

1.81

0.002907

2.07

IL13RA2

NM_000640

0.001225

1.80

0.000469

2.05

TRIB3
TES
PVRL4

NM_021158
NM_015641
NM_030916

0.032254
0.001225
0.009434

1.91
1.95
1.80

0.02104
0.000796
0.003985

2.05
2.03
2.00

Two inflammatory genes, C3 and IL-8 topped the lists in both MTX treated Hi
and Lo cells. C3 was number 1 on the list and was up regulated by 6.09 fold (p=0.005) in
MTX treated Hi cells. C3 was number 3 on the list in MTX treated Lo cells and up
regulated by 4.26 fold (p=0.013) (Table 5-1). C3 mRNA levels were verified by qRTPCR methods. C3 mRNA levels were confirmed to be significantly up regulated in MTX
treated Hi and Lo cells (Figure 5-4A). Specifically C3 mRNA levels were up regulated
by 158.4-fold in MTX treated Hi cells (p=0.018) and 3.9-fold in MTX treated Lo cells
(p=0.003). Also Lo control cells had 15.4 fold more C3 mRNA than Hi control cells
(p=0.034). C3 mRNA levels were also measured in TNF-α and MTX/TNF-α treated Hi
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and Lo cells. MTX/TNF-α treated Lo cells had 2.2 fold more C3 mRNA than TNF-α
treated Lo cells (p=0.0329) (Figure 5-4B).
IL-8 was number 6 on the list in MTX treated Hi cells and was up regulated by
4.06 fold (p=0.036). IL-8 was number 11 on the list and up regulated by 3.00 fold
(p=0.095) in MTX treated Lo cells (Table 5-1). IL-8 mRNA levels were also confirmed
by qRT-PCR to be significantly up regulated (Figure 5-4C), specifically IL-8 mRNA
levels were up regulated by 36.2-fold in MTX treated Hi cells (p=0.041) and 1.9-fold in
MTX treated Lo cells (p=0.015). Also Lo control cells had 6.7 fold more IL-8 mRNA
than Hi control cells (p=0.010).
Another inflammatory gene, MCP-1, that was previously shown to be regulated
by folate status (Brown et al. 2006), was not significantly different in the microarray
analysis of MTX treated Hi or Lo cells compared to their respective controls (data not
shown).
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Figure 5-4. QRT-PCR. The mRNA expression of selected targets was studied by
qRT-PCR. Gene expression of respective genes was calculated using the standard curve
method using the endogenous housekeeping control gene GAPDH for normalization.
Each bar represents mean±SD target expression levels normalized to GAPDH levels of
three samples. These experiments are representative of a total of three experiments with
similar results. A, C3. Hi and Lo cells were exposed to 0.5µM MTX for 48 hours. B, C3.
Hi and Lo cells were treated with MTX prior to treatment with TNF-α. C, IL-8. Hi and
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Lo cells were exposed to 0.5µM MTX for 48 hours. D, DHFR. Hi and Lo cells were
exposed to 0.5µM MTX for 48 hours. *P values <0.05 compared with respective control.
#P values <0.05 for Hi control compared to Lo control.
Conversely, expression was reduced by at least 50% for 83 genes in MTX treated
Hi cells and 85 genes in MTX treated Lo cells (Table 5-2); of these 69 were in common.
The most prominent in the list are a range of cell cycle related products as might be
expected following treatment with an anti-folate drug. Also of interest DHFR, which is
inhibited by MTX, was down regulated by 2.22 fold (p=0.003) in MTX treated Hi cells
and 2.43 fold (p=0.002) in MTX treated Lo cells (Table 5-2). DHFR mRNA levels were
confirmed by qRT-PCR to be down regulated, specifically DHFR mRNA levels were
down regulated by 1.9-fold in MTX treated Hi cells (p=0.010) and 3.6-fold in MTX
treated Lo cells (p=0.009) (Figure 5-4D).
A complete list of MTX regulated genes has been deposited in the National
Center for Biotechnology Information Gene Expression Omnibus (GEO,
http://www.nlm.nih.gov/geo/) and is accessible through GEO Series accession number
[will be available soon].
Candidate inflammatory gene mRNA levels were examined in TNF-α and
MTX/TNF-α treated cells. The chosen candidate genes were ICAM1, VCAM1, and Eselectin. None of the mRNA levels of these genes were significantly different between
TNF-α and MTX/TNF-α treated cells (data not shown).
Table 5-2. Genes Down Regulated by MTX in Hi and Lo Cells.
Gene name
polo-like kinase 1
histone cluster 1, H2bm
kinesin family member
20A
budding uninhibited by
benzimidazoles 1

Gene
Symbol
PLK1
HIST1H2B
M
KIF20A
BUB1

RefSeq
NM_005030
NM_003521

Hi MTX vs. Hi Control
Corrected
Foldp-value
Change
1.88E-05
-5.25
0.000397
-4.98

Lo MTX vs. Lo Control
Corrected
Foldp-value
Change
3.80E-05
-4.68
0.000584
-4.26

NM_005733

0.009434

-4.11

0.028454

-3.03

NM_004336

0.00019

-3.80

0.000206

-3.55
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homolog
protein regulator of
cytokinesis 1
DEP domain containing 1
topoisomerase II alpha
kinesin family member
15
cyclin A2
proline rich 11
transmembrane protein
71
NUF2, NDC80
kinetochore complex
component, homolog
family with sequence
similarity 111, member B
centromere protein I
histone cluster 1, H2bb
NDC80 kinetochore
complex component,
homolog
cyclin B2
discs, large (Drosophila)
homolog-associated
protein 5
cell division cycle 2, G1
to S and G2 to M
WD repeat domain 76
nei endonuclease VIIIlike 3
cyclin-dependent kinase
inhibitor 3
non-SMC condensin I
complex, subunit H
SHC SH2-domain
binding protein 1
centromere protein F
budding uninhibited by
benzimidazoles 1
homolog beta
collagen and calcium
binding EGF domains 1
hospholipid scramblase 4
KIAA0101
anillin, actin binding
protein
NDC80 homolog,
kinetochore complex
component
shugoshin-like 2
Rho GTPase activating
protein 11A
PDZ binding kinase
citron (rho-interacting,
serine/threonine kinase
21)

PRC1

NM_003981

7.72E-05

-3.80

5.13E-05

-3.74

DEPDC1

0.00138

-3.79

0.002273

-3.30

TOP2A
KIF15

NM_0011141
20
NM_001067
NM_020242

0.000673
0.000884

-3.63
-3.56

0.000794
0.000502

-3.30
-4.06

CCNA2
PRR11
TMEM71

NM_001237
NM_018304
NM_144649

0.000891
0.000251
0.001489

-3.47
-3.40
-3.40

0.001298
0.000271
0.00321

-3.08
-3.43
-2.82

NUF2

NM_145697

0.000247

-3.33

0.000469

-2.84

FAM111B

NM_198947

0.000616

-3.22

0.000449

-3.43

CENPI
HIST1H2B
B
SPC25

NM_006733
NM_021062

0.000208
0.002254

-3.15
-3.04

0.000143
0.003288

-3.40
-2.77

NM_020675

0.000431

-3.00

0.000372

-3.06

CCNB2
DLGAP5

NM_004701
NM_014750

0.001084
0.000691

-2.94
-2.86

0.001676
0.001149

-2.61
-2.50

CDC2

NM_001786

0.002365

-2.84

0.003357

-2.63

WDR76
NEIL3

NM_024908
NM_018248

0.001858
0.001214

-2.84
-2.79

0.00217
0.002907

-2.72
-2.34

CDKN3

NM_005192

0.010796

-2.79

0.01432

-2.61

NCAPH

NM_015341

0.000343

-2.78

0.000297

-2.87

SHCBP1

NM_024745

0.004586

-2.75

0.007303

-2.49

CENPF
BUB1B

NM_016343
NM_001211

0.000241
0.000867

-2.69
-2.62

0.000297
0.000614

-2.58
-2.70

CCBE1

NM_133459

0.004156

-2.59

0.004322

-2.54

PLSCR4

0.02513

-2.54

0.075709

-2.05

KIAA0101
ANLN

NM_0011283
04
NM_014736
NM_018685

0.000947
0.026609

-2.54
-2.53

0.000693
0.028161

-2.62
-2.51

NDC80

NM_006101

0.00131

-2.53

0.002907

-2.19

SGOL2
ARHGAP1
1A
PBK
CIT

NM_152524
NM_014783

0.001592
0.001195

-2.51
-2.51

0.000776
0.000796

-2.84
-2.63

NM_018492
NM_007174

0.001148
0.00357

-2.48
-2.48

0.000584
0.003553

-2.78
-2.48
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centromere protein K
NDC80 kinetochore
complex component,
homolog
kinesin family member
11
forkhead box M1
hyaluronan-mediated
motility receptor
membrane protein,
palmitoylated 1
cancer susceptibility
candidate 5
cell division cycle 20
homolog
kinesin family member
C1
primase, DNA,
polypeptide 1
meiosis-specific nuclear
structural 1
kinesin family member
4A
kinesin family member
18B
sperm associated antigen
5
minichromosome
maintenance complex
component 6
histone cluster 1, H1b
nucleolar and spindle
associated protein 1
excision repair crosscomplementing rodent
repair deficiency,
complementation group
6-like
dihydrofolate reductase
G-protein signaling
modulator 2
non-SMC condensin II
complex, subunit G2
transmembrane protein
106C
spindle and kinetochore
associated complex
subunit 3
cyclin B1
aldehyde dehydrogenase
1 family, member A1
asp (abnormal spindle)
homolog, microcephaly
associated
polymerase, epsilon 2
BRCA1 interacting
protein C-terminal
helicase 1
integrin, beta-like 1
fidgetin

CENPK
SPC24

NM_022145
NM_182513

0.005066
0.001261

-2.43
-2.42

0.003837
0.000622

-2.56
-2.72

KIF11

NM_004523

0.000301

-2.41

0.000321

-2.36

FOXM1
HMMR

0.00153
0.044808

-2.40
-2.38

0.001491
0.089897

-2.39
-2.08

MPP1

NM_202002
NM_0011425
56
NM_002436

0.03532

-2.38

0.083699

-2.02

CASC5

NM_170589

0.000884

-2.36

0.000802

-2.32

CDC20

NM_001255

0.031901

-2.35

0.033656

-2.34

KIFC1

NM_002263

0.000947

-2.33

0.000584

-2.49

PRIM1

NM_000946

0.00197

-2.31

0.000799

-2.67

MNS1

NM_018365

0.005897

-2.31

0.002181

-2.80

KIF4A

NM_012310

0.001548

-2.31

0.000802

-2.54

KIF18B

0.000257

-2.30

0.000332

-2.19

SPAG5

NM_0010804
43
NM_006461

0.009803

-2.29

0.017348

-2.08

MCM6

NM_005915

0.001497

-2.27

0.00036

-2.99

HIST1H1B
NUSAP1

NM_005322
NM_016359

0.00767
0.002992

-2.26
-2.23

0.004734
0.003799

-2.44
-2.15

ERCC6L

NM_017669

0.004792

-2.23

0.004222

-2.27

DHFR
GPSM2

AK293146
NM_013296

0.002732
0.039037

-2.22
-2.22

0.001585
0.056481

-2.43
-2.08

NCAPG2

NM_017760

0.008014

-2.21

0.006481

-2.28

TMEM106
C
SKA3

NM_0011438
42
NM_145061

0.005389

-2.21

0.003569

-2.38

0.020449

-2.20

0.02316

-2.16

CCNB1
ALDH1A1

NM_031966
NM_000689

0.004518
0.002022

-2.20
-2.18

0.001875
0.005222

-2.56
-1.88

ASPM

NM_018136

0.001036

-2.18

0.000728

-2.25

POLE2
BRIP1

NM_002692
NM_032043

0.001716
0.016101

-2.16
-2.15

0.000932
0.033478

-2.35
-1.92

ITGBL1
FIGN

NM_004791
NM_018086

0.017809
0.000544

-2.15
-2.14

0.035844
0.001157

-1.92
-1.88
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lamin B1
histone cluster 1, H3i
Fanconi anemia,
complementation group
D2
ribonucleotide reductase
M2
kinesin family member
23
maternal embryonic
leucine zipper kinase
antigen identified by
monoclonal antibody Ki67
ASF1 anti-silencing
function 1 homolog B
Opa interacting protein 5
transmembrane protein
195
cell division cycle
associated 8
GINS complex subunit 2
S-phase kinaseassociated protein 2
histone cluster 1, H2bh
aurora kinase A
spindle and kinetochore
associated complex
subunit 2
GTPase, IMAP family
member 2
E2F transcription factor 8
ubiquitin-conjugating
enzyme E2C
ubiquitin-like with PHD
and ring finger domains 1
replication factor C 4
high-mobility group box
2
transmembrane protein
97
transforming, acidic
coiled-coil containing
protein 3
chromosome 12 open
reading frame 48
histone cluster 1, H3a
kinesin family member
14
thyroid hormone receptor
interactor 13
breast cancer 1, early
onset
chromosome 1 open
reading frame 110
single-minded homolog 1
butyrylcholinesterase

LMNB1
HIST1H3I
FANCD2

NM_005573
NM_003533
NM_033084

0.00394
0.001916
0.003083

-2.13
-2.13
-2.12

0.00321
0.001864
0.001318

-2.20
-2.12
-2.45

RRM2

NM_001034

0.037498

-2.10

0.029957

-2.20

KIF23

NM_138555

0.001204

-2.10

0.001972

-1.93

MELK

NM_014791

0.000952

-2.09

0.000622

-2.18

MKI67

NM_002417

0.00284

-2.08

0.012216

-1.71

ASF1B

NM_018154

0.007787

-2.08

0.009392

-2.01

OIP5
TMEM195

0.003731
0.028216

-2.07
-2.06

0.00454
0.157843

-2.00
-1.59

CDCA8

NM_007280
NM_0010043
20
NM_018101

0.001225

-2.06

0.000505

-2.36

GINS2
SKP2

NM_016095
NM_005983

0.002318
0.000131

-2.05
-2.05

0.00058
5.13E-05

-2.56
-2.23

HIST1H2B
H
AURKA
SKA2

NM_003524

0.009348

-2.05

0.007019

-2.12

NM_198433
NM_182620

0.002761
0.001868

-2.04
-2.04

0.002068
0.003569

-2.13
-1.86

GIMAP2

NM_015660

0.029118

-2.02

0.058697

-1.81

E2F8

NM_024680

0.038974

-2.01

0.052401

-1.93

UBE2C

NM_181802

0.000673

UHRF1

0.016634

-1.81

0.003569

-2.27

0.001858
0.00745

-1.73
-1.94

0.0003
0.003641

-2.23
-2.15

TMEM97

NM_0010482
01
NM_002916
NM_0011306
88
NM_014573

0.004009

-1.72

0.000796

-2.09

TACC3

NM_006342

0.003552

-1.84

0.001491

-2.07

C12orf48

AK302724

0.00728

-1.72

0.001774

-2.06

HIST1H3A
KIF14

NM_003529
NM_014875

0.0481
0.008309

-1.65
-1.95

0.009468
0.005476

-2.06
-2.05

TRIP13

NM_004237

0.010858

-1.87

0.005458

-2.05

BRCA1

NR_027676

0.012441

-1.72

0.003357

-2.05

C1orf110

NM_178550

0.032012

-1.97

0.028158

-2.02

SIM1
BCHE

NM_005068
NM_000055

0.008161
0.061941

-1.84
-1.71

0.003979
0.021168

-2.02
-2.00

RFC4
HMGB2
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Greater than 2 fold change in Lo only
-1.95
0.000255
-2.27

KDEL (Lys-Asp-GluLeu) containing 2
minichromosome
maintenance complex
component 10

KDELC2

NM_153705

0.000208

-1.86

9.71E-05

-2.00

MCM10

NM_182751

0.010962

-1.83

0.005348

-2.00

Secreted Protein Quantification
Secreted C3 levels were measured in the media of Hi and Lo cells treated with 0.5
µM MTX for 48 hours. MTX treated Hi cells had 17.1 ng of C3 per mg protein, which
was significantly higher than 5.7 ng per mg protein in untreated Hi control cells, this
represented an up regulation of 3.0 fold (p=0.032) (Figure 5-5A). MTX treated Lo cells
had a secreted C3 level of 38.5 ng per mg protein, which was significantly higher than
29.3 ng per mg protein in untreated Lo control cells, this represented an up regulation of
1.3 fold (p=0.018). Also Lo control cells had significantly more secreted C3 than Hi
control cells, which represented an up regulation of 5.1 fold (p=0.001).
Secreted IL-8 levels were measured in the media of Hi and Lo cells treated with
0.5 µM MTX for 48 hours. MTX treated Hi cells had a secreted IL-8 level of 46.2 ng per
mg protein, which was significantly higher than 3.7 ng per mg protein in untreated cells,
which represented an up regulation of 12.5 fold (p=0.016) (Figure 5-5B). MTX treated
Lo cells had a secreted IL-8 level of 42.5 ng per mg protein, which was significantly
higher than 25.0 ng per mg protein in untreated cells, which represented an up regulation
of 1.7 fold (p=0.008). Also Lo control cells had significantly more secreted IL-8 than Hi
control cells, which represented an up regulation of 6.8 fold (p=0.007). Secreted IL-8
levels were also measured in TNF-α and MTX/TNF-α treated Hi and Lo cells, but there
was no significant difference (data not shown).
Secreted MCP-1 levels were measured in the media of Hi and Lo cells treated
with 0.5 µM MTX for 48 hours. MTX treated Hi cells had a secreted MCP-1 level of 14.4
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ng per mg protein, which was higher but not significantly different from 11.4 ng per mg
protein in untreated Hi cells (p=0.26) (Figure 5-5C). MTX treated Lo cells had a secreted
MCP-1 level of 21.1 ng per mg protein, which was higher but not significantly different
from 19.7 ng per mg protein in untreated Lo cells (p=0.53). Also Lo control cells had
significantly more secreted MCP-1 than Hi control cells, which represented an up
regulation of 1.7 fold (p=0.033). Secreted MCP-1 levels were also measured in TNF-α
and MTX/TNF-α treated Hi and Lo cells, but there was no significant difference (data not
shown).
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Figure 5-5. ELISAs. Hi and Lo cells were exposed to 0.5uM MTX for 48 hours.
Secreted target protein was measured in the media. Each bar represents the mean±SD of
three samples. A, C3. B, IL-8. C, MCP-1. These experiments are representative of a total
of three experiments with similar results. *P values <0.05 for MTX compared with
control. #P values <0.05 for Hi control compared to Lo control.

5.5 Discussion
Elevated homocysteine is often accompanied by low folate status but is also
influenced by dietary intake of vitamins, lifestyle, and genetic factors (Refsum et al.
2006). A high homocysteine and low folate phenotype is associated with many conditions
which also involve inflammation such as rheumatoid arthritis (RA) (Wallberg-Jonsson et
al. 2002). Chronic inflammation of synovium in rheumatoid arthritis involves migration
of leukocytes which interact with the endothelium via cell adhesion molecules and
cytokine/chemokine signaling. The increase in inflammation in RA leads to increased
comorbidity of cardiovascular disease (CVD) (Sattar et al. 2003). Methotrexate (MTX) is
an anti-folate drug used to treat RA, which may have an effect on CVD comorbidity and
mortality. The emerging consensus as reflected in a review by Westlake et al. (Westlake
et al. 2010) is that the use of MTX in the treatment of RA is associated with a reduction
in CVD comorbidity and mortality, due to its anti-inflammatory effects. We wanted to
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examine how MTX treatment may influence the expression of inflammatory genes
because of its conflicting properties of anti-folate and anti-inflammatory. We chose to
investigate the effects of MTX within the context of a well defined model system, Hi and
Lo EA.hy 926 endothelial cells adapted to normal and low folate, respectively.
Doses of MTX were chosen in the range of concentrations relevant to the
treatment of rheumatoid arthritis (Lebbe et al. 1994). In this study MTX was shown to
inhibit proliferation of endothelial cells in the range of concentrations from 0.1 to 0.5 µM,
and the 0.5 µM dose was chosen for further study. A study in human umbilical vein
endothelial cells (HUVECs) showed an inhibition of proliferation when treated with
doses of MTX comparable to in vivo levels after low dose administration (0.1-1.0 µM)
(Yamasaki et al. 2003).
Total intracellular folate was decreased in Hi cells when treated with 0.5 µM
MTX. In MTX treated Hi cells the composition of intracellular folate derivatives was
modified by MTX such that 5-MTHF levels were lower and folic acid levels were higher.
The retention of unmetabolized folic acid, which cannot be utilized, indicates that
dihydrofolate reductase (DHFR) was inhibited resulting in a change in the distribution of
folate derivatives. These results are consistent with studies by Baram et al. (Baram et al.
1987) on cultured human myeloid precursor cells (MPCs) that found MTX treated cells
had decreased levels of 5-MTHF, 10-formylTHF, and 5-formylTHF and increased levels
of DHF and 10-formylDHF, evident of inhibition of DHFR. We observed that Hi and Lo
cells treated with MTX down regulated DHFR, which could also account for the increase
in folic acid.

131

The effect of the anti-folate, MTX, was investigated using microarrays which
covered most of the genes within the human genome. In the present study it was
demonstrated that MTX increased the production of C3 and IL-8 in Hi as well as Lo cells
with no change in MCP-1 levels. C3 activation is responsible for local inflammation and
levels of which are known to be increased in synovial fluids of patients with rheumatoid
arthritis (Okroj et al. 2007). Although not direct evidence, a small study showed that
combination treatment with MTX and cyclophosphamide of pediatric SLE resulted in
increased C3 levels in serum (Lehman et al. 2004). Hi cells treated with MTX had a
much greater fold increase in C3 than MTX treated Lo cells, which could be related to
the dramatic drop in folate levels in Hi cells. In Lo cells in the presence of an
inflammatory stimulator, TNF-α, pre-treatment with MTX increased C3 levels. The antifolate properties of MTX seem to be capable of up regulating specific inflammatory
proteins.
It was previously published that Lo cells secreted more MCP-1 than Hi cells
(Brown et al. 2006), therefore chronic folate insufficiency was able to up regulate an
inflammatory protein. We have found that in Lo control cells C3 and IL-8 were more
highly expressed and had increased synthesis and export of protein compared to Hi
control cells. This finding may indicate that folate dysfunction is associated with a
heightened state of immune readiness.
In a study by Cascao et al. (2010) synovial fluid of rheumatoid arthritis patients
had increased IL-8, a neutrophil chemoattractant. Rheumatoid arthritis patients also had
increased circulating IL-8 levels, but after 4 months of MTX treatment circulating IL-8
levels were not significantly changed. MTX treatment is associated with a serious side
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effect, inflammation of the lung called pneumonitis, which has been shown to be related
to an elevation of IL-8 (Yoshida et al. 1999). Subsequently Yamauchi et al. (2004) has
shown that bronchial and alveolar epithelial cells treated with MTX up regulated IL-8.
We have shown that IL-8 was up regulated with a greater fold increase in MTX treated
Hi cells than MTX treated Lo cells, which again could be related to the dramatic drop in
folate levels in Hi cells.
MCP-1 is involved in both the recruitment of monocytes to atherosclerotic lesions
and to synovium in RA patients. Although MTX did not influence MCP-1 levels in
endothelial cells in this study, it remains to be seen whether MTX can influence MCP-1
levels in RA patients. An etiological component of RA is up regulation of systemic
inflammation, consequently these patients have an increased risk of developing CVD
(Sattar et al. 2003). Treatment of RA with MTX has been associated with an overall
decrease in CVD comorbidity and mortality in a recent meta-analysis (Westlake et al.
2010), although in vitro evidence presented in this set of experiments points to increases
in specific inflammatory products such as C3 and IL-8. This paradoxical decrease in
CVD comorbidity observed in RA patients and up regulation of specific inflammatory
genes in endothelial cells may mean that MTX treatment induces folate dysregulation
which may counteract some of its anti-inflammatory actions. We have found C3 and IL-8
to be up regulated in endothelial cells, but well designed studies in RA patients beginning
MTX will be needed to validate this observation, and to assess the benefit to CVD risk to
see if levels of these inflammatory products are related to modulation of CVD risk.

133

Chapter 6: General Discussion and Future Directions
6.1 General Discussion
The overall conclusions that can be drawn from the research work in this thesis
are:
A) There was gene-gene interaction between CBS 844ins68 genotypes and MTHFR
677C>T genotypes on tHcy and folate levels in healthy men. In healthy women 11
polymorphisms were genotyped and several were associated with altered levels of tHcy
as well as plasma and RBC folate derivatives.
In healthy males from the Industrial Workers study CBS 844ins68 genotypes had
no effect on tHcy and folate levels when considered alone but when considered in the
context of MTHFR 677C>T genotypes there was an impact on tHcy and folate levels only
within MTHFR 677TT individuals. The tHcy raising and folate lowering effect of the
MTHFR 677TT genotype was counteracted in those who were CBS 844ins68 carriers.
In the Premenopausal Women study tHcy levels in African Americans were
associated with the polymorphisms MTR 2756A>G and TYMS 1494del6. THcy levels in
Caucasians were associated with the polymorphisms MTHFR 677C>T, MTHFR
1298A>C, and MTR 2756A>G. Plasma and RBC folate derivatives in African Americans
were associated with the polymorphisms MTR 2756A>G, MTRR 66A>G, RFC1 80A>G,
and TYMS 5’VNTR. In Caucasians plasma and RBC folate derivatives were associated
with the polymorphisms MTHFR 677C>T, MTHFR 1298A>C, MTR 2756A>G, TYMS
1494del6, and RFC1 80A>G.
B) None of the 7 polymorphisms tested were associated with increased NTD risk in
children and mothers by TDT analyses.
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Although TDT analyses did not find any significant associations there was
evidence that rare crossover events between MTHFR 677 and 1298 polymorphisms may
increase risk of NTDs because two such genotypes were present in mothers only. Also
rare crossover events between TYMS 5’VNTR and 1494del6 were more frequent in
children and mothers.
C) None of the polymorphisms tested were associated with elevated tHcy levels or CAC
scores in SLE cases. In RA patients taking MTX several polymorphisms were associated
with altered levels of RBC folate derivatives. Several polymorphisms were associated
with discontinuation of MTX and attributable toxicities.
In the SLE study GFR was negatively correlated to tHcy levels and was therefore
used as a covariate in general linear models which examined the effects of genetic
polymorphisms on tHcy levels. Although none of the polymorphisms were found to
impact tHcy levels in SLE cases, the polymorphisms MTHFR 677C>T and 1298A>C
were associated with tHcy levels in controls.
In the RA study the polymorphisms MTHFD1 1958G>A and MTHFR 1298A>C
were associated with discontinuation of MTX therapy in African Americans and
Caucasians, respectively. The polymorphisms MTR 2756A>G and MTHFD1 1958G>A
were associated with attributable toxicities in African American and Caucasian current
users, respectively. The polymorphisms DHFR c.86+60_78 and TYMS 1494del6 were
associated with currently prescribed MTX dose in African Americans. RBC folate
derivatives were associated with the polymorphism DHFR c.86+60_78 in African
Americans. In Caucasians RBC folate derivatives were associated with the
polymorphisms MTHFR 677C>T, RFC1 80A>G, and MTRR 66A>G.
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D) In EA.hy 926 endothelial cells MTX treatment resulted in depletion of total folate,
altered composition of folate derivatives, and increased expression of the inflammatory
genes, C3 and IL-8.
Hi and Lo cells were treated with MTX and cellular proliferation was inhibited.
MTX treated Hi cells had depleted levels of total folate, an altered distribution of folate
derivatives, and higher levels of unmetabolized folic acid. Microarray analyses identified
a number of inflammatory genes which were up regulated in MTX treated Hi and Lo
cells. C3 and IL-8 were verified by qRT-PCR to be up regulated in MTX treated cells.
ELISAs also confirmed that secreted protein levels of C3 and IL-8 were higher in MTX
treated cells.
6.2 Future Directions
6.2.1 Healthy subjects
In the Industrial Workers study there are several polymorphisms which have been
genotyped and remain to be analyzed and published even if there are no associations with
tHcy and folate levels. These polymorphisms are: MTHFR 1298A>C, SHMT1 1420C>T,
RFC1 80G>A, TYMS 1494del6, and MTHFD1 1958G>A. TYMS 5’VNTR and DHFR
c.86+60_78 polymorphisms also need to be genotyped and analyzed. Although this study
consists of only men and some of these polymorphisms are associated with differences in
Hcy and folate levels only in women, the Industrial Workers study is large enough to
permit the analyses of gene-gene interactions.
The Premenopausal Women study showed that polymorphisms in the enzymes of
the folate/Hcy pathway impact tHcy and folate derivative levels. The use of high
precision methods to measure individual folate derivatives should be expanded to studies
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on healthy men. Also any subsequent studies should consider the number of subjects of
each race that would need to be recruited because a large scale study would enable
analyses of rare homozygotes. C3 and IL-8 levels could be measured in healthy
individuals and examined for associations with tHcy and folate levels.
6.2.2 Families with a child affected by NTDs
As previously mentioned TDT analyses on specific subsets of the NTD study
need to be performed. Subsets which may reveal increased genetic risk include maternal
smoking status, maternal supplementation status, race, and year of birth, which would
examine effects of genotypes prior to and after folic acid fortification in the US. TDT
analyses are relatively simple and a more complex analysis such as log-linear modeling
may uncover increased risk for NTDs associated with a particular genotype.
Polymorphisms in C3 and IL-8 could be searched for and genotyped in the NTD study.
6.2.3 Inflammatory diseases
In the SLE study only tHcy concentrations were measured. If another study was
planned then whole blood should be collected in a method compatible with measurement
of folate derivatives using LC/MRM/MS, which would require that whole blood be
immediately diluted in ascorbic acid to prevent the oxidation of folate derivatives. The
association between CAC scores and folate derivative levels could then be analyzed. The
current SLE study has serum and/or plasma samples available and candidate
inflammatory genes such as C3 and IL-8 could be measured and compared to controls.
C3 and IL-8 would be considered because MCP-1 was another inflammatory gene which
was first found to be up regulated in Lo compared to Hi cells. In the SLE study MCP-1
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levels were shown to be higher in SLE cases compared to controls (Brown et al.
2007).C3 and IL-8 levels should also be analyzed for association with CAC scores.
In the RA study analyses are underway which include baseline measurements of
tHcy and folate derivative levels prior to MTX therapy. Other future directions include
restricting the analyses of current users to just females because a few of the
polymorphisms seem to be associated with differences in Hcy and folate levels only in
women. Since C3 and IL-8 were up regulated in MTX treated Hi and Lo cells, levels of
these proteins should be measured in plasma samples and analyzed for associations with
tHcy and folate levels. The changes in C3 and IL-8 levels as RA patients begin MTX
therapy will also be of interest.
6.2.4 Cell culture
In cell culture experiments involving Hi and Lo cells treated with MTX and TNFα a future direction would be to measure secreted C3 levels in TNF-α and MTX/TNF-α
treated cells. Since MTX treatment was associated with an inhibition of proliferation, an
assay specific to cell death would be a better measure of MTX induced apoptosis than
counting the number of live cells. The trypan blue assay was able to dye the dead cells
but the length of time need to complete each assay limited the utility of this method. Even
though MTX treatment was applied when cells were confluent it was apparent that cell
division continued to take place after confluence and therefore the difference between the
number of live control cells and live MTX treated cells after 48 hours may have been
overestimated. Finally there are other inflammatory genes which were found to be
significantly up regulated by MTX treatment in the microarray analysis, such as IL-1A,
which need to be validated by qRT-PCR and ELISA.
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